In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Celecoxib	B-D000068579

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

The	O
rates	O
of	O
Hypertension	B-D006973

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

The	O
renal	O
effects	O
of	O
Celecoxib	B-D000068579

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
Sulfonamides	B-D013449

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Celecoxib	B-D000068579

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
Patients	B-D010361

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Celecoxib	B-D000068579

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
Risk	B-D012306

6	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Actavis	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS.)	O
Etodolac	B-D017308
extended-release	O
Tablets	B-D013607

(See	O
WARNINGS.)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS.)	O
1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
non-steroidal	O
anti-inflammatory	O
drug	O

ADVERSE	O
REACTIONS	O
A	O
total	O
of	O
1552	O
Patients	B-D010361

In	O
the	O
tabulations	O
below,	O
adverse	O
event	O
rates	O
are	O
generally	O
categorized	O
based	O
on	O
the	O
Incidence	B-D015994

As	O
with	O
other	O
NSAIDs,	O
the	O
cumulative	O
adverse	O
event	O
rates	O
may	O
increase	O
significantly	O
over	O
Time	B-D013995

In	O
Patients	B-D010361

Additional	O
NSAID	O
Adverse	O
Experiences	O
Reported	O
Occasionally	O
with	O
NSAIDs	O
or	O
Etodolac	B-D017308
Extended-Release	O
Tablets	B-D013607
Include	O
Body	O
as	O
a	O
whole	O
-	O
allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
Shock	B-D012769

The	O
most	O
frequently	O
observed	O
non-serious	O
adverse	O
reactions	O
include	O
Light	B-D008027

These	O
effects	O
seem	O
to	O
be	O
more	O
prominent	O
in	O
ambulatory	O
than	O
in	O
nonambulatory	O
Patients	B-D010361

Other	O
adverse	O
reactions	O
include	O
Euphoria	B-D005059

Aspirin	B-D001241
may	O
increase	O
the	O
likelihood	O
of	O
Hemorrhage	B-D006470

Furthermore,	O
Aspirin	B-D001241

Other	O
adverse	O
reactions	O
due	O
to	O
Aspirin	B-D001241

Other	O
adverse	O
reactions	O
obtained	O
from	O
postmarketing	O
experiences	O
with	O
ENDODAN	O
Tablets	B-D013607

Cardiovascular	O
Tachycardia	B-D013610

Patients	B-D010361
with	O
high	O
frequency	O
loss	O
may	O
have	O
difficulty	O
perceiving	O
Tinnitus	B-D014012

In	O
these	O
Patients	B-D010361

Hematologic	O
unspecified	O
Hemorrhage	B-D006470

Hypersensitivity	B-D006967
acute	O
Anaphylaxis	B-D000707

Psychiatric	O
drug	O
dependence,	O
drug	O
abuse,	O
somnolence,	O
Depression	B-D003863

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

•Diclofenac	O
Sodium	B-D012964
Extended-release	O
Tablets	B-D013607
,	O
USP	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

Other	O
adverse	O
reactions	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
Appetite	B-D001066

Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Etodolac	B-D017308
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse-reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
to	O
1,000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064

Nervous	B-D009420
System	I-D009420

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566

*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
Death	B-D003643

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS)	O

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
As	O
A	O
Whole:fever,	O
infection,	O
Sepsis	B-D018805

This	O
Risk	B-D012306

Ibuprofen	B-D007052
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
Ibuprofen	B-D007052

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052

Adverse	O
reactions	O
observed	O
during	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
Observation	B-D019370

More	O
than	O
500	O
of	O
these	O
Patients	B-D010361

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
Clinical	B-D016430
Trial	I-D016430

The	O
increases	O
in	O
Incidence	B-D015994

Incidence	B-D015994
Greater	O
Than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
*	O
Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
Patients	B-D010361

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
Patients	B-D010361

Reactions	O
are	O
classified	O
under	O
“Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O

GASTROINTESTINAL	O
Nausea	B-D009325
*,	O
epigastric	O
Pain	B-D010146

Henoch-Schonlein	O
Vasculitis	B-D014657

This	O
Risk	B-D012306

•	O
Diflunisal	B-D004061
Tablets	B-D013607

Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
adverse	O
reactions	O
observed	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Listed	O
below	O
are	O
the	O
adverse	O
reactions	O
reported	O
in	O
the	O
1,314	O
of	O
these	O
Patients	B-D010361

Five	O
hundred	O
thirteen	O
Patients	B-D010361

In	O
general,	O
the	O
adverse	O
reactions	O
listed	O
below	O
were	O
2	O
to	O
14	O
Time	B-D013995

Incidence	B-D015994
Greater	O
Than	O
1%	O
Gastrointestinal	O
The	O
most	O
frequent	O
types	O
of	O
adverse	O
reactions	O
occurring	O
with	O
Diflunisal	B-D004061

Psychiatric	O
Somnolence,	O
insomnia	O

Central	B-D002490
Nervous	I-D002490
System	I-D002490
Dizziness	B-D004244
	O

Special	O
Senses	O
Tinnitus	B-D014012
	O

Dermatologic	O
Rash*	O

Miscellaneous	O
Headache	B-D006261
*,	O
Fatigue	B-D005221

*	O
Incidence	B-D015994
between	O
3%	O
and	O
9%	O

Those	O
reactions	O
occurring	O
in	O
1%	O
to	O
3%	O
are	O
not	O
marked	O
with	O
an	O
asterisk	O

Incidence	B-D015994
Less	O
Than	O
1	O
in	O
100	O
The	O
following	O
adverse	O
reactions,	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100,	O
were	O
reported	O
in	O
Clinical	B-D016430
Trial	I-D016430

The	O
Probability	B-D011336

Dermatologic	O
Erythema	B-D004892
Multiforme	I-D004892

Gastrointestinal	O
Peptic	B-D010437
Ulcer	I-D010437

Liver	B-D008099
function	O
abnormalities;	O
Jaundice	B-D007565

Hematologic	O
Thrombocytopenia	B-D013921
;	O
Agranulocytosis	B-D000380

Genitourinary	O
Dysuria	B-D053159
;	O
renal	O
impairment,	O
including	O
renal	O
failure;	O
interstitial	O
Nephritis	B-D009393

Psychiatric	O
Nervousness,	O
Depression	B-D003863

Central	B-D002490
Nervous	I-D002490
System	I-D002490
Vertigo	B-D014717
;	O
Light	B-D008027

Special	O
Senses	O
Transient	O
visual	O
disturbances	O
including	O
blurred	O
vision	O

Hypersensitivity	B-D006967
Reactions	O
Acute	O
anaphylactic	O
reaction	O
with	O
bronchospasm;	O
Angioedema	B-D000799

Hypersensitivity	B-D006967
Vasculitis	B-D014657

Hypersensitivity	B-D006967
Syndrome	B-D013577

Miscellaneous	O
Asthenia	B-D001247
,	O
Edema	B-D004487

Causal	O
Relationship	O
Unknown	O
Other	O
reactions	O
have	O
been	O
reported	O
in	O
Clinical	B-D016430
Trial	I-D016430

However,	O
in	O
these	O
rarely	O
reported	O
events,	O
that	O
possibility	O
cannot	O
be	O
excluded	O

Therefore,	O
these	O
Observation	B-D019370

Respiratory	O
Dyspnea	B-D004417
	O

Cardiovascular	O
Palpitation,	O
Syncope	B-D013575

Musculoskeletal	O
Muscle	B-D009120
Cramp	I-D009120

Genitourinary	O
Nephrotic	B-D009404
Syndrome	I-D009404

Special	O
Senses	O
Hearing	B-D034381
Loss	I-D034381

Miscellaneous	O
Chest	B-D002637
Pain	I-D002637

A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
Fasciitis	B-D005208

Potential	O
Adverse	O
Effects	O
In	O
addition,	O
a	O
variety	O
of	O
adverse	O
effects	O
not	O
observed	O
with	O
Diflunisal	B-D004061

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
Fever	B-D005334

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Etodolac	B-D017308
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse-reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
to	O
1000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064

Nervous	B-D009420
System	I-D009420

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566

*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
Death	B-D003643

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

•	O
Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306

Cardiovascular	O
Risk	B-D012306
•	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

(5.1)	O
•	O
Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
(4,	O
5.1)	O
•	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs),	O
including	O
Diclofenac	B-D004008

Elderly	O
Patients	B-D010361

(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

The	O
lowest	O
possible	O
dose	O
of	O
Diclofenac	B-D004008

(5.1)	O
•NSAIDs,	O
including	O
Diclofenac	B-D004008

Diclofenac	B-D004008
Sodium	B-D012964

(5.2)	O
•Elevation	O
of	O
one	O
or	O
more	O
Liver	B-D008099

Diclofenac	B-D004008
Sodium	B-D012964

(5.3)	O
•Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Diclofenac	B-D004008
Sodium	B-D012964

(5.6)	O
•Hypertension	O
can	O
occur	O
with	O
NSAID	O
treatment	O

Blood	B-D001794
Pressure	I-D001794

(5.4)	O
•Fluid	O
retention	O
and	O
Edema	B-D004487

Diclofenac	B-D004008
Sodium	B-D012964

(5.5)	O
•Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

(5.7)	O
•NSAIDs	O
can	O
cause	O
serious	O
Skin	B-D012867

Diclofenac	B-D004008
Sodium	B-D012964

(5.8)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

5.3	O
Hepatic	O
Effects	O
Elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continued	O
therapy	O

Borderline	O
elevations	O
(i.e	O

less	O
than	O
3	O
Time	B-D013995

Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
Liver	B-D008099

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
Physicians	B-D010820

Caution	O
should	O
be	O
Exercise	B-D015444

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
Diclofenac	B-D004008

Blood	B-D001794
Pressure	I-D001794

5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

Diclofenac	B-D004008
Sodium	B-D012964

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008

Therefore,	O
treatment	O
with	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

Diclofenac	B-D004008
Sodium	B-D012964

Diclofenac	B-D004008
Sodium	B-D012964

5.9	O
Pregnancy	B-D011247
As	O
with	O
other	O
NSAIDs,	O
Diclofenac	B-D004008

5.10	O
Corticosteroid	O
Treatment	O
Diclofenac	B-D004008
Sodium	B-D012964

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.12	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
Blood	B-D001769

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

Unlike	O
Aspirin	B-D001241

Patients	B-D010361
treated	O
with	O
Diclofenac	B-D004008

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
Art	B-D001154

The	O
potential	O
effects	O
of	O
Diclofenac	B-D004008

5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
Diclofenac	B-D004008

Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
Eye	B-D005123

5.16	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>2%	O
of	O
Patients	B-D010361

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sand	B-D000080463
oz	O
Inc	O

at	O
1-800-398-5876	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

Of	O
these,	O
513	O
Patients	B-D010361

Additionally,	O
583	O
Patients	B-D010361

Of	O
these,	O
355	O
Patients	B-D010361

Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
Safety	B-D012449

Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
Patients	B-D010361

These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>1%	O
of	O
treated	O
Patients	B-D010361

Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported	O

Application	O
site	O
Dermatitis	B-D003872

Table	O
1:	O
Non-serious	O
Application	O
Site	O
Adverse	O
Reactions	O
(≥1%	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Gel	O
Patients	B-D010361
)	O
–	O
Short-term	O
Controlled	O
Trials	O
Adverse	O
Reaction†	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Gel	O
N=913	O
Placebo	O
(vehicle)	O
N=876	O
N	O
(%)	O
N	O
(%)	O
Any	O
application	O
site	O
reaction	O
62	O
(7)	O
19	O
(2)	O
Application	O
site	O
Dermatitis	B-D003872

In	O
the	O
placebo-controlled	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
was	O
5%	O
for	O
Patients	B-D010361

Application	O
site	O
reactions,	O
including	O
application	O
site	O
Dermatitis	B-D003872

Long-Term	O
Open-Label	O
Safety	B-D012449
Trial:	O
In	O
the	O
open-label,	O
long-term	O
Safety	B-D012449

In	O
this	O
study,	O
where	O
Patients	B-D010361

Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
Patients	B-D010361

The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
Dermatitis	B-D003872

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
Fever	B-D005334

Cardiovascular	O
Thrombotic	O
Events	O
WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

Etodolac	B-D017308
extended-release	O
Tablets	B-D013607

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

Adverse	O
Reactions	O
A	O
total	O
of	O
1552	O
Patients	B-D010361

In	O
the	O
tabulations	O
below,	O
adverse	O
event	O
rates	O
are	O
generally	O
categorized	O
based	O
on	O
the	O
Incidence	B-D015994

As	O
with	O
other	O
NSAIDs,	O
the	O
cumulative	O
adverse	O
event	O
rates	O
may	O
increase	O
significantly	O
over	O
Time	B-D013995

In	O
Patients	B-D010361

abnormal	O
renal	O
function*	O
Anemia	B-D000740
*	O
Asthenia	B-D001247

This	O
Risk	B-D012306

•	O
Diclofenac	B-D004008

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
•	O
Diclofenac	B-D004008

(4,	O
5.1)	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

(5.3)	O
•	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
Blood	B-D001794
Pressure	I-D001794

(5.4,	O
7)	O
•	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
Diclofenac	B-D004008

(5.5)	O
•	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
use	O
of	O
Diclofenac	B-D004008

(5.6)	O
•	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

(5.7)	O
•	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Diclofenac	B-D004008

Monitor	O
Patients	B-D010361

(5.8)	O
•	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
Diclofenac	B-D004008

(5.9)	O
•	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
Pregnant	B-D037841
Women	I-D037841

(5.10,	O
8.1)	O
•	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
Hematocrit	B-D006400

(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

•Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

•Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

•Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

•If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Diclofenac	B-D004008

•In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
In	O
Clinical	B-D016430
Trial	I-D016430

more	O
than	O
3	O
Time	B-D013995

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
Diclofenac	B-D004008

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008

The	O
renal	O
effects	O
of	O
Diclofenac	B-D004008

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactoid	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Diclofenac	B-D004008

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Diclofenac	B-D004008

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Diclofenac	B-D004008

NSAIDs,	O
including	O
Diclofenac	B-D004008

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
Art	B-D001154

The	O
potential	O
effects	O
of	O
Diclofenac	B-D004008

5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
Diclofenac	B-D004008

Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
Eye	B-D005123

5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
and	O
topical	O
NSAIDs	O
may	O
result	O
in	O
a	O
higher	O
rate	O
of	O
Hemorrhage	B-D006470

Do	O
not	O
use	O
combination	O
therapy	O
with	O
Diclofenac	B-D004008

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
•Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
•Hypertension	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
•Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
•Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
•Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>2%	O
of	O
Patients	B-D010361

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
GlaxoSmithKline	O
Consumer	O
Health	B-D006262
care	O
at	O
1-855-297-3031	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

During	O
clinical	O
development,	O
913	O
Patients	B-D010361

Of	O
these,	O
513	O
Patients	B-D010361

Additionally,	O
583	O
Patients	B-D010361

Of	O
these,	O
355	O
Patients	B-D010361

Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
Safety	B-D012449

Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
Patients	B-D010361

These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>1%	O
of	O
treated	O
Patients	B-D010361

Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported	O

Application	O
site	O
Dermatitis	B-D003872

Table	O
1	O

Non-serious	O
Application	O
Site	O
Adverse	O
Reactions	O
(≥1%	O
Diclofenac	B-D004008

Application	O
site	O
reactions,	O
including	O
application	O
site	O
Dermatitis	B-D003872

Long-Term	O
Open-Label	O
Safety	B-D012449
Trial:In	O
the	O
open-label,	O
long-term	O
Safety	B-D012449

In	O
this	O
study,	O
where	O
Patients	B-D010361

Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
Patients	B-D010361

The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
Dermatitis	B-D003872

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

•Diclofenac	O
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS	O
)	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS	O
)	O
•Hepatotoxicity	O
(see	O
WARNINGS	O
)	O
•Hypertension	O
(see	O
WARNINGS	O
)	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
(see	O
WARNINGS	O
)	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS	O
)	O
•Anaphylactic	O
Reactions	O
(see	O
WARNINGS	O
)	O
•Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS	O
)	O
•Hematologic	O
Toxicity	O
(see	O
WARNINGS	O
)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
Fever	B-D005334

1-866-562-4597	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
With	O
some	O
NSAIDs,	O
including	O
NEVANAC	O
0.1%,	O
there	O
exists	O
the	O
potential	O
for	O
increased	O
Bleeding	B-D001760
Time	I-D001760

There	O
have	O
been	O
reports	O
that	O
ocularly	O
applied	O
NSAIDs	O
may	O
cause	O
increased	O
bleeding	O
of	O
ocular	O
Tissues	B-D014024

It	O
is	O
recommended	O
that	O
NEVANAC	O
0.1%	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.2	O
Delayed	O
Healing	O
Topical	O
NSAIDs,	O
including	O
NEVANAC	O
0.1%,	O
may	O
slow	O
or	O
delay	O
healing	O

Topical	O
corticosteroids	O
are	O
also	O
known	O
to	O
slow	O
or	O
delay	O
healing	O

Concomitant	O
use	O
of	O
topical	O
NSAIDs	O
and	O
topical	O
Steroids	B-D013256

5.3	O
Cornea	B-D003315
l	O
Effects	O
Use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
Keratitis	B-D007634

In	O
some	O
susceptible	O
Patients	B-D010361

These	O
events	O
may	O
be	O
sight	O
threatening	O

Patients	B-D010361
with	O
evidence	O
of	O
Cornea	B-D003315

Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
suggests	O
that	O
Patients	B-D010361

Topical	O
NSAIDs	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
also	O
suggests	O
that	O
use	O
more	O
than	O
1	O
day	O
prior	O
to	O
surgery	O
or	O
use	O
beyond	O
14	O
days	O
post-surgery	O
may	O
increase	O
patient	O
Risk	B-D012306

5.4	O
Contact	O
Lens	O
Wear	O
NEVANAC*	O
0.1%	O
should	O
not	O
be	O
administered	O
while	O
using	O
Contact	B-D003261
Lenses	I-D003261

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
labeling:	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
Delayed	O
Healing	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Cornea	B-D003315
l	O
Effects	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Most	O
common	O
adverse	O
reactions	O
(5%	O
to	O
10%)	O
are	O
capsular	O
opacity,	O
decreased	O
Visual	B-D014792
Acuity	I-D014792

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Alcon	O
Laboratories	B-D007753
,	O
Inc	O

at	O
1-800-757-9195	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
most	O
frequently	O
reported	O
ocular	O
adverse	O
reactions	O
following	O
Cataract	B-D002386

These	O
reactions	O
occurred	O
in	O
approximately	O
5%	O
to	O
10%	O
of	O
Patients	B-D010361

Other	O
ocular	O
adverse	O
reactions	O
occurring	O
at	O
an	O
Incidence	B-D015994

Some	O
of	O
these	O
reactions	O
may	O
be	O
the	O
consequence	O
of	O
the	O
Cataract	B-D002386

Non-ocular	O
adverse	O
reactions	O
reported	O
at	O
an	O
Incidence	B-D015994

BOXED	O
WARNING	O
WARNING:	O
Risk	B-D012306

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Celecoxib	B-D000068579
Capsules	B-D002214

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Celecoxib	B-D000068579

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

The	O
rates	O
of	O
Hypertension	B-D006973

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
CLASS	O
study	O
[see	O
CLINICAL	O
STUDIES	O
(14.6)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

The	O
renal	O
effects	O
of	O
Celecoxib	B-D000068579

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Celecoxib	B-D000068579

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Celecoxib	B-D000068579

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
Risk	B-D012306

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)]	O
Hepatotoxicity	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.3)]	O
Hypertension	B-D006973
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp	O

at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
>2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CXB	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
Injury-Accidental	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

In	O
placebo	O
-	O
or	O
active	O
-	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
VIVLODEX	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

VIVLODEX	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
VIVLODEX	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
VIVLODEX	O
in	O
Patients	B-D010361

If	O
VIVLODEX	O
is	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Meloxicam	B-D000077239

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
high	O
Risk	B-D012306

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
VIVLODEX	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
VIVLODEX,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Meloxicam	B-D000077239

Avoid	O
the	O
use	O
of	O
VIVLODEX	O
in	O
Patients	B-D010361

If	O
VIVLODEX	O
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
was	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
VIVLODEX	O
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
VIVLODEX	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
VIVLODEX	O
in	O
Patients	B-D010361

If	O
VIVLODEX	O
is	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Meloxicam	B-D000077239
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
VIVLODEX	O
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Meloxicam	B-D000077239

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

VIVLODEX	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Meloxicam	B-D000077239
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
VIVLODEX,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
VIVLODEX	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

NSAIDs,	O
including	O
VIVLODEX,	O
may	O
increase	O
the	O
Risk	B-D012306

Concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
VIVLODEX	O
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥2%	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Iroko	O
Pharmaceuticals,	O
LLC	O
at	O
1-877-757-0676	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

Adverse	O
Reactions	O
in	O
Patients	B-D010361
with	O
Osteoarthritis	B-D010003
Pain	B-D010146
Eight	O
hundred	O
sixty-eight	O
(868)	O
Patients	B-D010361

Fifty	O
percent	O
(50%)	O
of	O
Patients	B-D010361

Two	O
hundred	O
sixty-nine	O
(269)	O
Patients	B-D010361

The	O
most	O
frequent	O
adverse	O
reactions	O
in	O
this	O
study	O
are	O
summarized	O
in	O
Table	O
1	O

Table	O
1	O
Summary	O
of	O
Adverse	O
Reactions	O
(≥2%)	O
–	O
12-Week	O
Phase	O
3	O
Study	O
in	O
Patients	B-D010361
With	O
Osteoarthritis	B-D010003
Pain	B-D010146
Adverse	O
Reactions	O
VIVLODEX	O
5	O
mg	O
or	O
10	O
mg	O
N=269	O
Placebo	O
N=133	O
Diarrhea	B-D003967
3%	O
1%	O
Nausea	B-D009325
2%	O
0	O
Abdominal	O
Discomfort	O
2%	O
0	O
Six	O
hundred	O
(600)	O
Patients	B-D010361

Of	O
these,	O
390	O
(65%)	O
Patients	B-D010361

The	O
most	O
frequent	O
adverse	O
reactions	O
in	O
this	O
study	O
are	O
summarized	O
in	O
Table	O
2	O

Table	O
2	O
Summary	O
of	O
Adverse	O
Reactions	O
(≥2%)	O
–	O
52-Week	O
Open-Label	O
Study	O
in	O
Patients	B-D010361
With	O
Osteoarthritis	B-D010003
Pain	B-D010146
Adverse	O
Reactions	O
VIVLODEX	O
10	O
mg	O
N=600	O
Arthralgia	B-D018771
6%	O
Urinary	B-D014551
Tract	I-D014551
Infection	O
6%	O
Osteoarthritis	B-D010003
5%	O
Hypertension	B-D006973
4%	O
Diarrhea	B-D003967
4%	O
Headache	B-D006261
4%	O
Upper	O
Respiratory	O
Tract	O
Infection	O
4%	O
Back	B-D001416
Pain	I-D001416
4%	O
nas	B-C015378

This	O
Risk	B-D012306

•	O
Diclofenac	B-D004008
Potassium	B-D011188

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
•Hepatotoxicity	O
(see	O
WARNINGS)	O
•Hypertension	O
(see	O
WARNINGS)	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
•Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
•Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
•Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
718	O
Patients	B-D010361

In	O
a	O
6-month,	O
double-blind	O
trial	O
comparing	O
Diclofenac	B-D004008

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

This	O
Risk	B-D012306

FLECTOR	O
PATCH	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
Patients	B-D010361

If	O
FLECTOR	O
PATCH	O
is	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
FLECTOR	O
PATCH	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
FLECTOR	O
PATCH	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
Acetaminophen	B-D000082

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
FLECTOR	O
PATCH,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
Patients	B-D010361

If	O
FLECTOR	O
PATCH	O
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
FLECTOR	O
PATCH	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
Patients	B-D010361

If	O
FLECTOR	O
PATCH	O
is	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
FLECTOR	O
PATCH	O
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

FLECTOR	O
PATCH	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
FLECTOR	O
PATCH,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
FLECTOR	O
PATCH	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

NSAIDs,	O
including	O
FLECTOR	O
PATCH,	O
may	O
increase	O
the	O
Risk	B-D012306

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
FLECTOR	O
PATCH	O
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Accidental	O
Exposure	O
in	O
Child	B-D002648
ren	O
Even	O
a	O
used	O
Flector	O
Patch	O
contains	O
a	O
large	O
amount	O
of	O
Diclofenac	B-D004008

The	O
potential	O
therefore	O
exists	O
for	O
a	O
small	O
Child	B-D002648

It	O
is	O
important	O
for	O
Patients	B-D010361

5.15	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
Flector	O
Patch	O
with	O
Eye	B-D005123

Advise	O
Patients	B-D010361

5.16	O
Oral	O
Nonsteroidal	O
Anti-inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
and	O
topical	O
NSAIDs	O
may	O
result	O
in	O
a	O
higher	O
rate	O
of	O
Hemorrhage	B-D006470

Do	O
not	O
use	O
combination	O
therapy	O
with	O
Flector	O
Patch	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
Risk	B-D012306

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
are	O
application	O
site	O
conditions,	O
occurring	O
in	O
11%	O
and	O
12%,	O
Respect	B-D000078682

at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
controlled	O
trials	O
during	O
the	O
Prema	B-C070504

Adverse	O
Events	O
Lead	B-D007854
ing	O
to	O
Discontinuation	O
of	O
Treatment	O
In	O
the	O
controlled	O
trials,	O
3%	O
of	O
Patients	B-D010361

The	O
most	O
common	O
adverse	O
events	O
Lead	B-D007854

Application	O
site	O
reactions	O
Lead	B-D007854

Common	O
Adverse	O
Events	O
Localized	O
Reactions	O
Overall	B-D016424
,	O
the	O
most	O
common	O
adverse	O
events	O
associated	O
with	O
FLECTOR	O
PATCH	O
treatment	O
were	O
Skin	B-D012867

Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

A	O
majority	O
of	O
Patients	B-D010361

Common	O
Adverse	O
Events	O
(by	O
body	O
system	O
and	O
preferred	O
term)	O
in	O
≥	O
1%	O
of	O
Patients	B-D010361
treated	O
with	O
FLECTOR	O
PATCH	O
or	O
Placebo	O
Patch	O
The	O
table	O
lists	O
adverse	O
events	O
occurring	O
in	O
placebo-treated	O
Patients	B-D010361

Adverse	O
events	O
in	O
the	O
placebo	O
group	O
may	O
therefore	O
reflect	O
effects	O
of	O
the	O
non-active	O
ingredients	O

Category	O
Diclofenac	B-D004008
N=572	O
Placebo	O
N=564	O
N	O
Percent	O
N	O
Percent	O
Application	O
Site	O
Conditions	O
64	O
11	O
70	O
12	O
Pruritus	B-D011537
31	O
5	O
44	O
8	O
Dermatitis	B-D003872
9	O
2	O
3	O
<1	O
Burning	O
2	O
<1	O
8	O
1	O
OtherIncludes:	O
application	O
site	O
dryness,	O
irritation,	O
Erythema	B-D004890

22	O
4	O
15	O
3	O
Gastrointestinal	O
Disorders	O
49	O
9	O
33	O
6	O
Nausea	B-D009325
17	O
3	O
11	O
2	O
Dysgeusia	B-D004408
10	O
2	O
3	O
<1	O
Dyspepsia	B-D004415
7	O
1	O
8	O
1	O
OtherIncludes:	O
Gastritis	B-D005756

15	O
3	O
11	O
2	O
Nervous	B-D009420
System	I-D009420
Disorders	O
13	O
2	O
18	O
3	O
Headache	B-D006261
7	O
1	O
10	O
2	O
Paresthesia	B-D010292
6	O
1	O
8	O
1	O
Somnolence	O
4	O
1	O
6	O
1	O
Other	O
Includes:	O
hypoesthesia,	O
Dizziness	B-D004244

4	O
1	O
3	O
<1	O
Foreign	O
labeling	O
describes	O
that	O
dermal	O
allergic	O
reactions	O
may	O
occur	O
with	O
FLECTOR	O
PATCH	O
treatment	O

Additionally,	O
the	O
treated	O
area	O
may	O
become	O
irritated	O
or	O
develop	O
itching,	O
Erythema	B-D004890

Contraindications	B-D000075202

ADMINISTRATION	O
OF	O
Misoprostol	B-D016595

Uterine	B-D014597
Rupture	I-D014597

Arthrotec	B-C078133

Patients	B-D010361

In	O
such	O
Patients	B-D010361

is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures	O

has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
Misoprostol	B-D016595

will	O
begin	O
Arthrotec	B-C078133

Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Arthrotec	B-C078133

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
Adverse	O
reactions	O
associated	O
with	O
Arthrotec	B-C078133

Gastrointestinal	O
GI	O
disorders	O
had	O
the	O
highest	O
reported	O
Incidence	B-D015994

These	O
events	O
were	O
generally	O
minor,	O
but	O
led	O
to	O
discontinuation	O
of	O
therapy	O
in	O
9%	O
of	O
Patients	B-D010361

For	O
GI	O
Ulcer	B-D014456

GI	O
disorder	O
Arthrotec	B-C078133

Diarrhea	B-D003967
and	O
Abdominal	B-D015746
Pain	I-D015746

Rare	O
instances	O
of	O
profound	O
Diarrhea	B-D003967

Patients	B-D010361
with	O
an	O
underlying	O
condition	O
such	O
as	O
inflammatory	O
bowel	O
Disease	B-D004194

The	O
Incidence	B-D015994

Gynecological	O
Gynecological	O
disorders	O
previously	O
reported	O
with	O
Misoprostol	B-D016595

Postmenopausal	O
Vagina	B-D014621

If	O
it	O
occurs,	O
diagnostic	O
Work	B-D014937

Elderly	O
Overall	B-D016424
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
Safety	B-D012449

Other	O
adverse	O
experiences	O
reported	O
occasionally	O
or	O
rarely	O
with	O
Arthrotec	B-C078133

Cardiovascular	B-D002319
System	I-D002319

Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Digestive:	O
Anorexia	B-D000855
,	O
Appetite	B-D001066

Female	B-D005260
reproductive	O
disorders:	O
Breast	B-D001940
Pain	B-D010146

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Hypersensitivity	B-D006967
:	O
Angioedema	B-D000799
,	O
laryngeal/pharyngeal	O
Edema	B-D004487

Liver	B-D008099
and	O
biliary	O
system:	O
Abnormal	O
hepatic	O
function,	O
Bilirubin	B-D001663

Male	B-D008297
reproductive	O
disorders:	O
Impotence,	O
perineal	O
Pain	B-D010146

Metabolic	O
and	O
nutritional:	O
Alkaline	B-D000469
Phosphatase	I-D000469

Musculoskeletal	B-D009141
System	I-D009141

Psychiatric:	O
Anxiety	B-D001007
,	O
concentration	O
impaired,	O
Confusion	B-D003221

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages:	O
Acne,	O
Alopecia	B-D000505

Special	O
senses:	O
Hearing	B-D006309
impairment,	O
Taste	B-D013649

Urinary	O
system:	O
Cystitis	B-D003556
,	O
Dysuria	B-D053159

Vision:	O
Amblyopia	B-D000550
,	O
blurred	O
vision,	O
Conjunctivitis	B-D003231

WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

This	O
Risk	B-D012306

DAYPRO	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
DAYPRO	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
DAYPRO	O
in	O
Patients	B-D010361

If	O
DAYPRO	O
is	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
DAYPRO,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
Inflammation	B-D007249

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
DAYPRO	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
Alanine	B-D000409

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
DAYPRO,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Oxaprozin	B-D000077431

Avoid	O
the	O
use	O
of	O
DAYPRO	O
in	O
Patients	B-D010361

If	O
DAYPRO	O
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
DAYPRO	O
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
DAYPRO	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
DAYPRO	O
in	O
Patients	B-D010361

If	O
DAYPRO	O
is	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Oxaprozin	B-D000077431
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
DAYPRO	O
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Oxaprozin	B-D000077431

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

DAYPRO	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Oxaprozin	B-D000077431
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
DAYPRO,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
DAYPRO	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

NSAIDs,	O
including	O
DAYPRO,	O
may	O
increase	O
the	O
Risk	B-D012306

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
DAYPRO	O
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Photosensitivity	O
Oxaprozin	B-D000077431
has	O
been	O
associated	O
with	O
rash	O
and/or	O
mild	O
photosensitivity	O
in	O
dermatologic	O
TES	B-C004551

An	O
increased	O
Incidence	B-D015994

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(>3	O
%)	O
are:	O
Constipation	B-D003248

Adverse	O
reaction	O
data	O
were	O
derived	O
from	O
Patients	B-D010361

Rates	O
for	O
events	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
these,	O
1721	O
Patients	B-D010361

Incidence	B-D015994
Greater	O
than	O
1%:	O
In	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hematologic	O
system:	O
Anemia	B-D000740

Nervous	B-D009420
System	I-D009420

Skin	B-D012867
and	O
appendages:	O
Pruritus	B-D011537

Special	O
senses:	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566

Incidence	B-D015994
Greater	O
than	O
1%:	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
Clinical	B-D016430
Trial	I-D016430

Body	O
as	O
a	O
whole:	O
Appetite	B-D001066

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hematologic	O
system:	O
aplastic	O
Anemia	B-D000740

Metabolic	O
system:	O
Hyperglycemia	B-D006943

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
:	O
Alopecia	B-D000505

Special	O
senses:	O
blurred	O
vision,	O
Conjunctivitis	B-D003231

Urogenital:	O
Cystitis	B-D003556

6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Body	O
as	O
a	O
whole:	O
Serum	B-D012713
Sickness	I-D012713

Digestive	B-D004064
System	I-D004064

Hematologic	O
system:	O
Agranulocytosis	B-D000380

Skin	B-D012867
:	O
pseudoporphyria,	O
exfoliative	O
Dermatitis	B-D003872

Urogenital:	O
acute	O
interstitial	O
Nephritis	B-D009393

WARNING:	O
Risk	B-D012306

ADMINISTRATION	O
OF	O
Misoprostol	B-D016595

Uterine	B-D014597
Rupture	I-D014597

Diclofenac	B-D004008

Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

In	O
such	O
Patients	B-D010361

●	O
is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures	O

●	O
has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
Misoprostol	B-D016595

●	O
will	O
begin	O
Diclofenac	B-D004008

Cardiovascular	O
Thrombotic	O
Events	O
●	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

●	O
Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
●	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

Diclofenac	B-D004008

ADMINISTRATION	O
OF	O
Misoprostol	B-D016595

Uterine	B-D014597
Rupture	I-D014597

Diclofenac	B-D004008

Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

In	O
such	O
Patients	B-D010361

•	O
is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures	O

•	O
has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
Misoprostol	B-D016595

•	O
will	O
begin	O
Diclofenac	B-D004008

Cardiovascular	O
Thrombotic	O
Events	O
Risk	B-D012306
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

•	O
Di	O
clofenac	O
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964

Monitor	O
Patients	B-D010361

Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
Hematocrit	B-D006400

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

5.3	O
Hepatotoxicity	O
In	O
Clinical	B-D016430
Trial	I-D016430

These	O
increases	O
were	O
generally	O
transient,	O
and	O
enzyme	O
levels	O
returned	O
to	O
within	O
the	O
normal	O
range	O
upon	O
discontinuation	O
of	O
therapy	O
with	O
Diclofenac	B-D004008

The	O
Misoprostol	B-D016595

In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
Diclofenac	B-D004008

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008

The	O
renal	O
effects	O
of	O
Diclofenac	B-D004008

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
/misoprostol	O
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Diclofenac	B-D004008

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

Diclofenac	B-D004008
Sodium	B-D012964

Advise	O
Pregnant	B-D037841
Women	I-D037841

Verify	O
the	O
Pregnancy	B-D011247

Advise	O
Female	B-D005260

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Diclofenac	B-D004008

NSAIDs,	O
including	O
Diclofenac	B-D004008

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
greater	O
than	O
2%	O
from	O
Clinical	B-D016430
Trial	I-D016430

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

Adverse	O
reaction	O
information	O
for	O
Diclofenac	B-D004008

Gastrointestinal	O
GI	O
disorders	O
had	O
the	O
highest	O
reported	O
Incidence	B-D015994

These	O
events	O
were	O
generally	O
minor,	O
but	O
led	O
to	O
discontinuation	O
of	O
therapy	O
in	O
9%	O
of	O
Patients	B-D010361

For	O
GI	O
Ulcer	B-D014456

GI	O
disorder	O
Diclofenac	B-D004008
Sodium	B-D012964
and	O
Misoprostol	B-D016595
Diclofenac	B-D004008
Abdominal	B-D015746
Pain	I-D015746

Diarrhea	B-D003967
and	O
Abdominal	B-D015746
Pain	I-D015746

Rare	O
instances	O
of	O
profound	O
Diarrhea	B-D003967

Patients	B-D010361
with	O
an	O
underlying	O
condition	O
such	O
as	O
inflammatory	O
bowel	O
Disease	B-D004194

The	O
Incidence	B-D015994

Gynecological	O
Gynecological	O
disorders	O
previously	O
reported	O
with	O
Misoprostol	B-D016595

Postmenopausal	O
Vagina	B-D014621

If	O
it	O
occurs,	O
diagnostic	O
Work	B-D014937

Elderly	O
Overall	B-D016424
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
Safety	B-D012449

Other	O
adverse	O
experiences	O
reported	O
occasionally	O
with	O
Diclofenac	B-D004008

Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Digestive:	O
Anorexia	B-D000855

Female	B-D005260
reproductive	O
disorders:	O
Breast	B-D001940

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional:	O
Alanine	B-D000409

Musculoskeletal	B-D009141
System	I-D009141

Psychiatric:	O
Anxiety	B-D001007

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505

Special	O
senses:	O
Taste	B-D013649

Renal	O
and	O
urinary	O
disorders:	O
Dysuria	B-D053159

Vision:	O
Diplopia	B-D004172

6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Body	O
as	O
a	O
whole:	O
Death	B-D003643

Cardiovascular	B-D002319
System	I-D002319

Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Congenital,	O
familial	O
and	O
genetic	O
disorders:	O
birth	O
defects	O

Digestive:	O
Enteritis	B-D004751

Female	B-D005260
reproductive	O
disorders:	O
intermenstrual	O
bleeding,	O
Leukorrhea	B-D007973

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Hypersensitivity	B-D006967
:	O
Angioedema	B-D000799

Liver	B-D008099
and	O
biliary	O
system:	O
abnormal	O
hepatic	O
function,	O
Bilirubin	B-D001663

Male	B-D008297
reproductive	O
disorders:	O
impotence,	O
perineal	O
Pain	B-D010146

Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
Glycosuria	B-D006029

Pregnancy	B-D011247
,	O
puerperium	O
and	O
perinatal	O
conditions:	O
abnormal	O
Uterine	B-D014590
Contraction	I-D014590

Psychiatric:	O
Confusion	B-D003221

Reproductive	O
system	O
and	O
Breast	B-D001940

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages:	O
acne,	O
bruising,	O
Erythema	B-D004892
Multiforme	I-D004892

Special	O
senses:	O
Hearing	B-D006309

Renal	O
and	O
urinary	O
disorders:	O
Cystitis	B-D003556

Vision:	O
Amblyopia	B-D000550

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
•	O
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
•	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
Cardiovascular	O
Risk	B-D012306
•	O
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
•	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5.WARNINGS	O
AND	O
PRECAUTIONS	O
•Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

•Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
Risk	B-D012306

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

•Elevated	O
Liver	B-D008099

Discontinue	O
use	O
of	O
CELEBREX	O
immediately	O
if	O
abnormal	O
Liver	B-D008099

•New	O
onset	O
or	O
worsening	O
of	O
Hypertension	B-D006973

Blood	B-D001794
Pressure	I-D001794

•Fluid	O
retention	O
and	O
Edema	B-D004487

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

•Renal	O
papillary	O
Necrosis	B-D009336

Use	O
CELEBREX	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
Heart	B-D006333
Failure	I-D006333

•Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
CELEBREX	O
in	O
Patients	B-D010361

•Serious	O
Skin	B-D012867

Discontinue	O
CELEBREX	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
Skin	B-D012867

5.1Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2Hypertension	O
As	O
with	O
all	O
NSAIDs,	O
CELEBREX	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
CELEBREX,	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
CELEBREX,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
Ulcer	B-D014456

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

Celebrex	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.5Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
CELEBREX	O
in	O
Patients	B-D010361

Therefore,	O
treatment	O
with	O
CELEBREX	O
is	O
not	O
recommended	O
in	O
these	O
Patients	B-D010361

If	O
CELEBREX	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

CELEBREX	O
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8Skin	O
Reactions	O
CELEBREX	O
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9Pregnancy	O
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
Treatment	O
CELEBREX	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
CELEBREX	O
should	O
have	O
their	O
hemoglobin	O
or	O
Hematocrit	B-D006400

CELEBREX	O
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
CELEBREX	O
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
Patients	B-D010361

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
CELEBREX	O
in	O
reducing	O
Inflammation	B-D007249

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
CELEBREX	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
Risk	B-D012306

6.ADVERSE	O
REACTIONS	O
Of	O
the	O
CELEBREX-treated	O
Patients	B-D010361

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
CELEBREX	O
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
CBX	O
=	O
CELEBREX	O
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
CELEBREX	O
treatment	O
groups	O
were	O
Dyspepsia	B-D004415

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
CELEBREX,	O
Diclofenac	B-D004008

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
CELEBREX	O
were	O
studied	O
in	O
primary	O
Dysmenorrhea	B-D004412

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
:	O
Exposure	O
to	O
CELEBREX	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

This	O
Risk	B-D012306

[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
Risk	B-D012306

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

A	O
Randomized	B-D016449
Controlled	I-D016449
Trial	I-D016449

Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
Risk	B-D012306

Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
Naproxen	B-D009288

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Celecoxib	B-D000068579

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

See	O
Clinical	O
Studies	O
(14.6,	O
14.7)	O
for	O
additional	O
Blood	B-D001794
Pressure	I-D001794

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.7)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

The	O
renal	O
effects	O
of	O
Celecoxib	B-D000068579

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
Sulfonamides	B-D013449

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Celecoxib	B-D000068579

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
Patients	B-D010361

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Celecoxib	B-D000068579

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
Risk	B-D012306

6	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Aurobindo	O
Pharma	O
USA,	O
Inc	O

at	O
1-866-850-2876	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
Diarrhea	B-D003967
Dyspepsia	B-D004415
Flatulence	B-D005414
Nausea	B-D009325
4.1%5.6%	O
8.8%	O
2.2%	O
3.5%	O
2.8%	O
3.8%	O
6.2%	O
1%	O
4.2%	O
7.7%	O
5.3%	O
12.2%	O
3.6%6%	O
9%9.3%10.9%4.1%3.4%	O
9%5.8%12.8%3.5%6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
Peripheral	O
Edema	B-D004487
Injury-Accidental	O
2.8%2.1%2.9%	O
3.6%1.1%2.3%	O
2.2%2.1%3%	O
2.6%1%2.6%	O
0.9%3.5%3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1%	O
to	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Assess	O
each	O
patient’s	O
Risk	B-D012306

Opioid	O
Analgesic	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS):	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
Analgesics	B-D000700

Under	O
the	O
requirements	O
of	O
the	O
REMS,	O
drug	O
companies	O
with	O
approved	O
opioid	O
analgesic	O
products	O
must	O
make	O
REMS-compliant	O
Education	B-D004493

Health	B-D006262
care	O
providers	O
are	O
strongly	O
encouraged	O
to	O
complete	O
a	O
REMS-compliant	O
Education	B-D004493

Monitor	O
for	O
respiratory	O
Depression	B-D003863
)	O

Accidental	O
Ingestion	O
Accidental	O
ingestion	O
of	O
even	O
one	O
dose	O
of	O
Hydrocodone	B-D006853

Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Prolonged	O
use	O
of	O
Hydrocodone	B-D006853

If	O
opioid	O
use	O
is	O
required	O
for	O
a	O
prolonged	O
period	O
in	O
a	O
pregnant	O
woman,	O
advise	O
the	O
patient	O
of	O
the	O
Risk	B-D012306

Cytochrome	O
P450	O
3A4	O
Interaction	O
The	O
concomitant	O
use	O
of	O
Hydrocodone	B-D006853

In	O
addition,	O
discontinuation	O
of	O
a	O
concomitantly	O
used	O
cytochrome	O
P450	O
3A4	O
inducer	O
may	O
result	O
in	O
an	O
increase	O
in	O
Hydrocodone	B-D006853

Monitor	O
Patients	B-D010361

Risk	B-D012306
s	O
From	O
Concomitant	O
Use	O
With	O
Benzodiazepines	B-D001569
Or	O
Other	O
CNS	O
Depressants	O
Concomitant	O
use	O
of	O
opioids	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants,	O
PRECAUTIONS:	O
Drug	B-D004347
Interactions	I-D004347
)	O

Reserve	O
concomitant	O
prescribing	O
of	O
Hydrocodone	B-D006853

L	O
imit	O
dosages	O
and	O
durations	O
to	O
the	O
minimum	O
required	O

F	O
ollow	O
Patients	B-D010361

Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Hydrocodone	B-D006853
bitartrate	O
and	O
Ibuprofen	B-D007052

G	O
astrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
described	O
below	O
and	O
elsewhere	O
in	O
the	O
labeling	O
including	O
the	O
WARNINGS	O
section	O

Addiction,	O
Abuse,	O
and	O
Misuse	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Interactions	O
with	O
Cytochrome	O
P450	O
3A4	O
Inhibitors	O
and	O
Inducers	O
Interactions	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants	O
Adrenal	B-D000309
Insufficiency	I-D000309
Severe	O
Hypotension	B-D007022
Seizures	B-D012640
Withdrawal	O
Cardiovascular	O
Thrombotic	O
Events	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Hepatotoxicity	O
Hypertension	B-D006973
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Anaphylactic	O
Reactions	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
Serious	O
Skin	B-D012867
Reactions	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Hematologic	O
Toxicity	O
Aseptic	O
Meningitis	B-D008581
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

Hydrocodone	B-D006853
bitartrate	O
and	O
Ibuprofen	B-D007052

Adverse	O
event	O
rates	O
generally	O
increased	O
with	O
increasing	O
daily	O
dose	O

The	O
event	O
rates	O
reported	O
below	O
are	O
from	O
approximately	O
150	O
Patients	B-D010361

The	O
Overall	B-D016424

The	O
following	O
lists	O
adverse	O
events	O
that	O
occurred	O
with	O
an	O
Incidence	B-D015994

To	O
distinguish	O
different	O
rates	O
of	O
occurrence	O
in	O
clinical	O
studies,	O
the	O
adverse	O
events	O
are	O
listed	O
as	O
follows:	O
name	O
of	O
adverse	O
event	O
=	O
less	O
than	O
3%	O
adverse	O
events	O
marked	O
with	O
an	O
asterisk	O
*	O
=	O
3%	O
to	O
9%	O
adverse	O
event	O
rates	O
over	O
9%	O
are	O
in	O
parentheses	O

B	O
ody	O
as	O
a	O
Whole	O
Abdominal	B-D015746
Pain	I-D015746

Cardiovascular	O
Palpitations;	O
Vasodilation	B-D014664
	O

Central	B-D002490
Nervous	I-D002490
System	I-D002490
Anxiety	B-D001007
*;	O
Confusion	B-D003221
;	O
Dizziness	B-D004244
(14%);	O
Hypertonia;	O
Insomnia*;	O
Nervousness*;	O
Paresthesia	B-D010292
;	O
Somnolence	O
(22%);	O
Thinking	B-D013850
abnormalities	O

Digestive	O
Anorexia	B-D000855
;	O
Constipation	B-D003248
(22%);	O
Diarrhea	B-D003967
*;	O
Dry	O
Mouth	B-D009055
Ulcer	B-D014456

Metabolic	O
and	O
Nutritional	O
Disorders	O
Edema	B-D004487
*	O

Respiratory	O
Dyspnea	B-D004417
;	O
Hiccup	B-D006606
s;	O
Pharyngitis	B-D010612
;	O
Rhinitis	B-D012220
	O

Skin	B-D012867
and	O
Appendages	O
Pruritus	B-D011537
*;	O
Sweating	B-D013546
*	O

Special	O
Senses	O
Tinnitus	B-D014012
	O

Urogenital	O
Urinary	O
frequency	O

Incidence	B-D015994
less	O
than	O
1%	O
Body	O
as	O
a	O
Whole	O
Allergic	O
reaction	O

Cardiovascular	O
Arrhythmia;	O
Hypotension	B-D007022
;	O
Tachycardia	B-D013610
	O

C	O
e	O
ntral	O
Nervous	B-D009420
System	I-D009420
Agitation;	O
Abnormal	O
Dreams	B-D004325

Digestive	O
Chalky	O
stool;	O
"Clenching	O
teeth";	O
Dysphagia;	O
Esophageal	O
Spasm	B-D013035

Me	O
tabolic	O
and	O
Nutritional	O
Weight	O
decrease	O

M	O
usculoskeletal	O
Arthralgia	B-D018771
;	O
Myalgia	B-D063806
	O

Respiratory	O
Asthma	B-D001249
;	O
Bronchitis	B-D001991
;	O
Hoarseness	B-D006685
;	O
Increased	O
Cough	B-D003371

Skin	B-D012867
and	O
Appendages	O
Rash;	O
Urticaria	B-D014581
	O

Special	O
Senses	O
Altered	O
vision;	O
Bad	O
Taste	B-D013649

Urogenital	O
Cystitis	B-D003556
;	O
Glycosuria	B-D006029
;	O
Impotence;	O
Urinary	B-D014549
Incontinence	I-D014549

Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

S	O
er	O
otonin	O
Syndrome	B-D013577

Adrenal	B-D000309
Insufficiency	I-D000309

Anaphylaxis	B-D000707
:	O
Anaphylaxis	B-D000707
has	O
been	O
reported	O
with	O
ingredients	O
contained	O
in	O
Hydrocodone	B-D006853

Androgen	O
deficiency:	O
Cases	O
of	O
androgen	O
deficiency	O
have	O
occurred	O
with	O
chronic	O
use	O
of	O
opioids	O
(see	O
CLINICAL	O
Pharmacology	B-D010600

Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

•	O
Diflunisal	B-D004061
Tablets	B-D013607

Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
adverse	O
reactions	O
observed	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Listed	O
below	O
are	O
the	O
adverse	O
reactions	O
reported	O
in	O
the	O
1,314	O
of	O
these	O
Patients	B-D010361

Five	O
hundred	O
thirteen	O
Patients	B-D010361

In	O
general,	O
the	O
adverse	O
reactions	O
listed	O
below	O
were	O
2	O
to	O
14	O
Time	B-D013995

Incidence	B-D015994
Greater	O
Than	O
1%	O
Gastrointestinal	O
The	O
most	O
frequent	O
types	O
of	O
adverse	O
reactions	O
occurring	O
with	O
Diflunisal	B-D004061

Psychiatric	O
Somnolence,	O
insomnia	O

Central	B-D002490
Nervous	I-D002490
System	I-D002490
Dizziness	B-D004244
	O

Special	O
Senses	O
Tinnitus	B-D014012
	O

Dermatologic	O
Rash*	O

Miscellaneous	O
Headache	B-D006261
*,	O
Fatigue	B-D005221

*	O
Incidence	B-D015994
between	O
3%	O
and	O
9%	O

Those	O
reactions	O
occurring	O
in	O
1%	O
to	O
3%	O
are	O
not	O
marked	O
with	O
an	O
asterisk	O

Incidence	B-D015994
Less	O
Than	O
1	O
in	O
100	O
The	O
following	O
adverse	O
reactions,	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100,	O
were	O
reported	O
in	O
Clinical	B-D016430
Trial	I-D016430

The	O
Probability	B-D011336

Dermatologic	O
Erythema	B-D004892
Multiforme	I-D004892

Gastrointestinal	O
Peptic	B-D010437
Ulcer	I-D010437

Liver	B-D008099
function	O
abnormalities;	O
Jaundice	B-D007565

Hematologic	O
Thrombocytopenia	B-D013921
;	O
Agranulocytosis	B-D000380

Genitourinary	O
Dysuria	B-D053159
;	O
renal	O
impairment,	O
including	O
renal	O
failure;	O
interstitial	O
Nephritis	B-D009393

Psychiatric	O
Nervousness,	O
Depression	B-D003863

Central	B-D002490
Nervous	I-D002490
System	I-D002490
Vertigo	B-D014717
;	O
Light	B-D008027

Special	O
Senses	O
Transient	O
visual	O
disturbances	O
including	O
blurred	O
vision	O

Hypersensitivity	B-D006967
Reactions	O
Acute	O
anaphylactic	O
reaction	O
with	O
bronchospasm;	O
Angioedema	B-D000799

Hypersensitivity	B-D006967
Vasculitis	B-D014657

Hypersensitivity	B-D006967
Syndrome	B-D013577

Miscellaneous	O
Asthenia	B-D001247
,	O
Edema	B-D004487

Causal	O
Relationship	O
Unknown	O
Other	O
reactions	O
have	O
been	O
reported	O
in	O
Clinical	B-D016430
Trial	I-D016430

However,	O
in	O
these	O
rarely	O
reported	O
events,	O
that	O
possibility	O
cannot	O
be	O
excluded	O

Therefore,	O
these	O
Observation	B-D019370

Respiratory	O
Dyspnea	B-D004417
	O

Cardiovascular	O
Palpitation,	O
Syncope	B-D013575

Musculoskeletal	O
Muscle	B-D009120
Cramp	I-D009120

Genitourinary	O
Nephrotic	B-D009404
Syndrome	I-D009404

Special	O
Senses	O
Hearing	B-D034381
Loss	I-D034381

Miscellaneous	O
Chest	B-D002637
Pain	I-D002637

A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
Fasciitis	B-D005208

Potential	O
Adverse	O
Effects	O
In	O
addition,	O
a	O
variety	O
of	O
adverse	O
effects	O
not	O
observed	O
with	O
Diflunisal	B-D004061

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Rising	O
Pharmaceuticals	O
at	O
1-866-562-4597	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
for	O
Ketorolac	B-D020911
Tromethamine	I-D020911

The	O
most	O
frequent	O
adverse	O
events	O
reported	O
with	O
the	O
use	O
of	O
Ketorolac	B-D020911
Tromethamine	I-D020911

These	O
events	O
were	O
reported	O
by	O
20%	O
-	O
40%	O
of	O
Patients	B-D010361

Other	O
adverse	O
events	O
occurring	O
approximately	O
1%	O
-	O
10%	O
of	O
the	O
Time	B-D013995

Clinical	O
Practice	O
The	O
following	O
events	O
have	O
been	O
Id	B-D007060

Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

The	O
events,	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
Ketorolac	B-D020911
Tromethamine	I-D020911

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
in	O
Patients	B-D010361

If	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
are	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Naproxen	B-D009288

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Naproxen	B-D009288

Avoid	O
the	O
use	O
of	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
in	O
Patients	B-D010361

If	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
are	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
in	O
Patients	B-D010361

If	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
are	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Naproxen	B-D009288
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
are	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Naproxen	B-D009288

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Naproxen	B-D009288
Sodium	B-D012964

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Naproxen	B-D009288
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

NSAIDs,	O
including	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
,	O
may	O
increase	O
the	O
Risk	B-D012306

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
The	O
most	O
frequent	O
adverse	O
events	O
were	O
Headache	B-D006261

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Alvogen,	O
Inc	O

at	O
1-866-770-3024	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

As	O
with	O
all	O
drugs	O
in	O
this	O
class,	O
the	O
frequency	O
and	O
severity	O
of	O
adverse	O
events	O
depends	O
on	O
several	O
factors:	O
the	O
dose	O
of	O
the	O
drug	O
and	O
duration	O
of	O
treatment;	O
the	O
age,	O
the	O
Sex	B-D012723

The	O
following	O
adverse	O
reactions	O
are	O
divided	O
into	O
three	O
parts	O
based	O
on	O
frequency	O
and	O
whether	O
or	O
not	O
the	O
possibility	O
exists	O
of	O
a	O
causal	O
relationship	O
between	O
drug	O
usage	O
and	O
these	O
adverse	O
events	O

In	O
those	O
reactions	O
listed	O
as	O
“Probable	O
Causal	O
Relationship”	O
there	O
is	O
at	O
least	O
one	O
case	O
for	O
each	O
adverse	O
reaction	O
where	O
there	O
is	O
evidence	O
to	O
suggest	O
that	O
there	O
is	O
a	O
causal	O
relationship	O
between	O
drug	O
usage	O
and	O
the	O
reported	O
event	O

The	O
adverse	O
reactions	O
reported	O
were	O
based	O
on	O
the	O
results	O
from	O
two	O
double-blind	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
total	O
of	O
542	O
Patients	B-D010361

Of	O
these	O
542	O
Patients	B-D010361

Adverse	O
reactions	O
reported	O
by	O
Patients	B-D010361

Those	O
adverse	O
reactions	O
observed	O
with	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
are	O
italicized	O

The	O
most	O
frequent	O
adverse	O
events	O
from	O
the	O
double-blind	O
and	O
open-label	O
Clinical	B-D016430
Trial	I-D016430

The	O
Incidence	B-D015994

Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
Patients	B-D010361

Incidence	B-D015994
greater	O
than	O
1%	O
(probable	O
causal	O
relationship)	O
Body	O
as	O
a	O
Whole—Pain	O
(back)*,	O
Pain	B-D010146

Gastrointestinal—Nausea*,	O
Diarrhea	B-D003967

Hematologic—Anemia,	O
Ecchymosis	B-D004438

Respiratory—Pharyngitis*,	O
Rhinitis	B-D012220

Renal—Urinary	O
tract	O
infection*,	O
Cystitis	B-D003556

Dermatologic—Skin	O
rash*,	O
Skin	B-D012867

Metabolic	O
and	O
Nutrition—Peripheral	O
Edema	B-D004487

Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Dizziness,	O
Paresthesia	B-D010292

Cardiovascular—Hypertension,	O
Edema	B-D004487

Musculoskeletal—Cramps	O
(leg),	O
Myalgia	B-D063806

Special	O
Senses—Tinnitus*,	O
Hearing	B-D006309

General—Thirst	O

Incidence	B-D015994
less	O
than	O
1%	O
(probable	O
causal	O
relationship)	O
Body	O
as	O
a	O
Whole—Abscess,	O
monilia,	O
Neck	B-D009333

Gastrointestinal—Anorexia,	O
Cholecystitis	B-D002764

Renal—Dysmenorrhea,	O
Dysuria	B-D053159

Hematologic—Leukopenia,	O
Bleeding	B-D001760
Time	I-D001760

Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Depression,	O
Anxiety	B-D001007

Dermatologic:	O
Angiodermatitis,	O
Herpes	B-D006561
Simplex	I-D006561

Special	O
Senses—Amblyopia,	O
Scleritis	B-D015423

Cardiovascular—Angina	O
pectoris,	O
Coronary	B-D003324
Artery	I-D003324
Disease	I-D003324

Respiratory—Asthma,	O
Dyspnea	B-D004417

Musculoskeletal—Myasthenia,	O
bone	O
disorder,	O
spontaneous	O
bone	O
fracture,	O
fibrotendinitis,	O
bone	O
Pain	B-D010146

Metabolic	O
and	O
Nutrition—Creatinine	O
increase,	O
glucosuria,	O
hypercholesteremia,	O
Albuminuria	B-D000419

General—Anaphylactoid	O
reactions,	O
angioneurotic	O
Edema	B-D004487

Incidence	B-D015994
less	O
than	O
1%	O
(causal	O
relationship	O
unknown)	O
Other	O
adverse	O
reactions	O
listed	O
in	O
the	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
are	O
shown	O
in	O
italics	O

These	O
Observation	B-D019370

Hematologic—Aplastic	O
Anemia,	B-D000743
Hemolytic	I-D000743

Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Aseptic	O
Meningitis	B-D008581

Dermatologic—Epidermal	O
necrolysis,	O
Erythema	B-D004892
Multiforme	I-D004892

Gastrointestinal—Non-peptic	O
GI	O
Ulcer	B-D014456

Cardiovascular—Vasculitis	O

Cardiovascular	O
Thrombotic	O
Events	O
•Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

•Diflunisal	O
Tablets	B-D013607

Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
adverse	O
reactions	O
observed	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Listed	O
below	O
are	O
the	O
adverse	O
reactions	O
reported	O
in	O
the	O
1,314	O
of	O
these	O
Patients	B-D010361

Five	O
hundred	O
thirteen	O
Patients	B-D010361

In	O
general,	O
the	O
adverse	O
reactions	O
listed	O
below	O
were	O
2	O
to	O
14	O
Time	B-D013995

Incidence	B-D015994
Greater	O
Than	O
1%	O
Gastrointestinal	O
The	O
most	O
frequent	O
types	O
of	O
adverse	O
reactions	O
occurring	O
with	O
Diflunisal	B-D004061

Psychiatric	O
Somnolence,	O
insomnia	O

Central	B-D002490
Nervous	I-D002490
System	I-D002490
Dizziness	B-D004244
	O

Special	O
Senses	O
Tinnitus	B-D014012
	O

Dermatologic	O
Rash*	O

Miscellaneous	O
Headache	B-D006261
*,	O
Fatigue	B-D005221

*	O
Incidence	B-D015994
between	O
3%	O
and	O
9%	O

Those	O
reactions	O
occurring	O
in	O
1%	O
to	O
3%	O
are	O
not	O
marked	O
with	O
an	O
asterisk	O

Incidence	B-D015994
Less	O
Than	O
1	O
in	O
100	O
The	O
following	O
adverse	O
reactions,	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100,	O
were	O
reported	O
in	O
Clinical	B-D016430
Trial	I-D016430

The	O
Probability	B-D011336

Dermatologic	O
Erythema	B-D004892
Multiforme	I-D004892

Gastrointestinal	O
Peptic	B-D010437
Ulcer	I-D010437

Liver	B-D008099
function	O
abnormalities;	O
Jaundice	B-D007565

Hematologic	O
Thrombocytopenia	B-D013921
;	O
Agranulocytosis	B-D000380

Genitourinary	O
Dysuria	B-D053159
;	O
renal	O
impairment,	O
including	O
renal	O
failure;	O
interstitial	O
Nephritis	B-D009393

Psychiatric	O
Nervousness,	O
Depression	B-D003863

Central	B-D002490
Nervous	I-D002490
System	I-D002490
Vertigo	B-D014717
;	O
Light	B-D008027

Special	O
Senses	O
Transient	O
visual	O
disturbances	O
including	O
blurred	O
vision	O

Hypersensitivity	B-D006967
Reactions	O
Acute	O
anaphylactic	O
reaction	O
with	O
bronchospasm;	O
Angioedema	B-D000799

Hypersensitivity	B-D006967
Vasculitis	B-D014657

Hypersensitivity	B-D006967
Syndrome	B-D013577

Miscellaneous	O
Asthenia	B-D001247
,	O
Edema	B-D004487

Causal	O
Relationship	O
Unknown	O
Other	O
reactions	O
have	O
been	O
reported	O
in	O
Clinical	B-D016430
Trial	I-D016430

However,	O
in	O
these	O
rarely	O
reported	O
events,	O
that	O
possibility	O
cannot	O
be	O
excluded	O

Therefore,	O
these	O
Observation	B-D019370

Respiratory	O
Dyspnea	B-D004417
	O

Cardiovascular	O
Palpitation,	O
Syncope	B-D013575

Musculoskeletal	O
Muscle	B-D009120
Cramp	I-D009120

Genitourinary	O
Nephrotic	B-D009404
Syndrome	I-D009404

Special	O
Senses	O
Hearing	B-D034381
Loss	I-D034381

Miscellaneous	O
Chest	B-D002637
Pain	I-D002637

A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
Fasciitis	B-D005208

Potential	O
Adverse	O
Effects	O
In	O
addition,	O
a	O
variety	O
of	O
adverse	O
effects	O
not	O
observed	O
with	O
Diflunisal	B-D004061

Cardiovascular	O
Thrombotic	O
Events	O
WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

Etodolac	B-D017308
extended-release	O
Tablets	B-D013607

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
A	O
total	O
of	O
1552	O
Patients	B-D010361

In	O
the	O
tabulations	O
below,	O
adverse	O
event	O
rates	O
are	O
generally	O
categorized	O
based	O
on	O
the	O
Incidence	B-D015994

As	O
with	O
other	O
NSAIDs,	O
the	O
cumulative	O
adverse	O
event	O
rates	O
may	O
increase	O
significantly	O
over	O
Time	B-D013995

In	O
Patients	B-D010361

Anemia	B-D000740
Asthenia	B-D001247

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDS)	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1)	O
Diclofenac	B-D004008
Sodium	B-D012964

(4)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Use	O
the	O
lowest	O
effective	O
dose	O
of	O
Diclofenac	B-D004008

(5.1)	O
NSAIDs	O
can	O
cause	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
Inflammation	B-D007249

Prescribe	O
Diclofenac	B-D004008

(5.2)	O
Elevation	O
of	O
one	O
or	O
more	O
Liver	B-D008099

Discontinue	O
Diclofenac	B-D004008

(5.3)	O
Hypertension	B-D006973
can	O
occur	O
with	O
NSAID	O
treatment	O

Monitor	O
Blood	B-D001794
Pressure	I-D001794

(5.4)	O
Use	O
Diclofenac	B-D004008

(5.5)	O
Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Use	O
Diclofenac	B-D004008

(5.6)	O
Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

(5.7)	O
NSAIDs	O
can	O
cause	O
serious	O
Skin	B-D012867

(5.8)	O
Not	O
for	O
use	O
during	O
Pregnancy	B-D011247

(5.9)	O
Do	O
not	O
administer	O
to	O
Patients	B-D010361

(5.10)	O
Avoid	O
exposure	O
of	O
treated	O
Knee	B-D007717

(5.11)	O
Avoid	O
contact	O
of	O
Diclofenac	B-D004008

(5.12)	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs	O

(5.13)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

All	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Inform	O
Patients	B-D010361

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Prescribe	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

For	O
high-risk	O
Patients	B-D010361

5.3	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
(less	O
than	O
3	O
Time	B-D013995

Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
Liver	B-D008099

In	O
Clinical	B-D016430
Trial	I-D016430

In	O
an	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
Patients	B-D010361

In	O
this	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
NSAID	O
therapy	O

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
sever	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Eosinophilia	B-D004802

To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
inform	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
Diclofenac	B-D004008

Caution	O
Patients	B-D010361

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008

Use	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Patients	B-D010361
taking	O
ACE-inhibitors,	O
Thiazides	B-D049971

5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
Diclofenac	B-D004008

5.6	O
Renal	O
Effects	O
Use	O
caution	O
when	O
initiating	O
treatment	O
with	O
Diclofenac	B-D004008

Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008

Therefore,	O
treatment	O
with	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

Do	O
not	O
prescribe	O
Diclofenac	B-D004008

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Seek	O
emergency	O
help	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Do	O
not	O
apply	O
Diclofenac	B-D004008

NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

5.9	O
Pregnancy	B-D011247
Diclofenac	B-D004008
Sodium	B-D012964

5.10	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross-reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.11	O
Sun	O
Exposure	O
Instruct	O
Patients	B-D010361

The	O
potential	O
effects	O
of	O
Diclofenac	B-D004008

5.12	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
Diclofenac	B-D004008

Advise	O
Patients	B-D010361

5.13	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
Diclofenac	B-D004008

Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
Diclofenac	B-D004008

5.14	O
Corticosteroid	O
Treatment	O
Diclofenac	B-D004008
Sodium	B-D012964

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

For	O
Patients	B-D010361

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.16	O
Hematological	O
Effects	O
The	O
effects	O
of	O
Diclofenac	B-D004008

There	O
was	O
no	O
significant	O
change	O
in	O
Platelet	B-D010974
Aggregation	I-D010974

Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
Blood	B-D001769

Check	O
hemoglobin	O
or	O
Hematocrit	B-D006400

NSAIDs	O
inhibit	O
Platelet	B-D010974
Aggregation	I-D010974

Unlike	O
Aspirin	B-D001241

Carefully	O
monitor	O
Patients	B-D010361

5.17	O
Monitoring	O
Because	O
serious	O
GI	O
tract	O
Ulcer	B-D014456

Check	O
CBC	O
and	O
a	O
Chemistry	B-D002621

Discontinue	O
Diclofenac	B-D004008

6	O

ADVERSE	O
REACTIONS	O
The	O
most	O
common	O
adverse	O
events	O
with	O
Diclofenac	B-D004008

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
IGI	O
Laboratories	B-D007753
,	O
Inc	O

at	O
1-856-697-1441,	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
Diclofenac	B-D004008

The	O
Population	B-D011153

The	O
most	O
common	O
adverse	O
events	O
with	O
Diclofenac	B-D004008

These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies	O

Application	O
site	O
reactions:	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment	O
related	O
adverse	O
events	O
in	O
Patients	B-D010361

Application	O
site	O
reactions	O
were	O
Character	B-D002605

The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
Skin	B-D012867

In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
Dermatitis	B-D003872

In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
Safety	B-D012449

Adverse	O
events	O
common	O
to	O
the	O
NSAID	O
class:	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
Diclofenac	B-D004008

The	O
combination	O
of	O
Diclofenac	B-D004008

less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
Creatinine	B-D003404

7%),	O
Urea	B-D014508

12%),	O
and	O
hemoglobin	O
(13%	O
vs	O

9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
Liver	B-D008099

Table	O
1:	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
Patients	B-D010361

Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
≥1%	O
of	O
Patients	B-D010361

Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
SolutionN=911	O
Topical	O
PlaceboN=332	O
Adverse	O
ReactionPreferred	O
Term	O
according	O
to	O
COSTART	O
N(%)	O
N(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non	O
–	O
U.S	O

postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
Diclofenac	B-D004008

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Body	O
as	O
a	O
Whole:	O
Abdominal	B-D015746
Pain	I-D015746

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

ADVERSE	O
REACTIONS	O
Of	O
the	O
423	O
Patients	B-D010361

Eighty-seven	O
percent	O
(87%)	O
of	O
the	O
Diclofenac	B-D004008

The	O
majority	O
of	O
these	O
reactions	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
resolved	O
upon	O
discontinuation	O
of	O
therapy	O

Of	O
the	O
211	O
Patients	B-D010361

Application	O
site	O
reactions	O
(ASRs)	O
were	O
the	O
most	O
frequent	O
AEs	O
in	O
both	O
Diclofenac	B-D004008

Of	O
note,	O
four	O
reactions,	O
contact	O
Dermatitis	B-D003872

Eighteen	O
percent	O
of	O
Diclofenac	B-D004008

These	O
discontinuations	O
were	O
mainly	O
due	O
to	O
Skin	B-D012867

Table	O
1	O
below	O
presents	O
the	O
AEs	O
reported	O
at	O
an	O
Incidence	B-D015994

Table	O
1	O

Adverse	O
Events	O
Reported	O
(>1%	O
in	O
Any	O
Treatment	O
Group)	O
During	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%	O
Phase	O
3	O
Clinical	B-D016430
Trial	I-D016430
s	O
Incidence	B-D015994
s	O
for	O
60-Day	O
and	O
90-Day	O
Treatments	O
60-day	O
Treatment	O
90-day	O
Treatment	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%	O
(%)	O
N=48	O
Gel	O
Vehicle	O
(%)	O
N=49	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%	O
(%)	O
N=114	O
Gel	O
Vehicle	O
(%)	O
N=114	O
BODY	O
AS	O
A	O
WHOLE	O
21	O
20	O
20	O
18	O
Abdominal	B-D015746
Pain	I-D015746
2	O
0	O
1	O
0	O
Accidental	O
Injury	O
0	O
0	O
4	O
2	O
Allergic	O
Reaction	O
0	O
0	O
1	O
3	O
Asthenia	B-D001247
0	O
0	O
2	O
0	O
Back	B-D001416
Pain	I-D001416
4	O
0	O
2	O
2	O
Chest	B-D002637
Pain	I-D002637
2	O
0	O
1	O
0	O
Chills	B-D023341
0	O
2	O
0	O
0	O
Flu	O
Syndrome	B-D013577
10	O
6	O
1	O
4	O
Headache	B-D006261
0	O
6	O
7	O
6	O
Infection	O
4	O
6	O
4	O
5	O
Neck	B-D019547
Pain	I-D019547
0	O
0	O
2	O
0	O
Pain	B-D010146
2	O
0	O
2	O
2	O
Cardiovascular	B-D002319
System	I-D002319

Adverse	O
Reactions	O
Reported	O
for	O
Oral	O
Diclofenac	B-D004008
Dosage	O
Form	B-D020478
(not	O
topical	O
Diclofenac	B-D004008

Body	O
as	O
a	O
Whole:	O
Abdominal	B-D015746
Pain	I-D015746

Cardiovascular:	O
Hypertension	B-D006973

Digestive:	O
Diarrhea	B-D003967

Hemic	O
and	O
Lymph	B-D008196
atic:	O
hemoglobin	B-C032001
D	I-C032001

Metabolic	O
and	O
Nutritional	O
Disorders:	O
Azotemia	B-D053099

Nervous	B-D009420
System	I-D009420
:	O
Dizziness	B-D004244

Respiratory:	O
Epistaxis	B-D004844

Skin	B-D012867
and	O
Appendages:	O
rash*,	O
Pruritus	B-D011537

Special	O
Senses:	O
Tinnitus	B-D014012

Urogenital:	O
Nephrotic	B-D009404
Syndrome	I-D009404

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
adverse	O
reactions	O
are	O
drowsiness	O
and	O
Dizziness	B-D004244

Less	O
frequent	O
adverse	O
reactions	O
are	O
Light	B-D008027

A	O
single	O
Incidence	B-D015994

Several	O
cases	O
of	O
dermatological	O
reactions	O
including	O
toxic	O
epidermal	O
necrolysis	O
and	O
Erythema	B-D004892
Multiforme	I-D004892

Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS	O
.)	O
Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

Boxed	O
Warning	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

Warnings	O
and	O
Precautions	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Diclofenac	B-D004008

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
Diclofenac	B-D004008

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edem	O
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008

The	O
renal	O
effects	O
of	O
Diclofenac	B-D004008

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactoid	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Diclofenac	B-D004008

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Diclofenac	B-D004008

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Diclofenac	B-D004008

NSAIDs,	O
including	O
Diclofenac	B-D004008

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
Art	B-D001154

The	O
potential	O
effects	O
of	O
Diclofenac	B-D004008

5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
Diclofenac	B-D004008

Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
Eye	B-D005123

5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
and	O
topical	O
NSAIDs	O
may	O
result	O
in	O
a	O
higher	O
rate	O
of	O
Hemorrhage	B-D006470

Do	O
not	O
use	O
combination	O
therapy	O
with	O
Diclofenac	B-D004008

Adverse	O
Reactions	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)]	O
Hepatotoxicity	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.11)]	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

During	O
clinical	O
development,	O
913	O
Patients	B-D010361

Of	O
these,	O
513	O
Patients	B-D010361

Additionally,	O
583	O
Patients	B-D010361

Of	O
these,	O
355	O
Patients	B-D010361

Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
Safety	B-D012449

Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
Patients	B-D010361

These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
1%	O
of	O
treated	O
Patients	B-D010361

Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported	O

Application	O
site	O
Dermatitis	B-D003872

Adverse	O
Reaction†	O
Diclofenac	B-D004008
Sodium	B-D012964

62	O
(7)	O
19	O
(2)	O
Application	O
site	O
Dermatitis	B-D003872

Application	O
site	O
reactions,	O
including	O
application	O
site	O
Dermatitis	B-D003872

Long-Term	O
Open-Label	O
Safety	B-D012449
Trial:	O
In	O
the	O
open-label,	O
long-term	O
Safety	B-D012449

In	O
this	O
study,	O
where	O
Patients	B-D010361

Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
Patients	B-D010361

The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
Dermatitis	B-D003872

Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS	O
.)	O
Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

Oral	O
Ketorolac	B-D020911
Tromethamine	I-D020911

The	O
total	O
combined	O
duration	O
of	O
use	O
of	O
oral	O
Ketorolac	B-D020911
Tromethamine	I-D020911

Ketorolac	B-D020911
Tromethamine	I-D020911

Increasing	O
the	O
dose	O
of	O
Ketorolac	B-D020911
Tromethamine	I-D020911

GASTROINTESTINAL	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Therefore,	O
Ketorolac	B-D020911
Tromethamine	I-D020911

Elderly	O
Patients	B-D010361

CARDIOVASCULAR	O
THROMBOTIC	O
EVENTS	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Ketorolac	B-D020911
Tromethamine	I-D020911

RENAL	O
Risk	B-D012306

Risk	B-D012306

Ketorolac	B-D020911
Tromethamine	I-D020911

Hypersensitivity	B-D006967
reactions,	O
ranging	O
from	O
bronchospasm	O
to	O
anaphylactic	O
Shock	B-D012769

Ketorolac	B-D020911
Tromethamine	I-D020911

INTRATHECAL	O
OR	O
EPIDURAL	O
ADMINISTRATION	O
Ketorolac	B-D020911
Tromethamine	I-D020911

Risk	B-D012306

CONCOMITANT	O
USE	O
WITH	O
NSAIDs	O
Ketorolac	B-D020911
Tromethamine	I-D020911

SPECIAL	O
Population	B-D011153

Doses	O
of	O
Ketorolac	B-D020911
Tromethamine	I-D020911

DOSAGE	O
AND	O
ADMINISTRATION	O
Ketorolac	B-D020911
Tromethamine	I-D020911
Tablets	B-D013607
Ketorolac	B-D020911
Tromethamine	I-D020911

The	O
recommended	O
total	O
daily	O
dose	O
of	O
Ketorolac	B-D020911
Tromethamine	I-D020911

ADVERSE	O
REACTIONS	O
Systemic:	O
Adverse	O
experiences	O
following	O
the	O
administration	O
of	O
Lidocaine	B-D008012

These	O
adverse	O
experiences	O
are,	O
in	O
general,	O
dose-related	O
and	O
may	O
result	O
from	O
high	O
Plasma	B-D010949

Serious	O
adverse	O
experiences	O
are	O
generally	O
systemic	O
in	O
Nature	B-D019368

The	O
following	O
types	O
are	O
those	O
most	O
commonly	O
reported:	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
CNS	O
manifestations	O
are	O
excitatory	O
and/or	O
depressant	O
and	O
may	O
be	O
Character	B-D002605

The	O
excitatory	O
manifestations	O
may	O
be	O
very	O
brief	O
or	O
may	O
not	O
occur	O
at	O
all,	O
in	O
which	O
case	O
the	O
first	O
manifestation	O
of	O
toxicity	O
may	O
be	O
drowsiness	O
merging	O
into	O
Unconsciousness	B-D014474

Drowsiness	O
following	O
the	O
administration	O
of	O
Lidocaine	B-D008012

Cardiovascular	B-D002319
System	I-D002319
:	O
Cardiovascular	O
manifestations	O
are	O
usually	O
depressant	O
and	O
are	O
Character	B-D002605

Allergic:	O
Allergic	O
reactions	O
are	O
Character	B-D002605

Allergic	O
reactions	O
may	O
occur	O
as	O
a	O
result	O
of	O
sensitivity	O
either	O
to	O
local	O
anesthetic	O
agents	O
or	O
to	O
the	O
methylparaben	B-C015358
used	O
as	O
a	O
preservative	O
in	O
multiple	O
dose	O
vials	O

Allergic	O
reactions	O
as	O
a	O
result	O
of	O
sensitivity	O
to	O
Lidocaine	B-D008012

The	O
detection	O
of	O
sensitivity	O
by	O
Skin	B-D012867

Neurologic:	O
The	O
Incidence	B-D015994

In	O
a	O
prospective	O
Review	B-D016454

Many	O
of	O
these	O
Observation	B-D019370

In	O
the	O
practice	O
of	O
caudal	O
or	O
lumbar	O
epidural	O
block,	O
occasional	O
unintentional	O
penetration	O
of	O
the	O
Subarachnoid	B-D013346
Space	I-D013346

Subsequent	O
adverse	O
effects	O
may	O
depend	O
partially	O
on	O
the	O
amount	O
of	O
drug	O
administered	O
subdurally	O

These	O
may	O
include	O
spinal	O
block	O
of	O
varying	O
magnitude	O
(including	O
total	O
spinal	O
block),	O
Hypotension	B-D007022

Persistent	O
motor,	O
sensory	O
and/or	O
autonomic	O
(sphincter	O
control)	O
deficit	O
of	O
some	O
lower	O
spinal	O
segments	O
with	O
slow	O
recovery	O
(several	O
months)	O
or	O
incomplete	O
recovery	O
have	O
been	O
reported	O
in	O
rare	O
instances	O
when	O
caudal	O
or	O
lumbar	O
epidural	O
block	O
has	O
been	O
attempted	O

Back	B-D001415
ache	O
and	O
Headache	B-D006261

There	O
have	O
been	O
reported	O
cases	O
of	O
permanent	O
injury	O
to	O
extraocular	O
Muscles	B-D009132

BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

•	O
Diflunisal	B-D004061
Tablets	B-D013607

Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

Adverse	O
Reactions	O
The	O
adverse	O
reactions	O
observed	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Listed	O
below	O
are	O
the	O
adverse	O
reactions	O
reported	O
in	O
the	O
1,314	O
of	O
these	O
Patients	B-D010361

Five	O
hundred	O
thirteen	O
Patients	B-D010361

In	O
general,	O
the	O
adverse	O
reactions	O
listed	O
below	O
were	O
2	O
to	O
14	O
Time	B-D013995

Incidence	B-D015994
Greater	O
Than	O
1%	O
Gastrointestinal	O
The	O
most	O
frequent	O
types	O
of	O
adverse	O
reactions	O
occurring	O
with	O
Diflunisal	B-D004061

Psychiatric	O
Somnolence,	O
insomnia	O

Central	B-D002490
Nervous	I-D002490
System	I-D002490
Dizziness	B-D004244
	O

Special	O
Senses	O
Tinnitus	B-D014012
	O

Dermatologic	O
Rash*	O

Miscellaneous	O
Headache	B-D006261
*,	O
Fatigue	B-D005221

*	O
Incidence	B-D015994
between	O
3%	O
and	O
9%	O

Those	O
reactions	O
occurring	O
in	O
1%	O
to	O
3%	O
are	O
not	O
marked	O
with	O
an	O
asterisk	O

Incidence	B-D015994
Less	O
Than	O
1	O
in	O
100	O
The	O
following	O
adverse	O
reactions,	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100,	O
were	O
reported	O
in	O
Clinical	B-D016430
Trial	I-D016430

The	O
Probability	B-D011336

Dermatologic	O
Erythema	B-D004892
Multiforme	I-D004892

Gastrointestinal	O
Peptic	B-D010437
Ulcer	I-D010437

Liver	B-D008099
function	O
abnormalities;	O
Jaundice	B-D007565

Hematologic	O
Thrombocytopenia	B-D013921
;	O
Agranulocytosis	B-D000380

Genitourinary	O
Dysuria	B-D053159
;	O
renal	O
impairment,	O
including	O
renal	O
failure;	O
interstitial	O
Nephritis	B-D009393

Psychiatric	O
Nervousness,	O
Depression	B-D003863

Central	B-D002490
Nervous	I-D002490
System	I-D002490
Vertigo	B-D014717
;	O
Light	B-D008027

Special	O
Senses	O
Transient	O
visual	O
disturbances	O
including	O
blurred	O
vision	O

Hypersensitivity	B-D006967
Reactions	O
Acute	O
anaphylactic	O
reaction	O
with	O
bronchospasm;	O
Angioedema	B-D000799

Hypersensitivity	B-D006967
Vasculitis	B-D014657

Hypersensitivity	B-D006967
Syndrome	B-D013577

Miscellaneous	O
Asthenia	B-D001247
,	O
Edema	B-D004487

Causal	O
Relationship	O
Unknown	O
Other	O
reactions	O
have	O
been	O
reported	O
in	O
Clinical	B-D016430
Trial	I-D016430

However,	O
in	O
these	O
rarely	O
reported	O
events,	O
that	O
possibility	O
cannot	O
be	O
excluded	O

Therefore,	O
these	O
Observation	B-D019370

Respiratory	O
Dyspnea	B-D004417
	O

Cardiovascular	O
Palpitation,	O
Syncope	B-D013575

Musculoskeletal	O
Muscle	B-D009120
Cramp	I-D009120

Genitourinary	O
Nephrotic	B-D009404
Syndrome	I-D009404

Special	O
Senses	O
Hearing	B-D034381
Loss	I-D034381

Miscellaneous	O
Chest	B-D002637
Pain	I-D002637

A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
Fasciitis	B-D005208

Potential	O
Adverse	O
Effects	O
In	O
addition,	O
a	O
variety	O
of	O
adverse	O
effects	O
not	O
observed	O
with	O
Diflunisal	B-D004061

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
nonsteroidal	O
antiinflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,	O
14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
Risk	B-D012306

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

Elevated	O
Liver	B-D008099

Discontinue	O
use	O
of	O
Celecoxib	B-D000068579

New	O
onset	O
or	O
worsening	O
of	O
Hypertension	B-D006973

Blood	B-D001794
Pressure	I-D001794

Fluid	O
retention	O
and	O
Edema	B-D004487

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Renal	O
papillary	O
Necrosis	B-D009336

Use	O
Celecoxib	B-D000068579

Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
Celecoxib	B-D000068579

Serious	O
Skin	B-D012867

Discontinue	O
Celecoxib	B-D000068579

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361
,	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered	O

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

Therefore,	O
treatment	O
with	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
postmarketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9	O
Pregnancy	B-D011247
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

Celecoxib	B-D000068579
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
Patients	B-D010361

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
Celecoxib	B-D000068579

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sydon	O
Labs,	O
LLC	O
at	O
1	O
866-487-4695	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
>2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4,	O
146	O
Placebo	O
N=1,	O
864	O
NAP	O
N=1,	O
366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
Diarrhea	B-D003967
Dyspepsia	B-D004415
Flatulence	B-D005414
Nausea	B-D009325
4.1%5.6%8.8%2.2%3.5%	O
2.8%3.8%6.2%1%4.2%	O
7.7%5.3%12.2%3.6%6%	O
9%9.3%10.9%4.1%3.4%	O
9%5.8%12.8%3.5%6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
Peripheral	O
Edema	B-D004487
Injury-Accidental	O
2.8%2.1%2.9%	O
3.6%1.1%2.3%	O
2.2%2.1%3%	O
2.6%1%2.6%	O
0.9%3.5%3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

In	O
placebo-	O
or	O
active-controlled	O
Clinical	B-D016430
Trial	I-D016430

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(>5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
>5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
>5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
postdental	O
extraction	O
alveolar	O
Osteitis	B-D010000

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDS)	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(	O
5.1)	O
Diclofenac	B-D004008
Sodium	B-D012964

(	O
4)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(	O
5.2)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Use	O
the	O
lowest	O
effective	O
dose	O
of	O
Diclofenac	B-D004008

(	O
5.1)	O
NSAIDs	O
can	O
cause	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
Inflammation	B-D007249

Prescribe	O
Diclofenac	B-D004008

(	O
5.2)	O
Elevation	O
of	O
one	O
or	O
more	O
Liver	B-D008099

Discontinue	O
Diclofenac	B-D004008

(	O
5.3)	O
Hypertension	B-D006973
can	O
occur	O
with	O
NSAID	O
treatment	O

Monitor	O
Blood	B-D001794
Pressure	I-D001794

(	O
5.4)	O
Use	O
Diclofenac	B-D004008

(	O
5.5)	O
Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Use	O
Diclofenac	B-D004008

(	O
5.6)	O
Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

(	O
5.7)	O
NSAIDs	O
can	O
cause	O
serious	O
Skin	B-D012867

(	O
5.8)	O
Not	O
for	O
use	O
during	O
Pregnancy	B-D011247

(	O
5.9)	O
Do	O
not	O
administer	O
to	O
Patients	B-D010361

(	O
5.10)	O
Avoid	O
exposure	O
of	O
treated	O
Knee	B-D007717

(	O
5.11)	O
Avoid	O
contact	O
of	O
Diclofenac	B-D004008

(	O
5.12)	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs	O

(	O
5.13)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

All	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Inform	O
Patients	B-D010361

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Prescribe	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

For	O
high-risk	O
Patients	B-D010361

5.3	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
(less	O
than	O
3	O
Time	B-D013995

Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
Liver	B-D008099

In	O
Clinical	B-D016430
Trial	I-D016430

In	O
an	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
Patients	B-D010361

In	O
this	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
NSAID	O
therapy	O

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
sever	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Eosinophilia	B-D004802

To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
inform	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
Diclofenac	B-D004008

Caution	O
Patients	B-D010361

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008

Use	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Patients	B-D010361
taking	O
ACE-inhibitors,	O
Thiazides	B-D049971

5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
Diclofenac	B-D004008

5.6	O
Renal	O
Effects	O
Use	O
caution	O
when	O
initiating	O
treatment	O
with	O
Diclofenac	B-D004008

Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008

Therefore,	O
treatment	O
with	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

Do	O
not	O
prescribe	O
Diclofenac	B-D004008

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Seek	O
emergency	O
help	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Do	O
not	O
apply	O
Diclofenac	B-D004008

NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

5.9	O
Pregnancy	B-D011247
Diclofenac	B-D004008
Sodium	B-D012964

5.10	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross-reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.11	O
Sun	O
Exposure	O
Instruct	O
Patients	B-D010361

The	O
potential	O
effects	O
of	O
Diclofenac	B-D004008

5.12	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
Diclofenac	B-D004008

Advise	O
Patients	B-D010361

5.13	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
Diclofenac	B-D004008

Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
Diclofenac	B-D004008

5.14	O
Corticosteroid	O
Treatment	O
Diclofenac	B-D004008
Sodium	B-D012964

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

For	O
Patients	B-D010361

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.16	O
Hematological	O
Effects	O
The	O
effects	O
of	O
Diclofenac	B-D004008

There	O
was	O
no	O
significant	O
change	O
in	O
Platelet	B-D010974
Aggregation	I-D010974

Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
Blood	B-D001769

Check	O
hemoglobin	O
or	O
Hematocrit	B-D006400

NSAIDs	O
inhibit	O
Platelet	B-D010974
Aggregation	I-D010974

Unlike	O
Aspirin	B-D001241

Carefully	O
monitor	O
Patients	B-D010361

5.17	O
Monitoring	O
Because	O
serious	O
GI	O
tract	O
Ulcer	B-D014456

Check	O
CBC	O
and	O
a	O
Chemistry	B-D002621

Discontinue	O
Diclofenac	B-D004008

6	O

ADVERSE	O
REACTIONS	O
The	O
most	O
common	O
adverse	O
events	O
with	O
Diclofenac	B-D004008

(	O
6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Teligent	O
Pharma,	O
Inc	O

at	O
1-856-697-1441,	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
Diclofenac	B-D004008

The	O
Population	B-D011153

The	O
most	O
common	O
adverse	O
events	O
with	O
Diclofenac	B-D004008

These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies	O

Application	O
site	O
reactions:	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment	O
related	O
adverse	O
events	O
in	O
Patients	B-D010361

Application	O
site	O
reactions	O
were	O
Character	B-D002605

The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
Skin	B-D012867

In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
Dermatitis	B-D003872

In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
Safety	B-D012449

Adverse	O
events	O
common	O
to	O
the	O
NSAID	O
class:	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
Diclofenac	B-D004008

The	O
combination	O
of	O
Diclofenac	B-D004008

less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
Creatinine	B-D003404

7%),	O
Urea	B-D014508

12%),	O
and	O
hemoglobin	O
(13%	O
vs	O

9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
Liver	B-D008099

Table	O
1:	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
=1%	O
of	O
Patients	B-D010361

Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
=1%	O
of	O
Patients	B-D010361

Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
N=911	O
Topical	O
Placebo	O
N=332	O
Adverse	O
Reaction	O
Preferred	O
Term	O
according	O
to	O
COSTART	O
N(%)	O
N(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non	O
–	O
U.S	O

postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
Diclofenac	B-D004008

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Body	O
as	O
a	O
Whole:	O
Abdominal	B-D015746
Pain	I-D015746

This	O
Risk	B-D012306

•	O
Solaraze	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

ADVERSE	O
REACTIONS	O
Of	O
the	O
423	O
Patients	B-D010361

Eighty-seven	O
percent	O
(87%)	O
of	O
the	O
Solaraze®-treated	O
Patients	B-D010361

The	O
majority	O
of	O
these	O
reactions	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
resolved	O
upon	O
discontinuation	O
of	O
therapy	O

Of	O
the	O
211	O
Patients	B-D010361

Application	O
site	O
reactions	O
(ASRs)	O
were	O
the	O
most	O
frequent	O
AEs	O
in	O
both	O
Solaraze®-and	O
vehicle-treated	O
groups	O

Of	O
note,	O
four	O
reactions,	O
contact	O
Dermatitis	B-D003872

Eighteen	O
percent	O
of	O
Solaraze®-treated	O
Patients	B-D010361

These	O
discontinuations	O
were	O
mainly	O
due	O
to	O
Skin	B-D012867

Table	O
1	O
below	O
presents	O
the	O
AEs	O
reported	O
at	O
an	O
Incidence	B-D015994

Table	O
1	O

Adverse	O
Events	O
Reported	O
(>1%	O
in	O
Any	O
Treatment	O
Group)	O
During	O
Solaraze®	O
Phase	O
3	O
Clinical	B-D016430
Trial	I-D016430
s	O
Incidence	B-D015994
s	O
for	O
60-Day	O
and	O
90-Day	O
Treatments	O
60-day	O
Treatment	O
90-day	O
Treatment	O
Solaraze®	O
(%)	O
Gel	O
Vehicle	O
(%)	O
Solaraze®	O
(%)	O
Gel	O
Vehicle	O
(%)	O
N=48	O
N=49	O
N=114	O
N=114	O
BODY	O
AS	O
A	O
WHOLE	O
21	O
20	O
20	O
18	O
Abdominal	B-D015746
Pain	I-D015746
2	O
0	O
1	O
0	O
Accidental	O
Injury	O
0	O
0	O
4	O
2	O
Allergic	O
Reaction	O
0	O
0	O
1	O
3	O
Asthenia	B-D001247
0	O
0	O
2	O
0	O
Back	B-D001416
Pain	I-D001416
4	O
0	O
2	O
2	O
Chest	B-D002637
Pain	I-D002637
2	O
0	O
1	O
0	O
Chills	B-D023341
0	O
2	O
0	O
0	O
Flu	O
Syndrome	B-D013577
10	O
6	O
1	O
4	O
Headache	B-D006261
0	O
6	O
7	O
6	O
Infection	O
4	O
6	O
4	O
5	O
Neck	B-D019547
Pain	I-D019547
0	O
0	O
2	O
0	O
Pain	B-D010146
2	O
0	O
2	O
2	O
Cardiovascular	B-D002319
System	I-D002319

Adverse	O
Reactions	O
Reported	O
for	O
Oral	O
Diclofenac	B-D004008
Dosage	O
Form	B-D020478
(not	O
topical	O
Solaraze	O
®	O
Gel):	O
*Incidence	O
Greater	O
than	O
1%	O
marked	O
with	O
asterisk	O

Body	O
as	O
a	O
Whole:	O
Abdominal	B-D015746
Pain	I-D015746

Cardiovascular:	O
Hypertension	B-D006973

Digestive:	O
Diarrhea	B-D003967

Hemic	O
and	O
Lymph	B-D008196
atic:	O
hemoglobin	B-C032001
D	I-C032001

Metabolic	O
and	O
Nutritional	O
Disorders:	O
Azotemia	B-D053099

Nervous	B-D009420
System	I-D009420
:	O
Dizziness	B-D004244

Respiratory:	O
Epistaxis	B-D004844

Skin	B-D012867
and	O
Appendages:	O
rash*,	O
Pruritus	B-D011537

Special	O
Senses:	O
Tinnitus	B-D014012

Urogenital:	O
Nephrotic	B-D009404
Syndrome	I-D009404

Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS.)	O
Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS.)	O
ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
Appetite	B-D001066

WARNING:	O
Risk	B-D012306

ADMINISTRATION	O
OF	O
Misoprostol	B-D016595

Uterine	B-D014597
Rupture	I-D014597

Diclofenac	B-D004008

Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

In	O
such	O
Patients	B-D010361

●	O
is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures	O

●	O
has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
Misoprostol	B-D016595

●	O
will	O
begin	O
Diclofenac	B-D004008

Cardiovascular	O
Thrombotic	O
Events	O
●	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

●	O
Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
●	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

Diclofenac	B-D004008

ADMINISTRATION	O
OF	O
Misoprostol	B-D016595

Uterine	B-D014597
Rupture	I-D014597

Diclofenac	B-D004008

Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

In	O
such	O
Patients	B-D010361

•	O
is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures	O

•	O
has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
Misoprostol	B-D016595

•	O
will	O
begin	O
Diclofenac	B-D004008

Cardiovascular	O
Thrombotic	O
Events	O
Risk	B-D012306
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

•	O
Di	O
clofenac	O
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964

Monitor	O
Patients	B-D010361

Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

(	O
5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
Hematocrit	B-D006400

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

●	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

●	O
Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

●	O
Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

●	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Diclofenac	B-D004008

●	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
In	O
Clinical	B-D016430
Trial	I-D016430

These	O
increases	O
were	O
generally	O
transient,	O
and	O
enzyme	O
levels	O
returned	O
to	O
within	O
the	O
normal	O
range	O
upon	O
discontinuation	O
of	O
therapy	O
with	O
Diclofenac	B-D004008

The	O
Misoprostol	B-D016595

In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
Diclofenac	B-D004008

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008

The	O
renal	O
effects	O
of	O
Diclofenac	B-D004008

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
/misoprostol	O
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Diclofenac	B-D004008

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

Diclofenac	B-D004008
Sodium	B-D012964

Advise	O
Pregnant	B-D037841
Women	I-D037841

Verify	O
the	O
Pregnancy	B-D011247

Advise	O
Female	B-D005260

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Diclofenac	B-D004008

NSAIDs,	O
including	O
Diclofenac	B-D004008

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
greater	O
than	O
2%	O
from	O
Clinical	B-D016430
Trial	I-D016430

1-855-361-3993	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

Adverse	O
reaction	O
information	O
for	O
Diclofenac	B-D004008

Gastrointestinal	O
GI	O
disorders	O
had	O
the	O
highest	O
reported	O
Incidence	B-D015994

These	O
events	O
were	O
generally	O
minor,	O
but	O
led	O
to	O
discontinuation	O
of	O
therapy	O
in	O
9%	O
of	O
Patients	B-D010361

For	O
GI	O
Ulcer	B-D014456

GI	O
disorder	O
Diclofenac	B-D004008
Sodium	B-D012964
and	O
Misoprostol	B-D016595
Diclofenac	B-D004008
Abdominal	B-D015746
Pain	I-D015746

Diarrhea	B-D003967
and	O
Abdominal	B-D015746
Pain	I-D015746

Rare	O
instances	O
of	O
profound	O
Diarrhea	B-D003967

Patients	B-D010361
with	O
an	O
underlying	O
condition	O
such	O
as	O
inflammatory	O
bowel	O
Disease	B-D004194

The	O
Incidence	B-D015994

Gynecological	O
Gynecological	O
disorders	O
previously	O
reported	O
with	O
Misoprostol	B-D016595

Postmenopausal	O
Vagina	B-D014621

If	O
it	O
occurs,	O
diagnostic	O
Work	B-D014937

Elderly	O
Overall	B-D016424
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
Safety	B-D012449

Other	O
adverse	O
experiences	O
reported	O
occasionally	O
with	O
Diclofenac	B-D004008

Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Digestive:	O
Anorexia	B-D000855

Female	B-D005260
reproductive	O
disorders:	O
Breast	B-D001940

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional:	O
Alanine	B-D000409

Musculoskeletal	B-D009141
System	I-D009141

Psychiatric:	O
Anxiety	B-D001007

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505

Special	O
senses:	O
Taste	B-D013649

Renal	O
and	O
urinary	O
disorders:	O
Dysuria	B-D053159

Vision:	O
Diplopia	B-D004172

6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Body	O
as	O
a	O
whole:	O
Death	B-D003643

Cardiovascular	B-D002319
System	I-D002319

Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Congenital,	O
familial	O
and	O
genetic	O
disorders:	O
birth	O
defects	O

Digestive:	O
Enteritis	B-D004751

Female	B-D005260
reproductive	O
disorders:	O
intermenstrual	O
bleeding,	O
Leukorrhea	B-D007973

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Hypersensitivity	B-D006967
:	O
Angioedema	B-D000799

Liver	B-D008099
and	O
biliary	O
system:	O
abnormal	O
hepatic	O
function,	O
Bilirubin	B-D001663

Male	B-D008297
reproductive	O
disorders:	O
impotence,	O
perineal	O
Pain	B-D010146

Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
Glycosuria	B-D006029

Pregnancy	B-D011247
,	O
puerperium	O
and	O
perinatal	O
conditions:	O
abnormal	O
Uterine	B-D014590
Contraction	I-D014590

Psychiatric:	O
Confusion	B-D003221

Reproductive	O
system	O
and	O
Breast	B-D001940

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages:	O
acne,	O
bruising,	O
Erythema	B-D004892
Multiforme	I-D004892

Special	O
senses:	O
Hearing	B-D006309

Renal	O
and	O
urinary	O
disorders:	O
Cystitis	B-D003556

Vision:	O
Amblyopia	B-D000550

Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Etodolac	B-D017308
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse-reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
to	O
1,000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064

Nervous	B-D009420
System	I-D009420

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566

Musculoskeletal	O
-	O
Arthralgia	B-D018771
*Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566

Musculoskeletal	O
-	O
Muscle	O
Pain	B-D010146

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
Death	B-D003643

at	O
1-855-361-3993;	O
email	O
drugsafety@avkare.com	O
;	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
	O

WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
Diclofenac	B-D004008
Sodium	B-D012964
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

(4,	O
5.1)	O
NSAIDs,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964

Monitor	O
Patients	B-D010361

(5.14)	O
Eye	B-D005123
Contact:	O
Avoid	O
contact	O
of	O
Diclofenac	B-D004008

(5.15)	O
Oral	O
Nonsteroidal	O
Anti-inflammatory	O
Drugs:	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs	O

(5.16)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Diclofenac	B-D004008

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
Diclofenac	B-D004008

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
taking	O
angiotension	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
was	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008

The	O
renal	O
effects	O
of	O
Diclofenac	B-D004008

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Diclofenac	B-D004008

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

Do	O
not	O
apply	O
Diclofenac	B-D004008

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Diclofenac	B-D004008

NSAIDs,	O
including	O
Diclofenac	B-D004008

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

The	O
effects	O
of	O
Diclofenac	B-D004008

There	O
was	O
no	O
significant	O
change	O
in	O
Platelet	B-D010974
Aggregation	I-D010974

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Sun	O
Exposure	O
Instruct	O
Patients	B-D010361

The	O
potential	O
effects	O
of	O
Diclofenac	B-D004008

5.15	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
Diclofenac	B-D004008

Advise	O
Patients	B-D010361

5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
Diclofenac	B-D004008

Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
Diclofenac	B-D004008

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
The	O
most	O
common	O
adverse	O
reactions	O
with	O
Diclofenac	B-D004008

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Taro	O
Pharmaceuticals	O
U.S.A.,	O
Inc	O

at	O
1-866-923-4914	O
or	O
the	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
Diclofenac	B-D004008

The	O
Population	B-D011153

The	O
most	O
common	O
adverse	O
events	O
with	O
Diclofenac	B-D004008

These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies	O

Application	O
Site	O
Reactions	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment-related	O
adverse	O
events	O
in	O
Patients	B-D010361

Application	O
site	O
reactions	O
were	O
Character	B-D002605

The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
Skin	B-D012867

In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
Dermatitis	B-D003872

In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
Safety	B-D012449

Adverse	O
Events	O
Common	O
to	O
the	O
NSAID	O
Class	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
Diclofenac	B-D004008

The	O
combination	O
of	O
Diclofenac	B-D004008

less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
Creatinine	B-D003404

7%),	O
Urea	B-D014508

12%),	O
and	O
hemoglobin	O
(13%	O
vs	O

9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
Liver	B-D008099

Table	O
1	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
Patients	B-D010361

Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
Patients	B-D010361

Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
SolutionN=911	O
TopicalPlaceboN=332	O
Adverse	O
ReactionPreferred	O
Term	O
according	O
to	O
COSTART	O
N	O
(%)	O
N	O
(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non-U.S	O

postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
Diclofenac	B-D004008

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Body	O
as	O
a	O
Whole:	O
Abdominal	B-D015746
Pain	I-D015746

Risk	B-D012307
Factors	I-D012307

Anticoagulants	B-D000925

Intracranial	O
Hemorrhage	B-D006470
In	O
Europe	B-D005060
an	O
Stroke	B-D020521
Prevention	O
Study-2	O
(ESPS2),	O
the	O
annualized	O
event	O
rate	O
for	O
intracranial	O
Hemorrhage	B-D006470

Gastrointestinal	O
(GI)	O
Side	O
Effects	O
GI	O
side	O
effects	O
include	O
Stomach	B-D013270

Although	O
minor	O
upper	O
GI	O
symptoms,	O
such	O
as	O
Dyspepsia	B-D004415

Inform	O
Patients	B-D010361

In	O
ESPS2,	O
the	O
annualized	O
event	O
rate	O
for	O
gastrointestinal	O
bleeding	O
was	O
2.97%/year	O
in	O
the	O
Aspirin	B-D001241

Peptic	B-D010437
Ulcer	I-D010437
Disease	B-D004194
Avoid	O
using	O
Aspirin	B-D001241

Alcohol	O
Warning	O
Because	O
Aspirin	B-D001241

5.2	O
Renal	O
Failure	O
Avoid	O
Aspirin	B-D001241

5.3	O
Hepatic	B-D048550
Insufficiency	I-D048550
Elevations	O
of	O
hepatic	O
Enzymes	B-D004798

5.4	O
Coronary	B-D003324
Artery	I-D003324
Disease	I-D003324
Dipyridamole	B-D004176
has	O
a	O
vasodilatory	O
effect	O

Chest	B-D002637
Pain	I-D002637

For	O
Stroke	B-D020521

5.5	O
Hypotension	B-D007022
Dipyridamole	B-D004176
produces	O
peripheral	O
Vasodilation	B-D014664

5.6	O
General	O
Aspirin	B-D001241
and	O
extended-release	O
Dipyridamole	B-D004176

6	O
ADVERSE	O
REACTIONS	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(>10%	O
and	O
greater	O
than	O
placebo)	O
were	O
Headache	B-D006261

at	O
1-877-993-8779	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling:	O
Hypersensitivity	B-D006967
[see	O
Contraindications	B-D000075202
(4.1)	O
]	O

Allergy	O
[see	O
Contraindications	B-D000075202
(4.2)	O
]	O

Risk	B-D012306
of	O
Bleeding	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
efficacy	O
and	O
Safety	B-D012449

ESPS2	O
was	O
a	O
double-blind,	O
placebo	O
controlled	O
study	O
that	O
evaluated	O
6602	O
Patients	B-D010361

Patients	B-D010361
were	O
randomized	O
to	O
either	O
Aspirin	B-D001241

This	O
24-month,	O
multicenter,	O
double-blind,	O
randomized	O
study	O
(ESPS2)	O
was	O
conducted	O
to	O
compare	O
the	O
efficacy	O
and	O
Safety	B-D012449

The	O
study	O
was	O
conducted	O
in	O
a	O
total	O
of	O
6602	O
Male	B-D008297

Table	O
1	O
presents	O
the	O
annualized	O
event	O
rate	O
for	O
adverse	O
events	O
that	O
occurred	O
in	O
1%/year	O
or	O
more	O
of	O
Patients	B-D010361

There	O
is	O
no	O
clear	O
benefit	O
of	O
the	O
Dipyridamole	B-D004176

Table	O
1	O
Incidence	B-D015994
of	O
Adverse	O
Events	O
in	O
ESPS2a	O
a	O
Reported	O
by	O
≥1%/year	O
of	O
Patients	B-D010361

b	O
Annual	O
event	O
rate	O
per	O
100pt-years=	O
100*	O
number	O
of	O
subjects	O
with	O
event/subject-years	O

Subject-years	O
is	O
defined	O
as	O
cumulative	O
number	O
of	O
days	O
on	O
treatment	O
divided	O
by	O
365.25	O

Note:	O
ER-DP	O
=	O
extended-release	O
Dipyridamole	B-D004176

The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BID	O
NOS	O
=	O
not	O
otherwise	O
specified	O

Individual	O
Treatment	O
Group	O
Body	O
System/Preferred	O
Term	O
Aspirin	B-D001241
and	O
Extended-release	O
Dipyridamole	B-D004176
Capsules	B-D002214
n	O
(%/year)b	O
ER-DP	O
Alone	O
n	O
(%/year)b	O
ASA	O
Alone	O
n	O
(%/year)b	O
Placebo	O
n	O
(%/year)b	O
Total	O
Number	O
of	O
Patients	B-D010361
1650	O
1654	O
1649	O
1649	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Disorders	O
Headache	B-D006261
647	O
(28.25)	O
634	O
(27.91)	O
558	O
(22.10)	O
543	O
(22.29)	O
Gastrointestinal	O
System	O
Disorders	O
Dyspepsia	B-D004415
303	O
(13.23)	O
288	O
(12.68)	O
299	O
(11.84)	O
275	O
(11.29)	O
Abdominal	B-D015746
Pain	I-D015746
289	O
(12.62)	O
255	O
(11.22)	O
262	O
(10.38)	O
239	O
(9.81)	O
Nausea	B-D009325
264	O
(11.53)	O
254	O
(11.18)	O
210	O
(8.32)	O
232	O
(9.53)	O
Diarrhea	B-D003967
210	O
(9.17)	O
257	O
(11.31)	O
112	O
(4.44)	O
161	O
(6.61)	O
Vomiting	B-D014839
138	O
(6.03)	O
129	O
(5.68)	O
101	O
(4.00)	O
118	O
(4.84)	O
Platelet,	O
Bleeding	O
and	O
Clotting	O
Disorders	O
Hemorrhage	B-D006470
NOS	O
52	O
(2.27)	O
24	O
(1.06)	O
46	O
(1.82)	O
24	O
(0.99)	O
Discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
ESPS2	O
was	O
25%	O
for	O
Aspirin	B-D001241

b	O
Annual	O
event	O
rate	O
per	O
100pt-years=	O
100*	O
number	O
of	O
subjects	O
with	O
event/subject-years	O

Subject-years	O
is	O
defined	O
as	O
cumulative	O
number	O
of	O
days	O
on	O
treatment	O
divided	O
by	O
365.25	O

Note:	O
ER-DP	O
=	O
extended-release	O
Dipyridamole	B-D004176

The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BID	O
Headache	B-D006261
was	O
most	O
notable	O
in	O
the	O
first	O
month	O
of	O
treatment	O

Treatment	O
Groups	O
Aspirin	B-D001241
and	O
Extended-release	O
Dipyridamole	B-D004176
Capsules	B-D002214
n(%/year)b	O
ER-DP	O
n(%/year)b	O
ASA	O
n(%/year)b	O
Placebo	O
n(%/year)b	O
Total	O
Number	O
of	O
Patients	B-D010361
1650	O
1654	O
1649	O
1649	O
Patients	B-D010361
with	O
at	O
least	O
one	O
Adverse	O
Event	O
that	O
led	O
to	O
treatment	O
discontinuation	O
417	O
(18.21)	O
419	O
(18.44)	O
318	O
(12.59)	O
352	O
(14.45)	O
Headache	B-D006261
165	O
(7.20)	O
166	O
(7.31)	O
57	O
(2.26)	O
69	O
(2.83)	O
Nausea	B-D009325
91	O
(3.97)	O
95	O
(4.18)	O
51	O
(2.02)	O
53	O
(2.18)	O
Abdominal	B-D015746
Pain	I-D015746
74	O
(3.23)	O
64	O
(2.82)	O
56	O
(2.22)	O
52	O
(2.13)	O
Vomiting	B-D014839
53	O
(2.31)	O
52	O
(2.29)	O
28	O
(1.11)	O
24	O
(0.99)	O
Headache	B-D006261
was	O
most	O
notable	O
in	O
the	O
first	O
month	O
of	O
treatment	O

6.2	O
Post	O
Marketing	B-D040541
Experience	O
The	O
following	O
is	O
a	O
list	O
of	O
additional	O
adverse	O
reactions	O
that	O
have	O
been	O
reported	O
either	O
in	O
the	O
Literature	B-D008091

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Decisions	O
to	O
include	O
these	O
reactions	O
in	O
labeling	O
are	O
typically	O
based	O
on	O
one	O
or	O
more	O
of	O
the	O
following	O
factors:	O
(1)	O
seriousness	O
of	O
the	O
reaction,	O
(2)	O
frequency	O
of	O
reporting,	O
or	O
(3)	O
strength	O
of	O
causal	O
connection	O
to	O
Aspirin	B-D001241

Body	O
as	O
a	O
Whole	O
Hypothermia	B-D007035
,	O
Chest	B-D002637
Pain	I-D002637

WARNING	O
If	O
persistent	O
Skin	B-D012867

(5.1)	O
DURLAZA	O
can	O
cause	O
Gastric	B-D005753
Mucosa	I-D005753

Patients	B-D010361
with	O
a	O
History	B-D006664

(5.2)	O
DURLAZA	O
can	O
cause	O
fetal	O
harm	O
when	O
administered	O
to	O
a	O
pregnant	O
woman	O

(5.3,	O
8.1)	O
5.1	O
Risk	B-D012306
of	O
Bleeding	O
DURLAZA	O
increases	O
the	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307

5.2	O
Peptic	B-D010437
Ulcer	I-D010437
Disease	B-D004194
DURLAZA	O
may	O
cause	O
gastric	O
Ulcer	B-D014456

Avoid	O
DURLAZA	O
in	O
Patients	B-D010361

5.3	O
Fetal	O
Toxicity	O
DURLAZA	O
can	O
cause	O
fetal	O
harm	O
when	O
administered	O
to	O
a	O
pregnant	O
woman	O

Maternal	O
Aspirin	B-D001241

Because	O
NSAIDs	O
may	O
cause	O
Prema	B-C070504

6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
adverse	O
reactions	O
are	O
Gastrointestinal	O
(6)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
New	O
Haven	O
Pharmaceuticals	O
at	O
(877)	O
824-2483	O
or	O
www.newhavenpharma.com	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
The	O
following	O
is	O
a	O
list	O
of	O
adverse	O
reactions	O
that	O
have	O
been	O
reported	O
in	O
the	O
Literature	B-D008091

Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
Agitation,	O
CERE	B-C079279

Fluid	O
and	O
Electrolyte:	O
Hyperkalemia	B-D006947
,	O
metabolic	O
Acidosis,	B-D000142
Respiratory	I-D000142

Gastrointestinal:	O
Dyspepsia	B-D004415
,	O
hepatic	O
enzyme	O
elevation,	O
Hepatitis	B-D006505

Renal:	O
Interstitial	O
Nephritis	B-D009393

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
The	O
Risk	B-D012306
of	O
Bleeding	O
Intracranial	O
Hemorrhage	B-D006470
In	O
ESPS2	O
the	O
Incidence	B-D015994

Coagulation	O
Abnormalities	O
Even	O
low	O
doses	O
of	O
Aspirin	B-D001241

This	O
can	O
adversely	O
Affect	B-D000339

Gastrointestinal	O
(GI)	O
Side	O
Effects	O
GI	O
side	O
effects	O
include	O
Stomach	B-D013270

Although	O
minor	O
upper	O
GI	O
symptoms,	O
such	O
as	O
Dyspepsia	B-D004415

Inform	O
Patients	B-D010361

In	O
ESPS2	O
the	O
Incidence	B-D015994

Peptic	B-D010437
Ulcer	I-D010437
Disease	B-D004194
Avoid	O
using	O
Aspirin	B-D001241

Alcohol	O
Warning	O
Because	O
AGGRENOX	O
contains	O
Aspirin	B-D001241

5.2	O
Renal	O
Failure	O
Avoid	O
Aspirin	B-D001241

5.3	O
Hepatic	B-D048550
Insufficiency	I-D048550
Elevations	O
of	O
hepatic	O
Enzymes	B-D004798

5.4	O
Pregnancy	B-D011247
Because	O
AGGRENOX	O
contains	O
Aspirin	B-D001241

Maternal	O
Aspirin	B-D001241

Because	O
of	O
the	O
above	O
and	O
because	O
of	O
the	O
known	O
effects	O
of	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
on	O
the	O
fetal	O
Cardiovascular	B-D002319
System	I-D002319

Aspirin	B-D001241
has	O
been	O
shown	O
to	O
be	O
teratogenic	O
in	O
Rats	B-D051381

These	O
doses,	O
which	O
also	O
resulted	O
in	O
a	O
high	O
resorption	O
rate	O
in	O
Rats	B-D051381

Reproduction	B-D012098
studies	O
with	O
Dipyridamole	B-D004176

When	O
330	O
mg	O
Aspirin	B-D001241

There	O
are	O
no	O
adequate	O
and	O
well-controlled	O
studies	O
of	O
the	O
use	O
of	O
AGGRENOX	O
in	O
Pregnant	B-D037841
Women	I-D037841

If	O
AGGRENOX	O
is	O
used	O
during	O
Pregnancy	B-D011247

5.5	O
Coronary	B-D003324
Artery	I-D003324
Disease	I-D003324
Dipyridamole	B-D004176
has	O
a	O
vasodilatory	O
effect	O

Chest	B-D002637
Pain	I-D002637

For	O
Stroke	B-D020521

5.6	O
Hypotension	B-D007022
Dipyridamole	B-D004176
produces	O
peripheral	O
Vasodilation	B-D014664

5.7	O
General	O
AGGRENOX	O
Capsules	B-D002214

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling:	O
Hypersensitivity	B-D006967
[	O
see	O
Contraindications	B-D000075202
(4.1)	O
]	O

Allergy	O
[	O
see	O
Contraindications	B-D000075202
(4.2)	O
]	O

Risk	B-D012306
of	O
Bleeding	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O

The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(>10%	O
and	O
greater	O
than	O
placebo)	O
were	O
Headache	B-D006261

at	O
(800)	O
542-6257	O
or	O
(800)	O
459-9906	O
TTY	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
efficacy	O
and	O
Safety	B-D012449

ESPS2	O
was	O
a	O
double-blind,	O
placebo	O
controlled	O
study	O
that	O
evaluated	O
6602	O
Patients	B-D010361

Patients	B-D010361
were	O
randomized	O
to	O
either	O
AGGRENOX,	O
Aspirin	B-D001241

This	O
24-month,	O
multicenter,	O
double-blind,	O
randomized	O
study	O
(ESPS2)	O
was	O
conducted	O
to	O
compare	O
the	O
efficacy	O
and	O
Safety	B-D012449

The	O
study	O
was	O
conducted	O
in	O
a	O
total	O
of	O
6602	O
Male	B-D008297

Table	O
1	O
presents	O
the	O
Incidence	B-D015994

There	O
is	O
no	O
clear	O
benefit	O
of	O
the	O
Dipyridamole	B-D004176

Table	O
1	O
Incidence	B-D015994
of	O
Adverse	O
Events	O
in	O
ESPS2*	O
Individual	O
Treatment	O
Group	O
Body	O
System/Preferred	O
Term	O
AGGRENOX	O
ER-DP	O
Alone	O
ASA	O
Alone	O
Placebo	O
*	O
Reported	O
by	O
≥1%	O
of	O
Patients	B-D010361

Note:	O
ER-DP	O
=	O
extended-release	O
Dipyridamole	B-D004176

The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BIDNOS	O
=	O
not	O
otherwise	O
specified	O

Total	O
Number	O
of	O
Patients	B-D010361
1650	O
1654	O
1649	O
1649	O
Total	O
Number	O
(%)	O
of	O
Patients	B-D010361
With	O
at	O
Least	O
One	O
On-Treatment	O
Adverse	O
Event	O
1319	O
(80%)	O
1305	O
(79%)	O
1323	O
(80%)	O
1304	O
(79%)	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Disorders	O
Headache	B-D006261
647	O
(39%)	O
634	O
(38%)	O
558	O
(34%)	O
543	O
(33%)	O
Convulsions	O
28	O
(2%)	O
15	O
(1%)	O
28	O
(2%)	O
26	O
(2%)	O
Gastrointestinal	O
System	O
Disorders	O
Dyspepsia	B-D004415
303	O
(18%)	O
288	O
(17%)	O
299	O
(18%)	O
275	O
(17%)	O
Abdominal	B-D015746
Pain	I-D015746
289	O
(18%)	O
255	O
(15%)	O
262	O
(16%)	O
239	O
(14%)	O
Nausea	B-D009325
264	O
(16%)	O
254	O
(15%)	O
210	O
(13%)	O
232	O
(14%)	O
Diarrhea	B-D003967
210	O
(13%)	O
257	O
(16%)	O
112	O
(7%)	O
161	O
(10%)	O
Vomiting	B-D014839
138	O
(8%)	O
129	O
(8%)	O
101	O
(	O
6%)	O
118	O
(7%)	O
Hemorrhage	B-D006470
Rectum	B-D012007
26	O
(2%)	O
22	O
(1%)	O
16	O
(1%)	O
13	O
(1%)	O
Melena	B-D008551
31	O
(2%)	O
10	O
(1%)	O
20	O
(1%)	O
13	O
(1%)	O
Hemorrhoids	B-D006484
16	O
(1%)	O
13	O
(1%)	O
10	O
(1%)	O
10	O
(1%)	O
GI	O
Hemorrhage	B-D006470
20	O
(1%)	O
5	O
(0%)	O
15	O
(1%)	O
7	O
(0%)	O
Body	O
as	O
a	O
Whole	O
-	O
General	O
Disorders	O
Pain	B-D010146
105	O
(6%)	O
88	O
(5%)	O
103	O
(6%)	O
99	O
(6%)	O
Fatigue	B-D005221
95	O
(6%)	O
93	O
(6%)	O
97	O
(6%)	O
90	O
(5%)	O
Back	B-D001416
Pain	I-D001416
76	O
(5%)	O
77	O
(5%)	O
74	O
(4%)	O
65	O
(4%)	O
Accidental	O
Injury	O
42	O
(3%)	O
24	O
(1%)	O
51	O
(3%)	O
37	O
(2%)	O
Malaise	O
27	O
(2%)	O
23	O
(1%)	O
26	O
(2%)	O
22	O
(1%)	O
Asthenia	B-D001247
29	O
(2%)	O
19	O
(1%)	O
17	O
(1%)	O
18	O
(1%)	O
Syncope	B-D013575
17	O
(1%)	O
13	O
(1%)	O
16	O
(1%)	O
8	O
(0%)	O
Psychiatric	O
Disorders	O
Amnesia	B-D000647
39	O
(2%)	O
40	O
(2%)	O
57	O
(3%)	O
34	O
(2%)	O
Confusion	B-D003221
18	O
(1%)	O
9	O
(1%)	O
22	O
(1%)	O
15	O
(1%)	O
Anorexia	B-D000855
19	O
(1%)	O
17	O
(1%)	O
10	O
(1%)	O
15	O
(1%)	O
Somnolence	O
20	O
(1%)	O
13	O
(1%)	O
18	O
(1%)	O
9	O
(1%)	O
Musculoskeletal	B-D009141
System	I-D009141
Disorders	O
Arthralgia	B-D018771
91	O
(6%)	O
75	O
(5%)	O
91	O
(6%)	O
76	O
(5%)	O
Arthritis	B-D001168
34	O
(2%)	O
25	O
(2%)	O
17	O
(1%)	O
19	O
(1%)	O
Art	B-D001154
hrosis	O
18	O
(1%)	O
22	O
(1%)	O
13	O
(1%)	O
14	O
(1%)	O
Myalgia	B-D063806
20	O
(1%)	O
16	O
(1%)	O
11	O
(1%)	O
11	O
(1%)	O
Respiratory	B-D012137
System	I-D012137
Disorders	O
Cough	B-D003371
ing	O
25	O
(2%)	O
18	O
(1%)	O
32	O
(2%)	O
21	O
(1%)	O
Upper	O
Respiratory	O
Tract	O
Infection	O
16	O
(1%)	O
9	O
(1%)	O
16	O
(1%)	O
14	O
(1%)	O
Cardiovascular	O
Disorders,	O
General	O
Cardia	B-D002299
c	O
Failure	O
26	O
(2%)	O
17	O
(1%)	O
30	O
(2%)	O
25	O
(2%)	O
Platelet,	O
Bleeding	O
&	O
Clotting	O
Disorders	O
Hemorrhage	B-D006470
NOS	O
52	O
(3%)	O
24	O
(1%)	O
46	O
(3%)	O
24	O
(1%)	O
Epistaxis	B-D004844
39	O
(2%)	O
16	O
(1%)	O
45	O
(3%)	O
25	O
(2%)	O
Purpura	B-D011693
23	O
(1%)	O
8	O
(0%)	O
9	O
(1%)	O
7	O
(0%)	O
Neoplasm	O
Neoplasm	O
NOS	O
28	O
(2%)	O
16	O
(1%)	O
23	O
(1%)	O
20	O
(1%)	O
Red	O
Blood	B-D001769
Cell	O
Disorders	O
Anemia	B-D000740
27	O
(2%)	O
16	O
(1%)	O
19	O
(1%)	O
9	O
(1%)	O
Discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
ESPS2	O
was	O
25%	O
for	O
AGGRENOX,	O
25%	O
for	O
extended-release	O
Dipyridamole	B-D004176

The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BID	O
Total	O
Number	O
of	O
Patients	B-D010361
1650	O
1654	O
1649	O
1649	O
Patients	B-D010361
with	O
at	O
least	O
one	O
Adverse	O
Eventthat	O
led	O
to	O
treatment	O
discontinuation	O
417	O
(25%)	O
419	O
(25%)	O
318	O
(19%)	O
352	O
(21%)	O
Headache	B-D006261
165	O
(10%)	O
166	O
(10%)	O
57	O
(3%)	O
69	O
(4%)	O
Dizziness	B-D004244
85	O
(5%)	O
97	O
(6%)	O
69	O
(4%)	O
68	O
(4%)	O
Nausea	B-D009325
91	O
(6%)	O
95	O
(6%)	O
51	O
(3%)	O
53	O
(3%)	O
Abdominal	B-D015746
Pain	I-D015746
74	O
(4%)	O
64	O
(4%)	O
56	O
(3%)	O
52	O
(3%)	O
Dyspepsia	B-D004415
59	O
(4%)	O
61	O
(4%)	O
49	O
(3%)	O
46	O
(3%)	O
Vomiting	B-D014839
53	O
(3%)	O
52	O
(3%)	O
28	O
(2%)	O
24	O
(1%)	O
Diarrhea	B-D003967
35	O
(2%)	O
41	O
(2%)	O
9	O
(<1%)	O
16	O
(<1%)	O
Stroke	B-D020521
39	O
(2%)	O
48	O
(3%)	O
57	O
(3%)	O
73	O
(4%)	O
Transient	O
Ischemic	O
Attack	O
35	O
(2%)	O
40	O
(2%)	O
26	O
(2%)	O
48	O
(3%)	O
Angina	B-D000787
Pectoris	I-D000787
23	O
(1%)	O
20	O
(1%)	O
16	O
(<1%)	O
26	O
(2%)	O
Headache	B-D006261
was	O
most	O
notable	O
in	O
the	O
first	O
month	O
of	O
treatment	O

Other	O
Adverse	O
Events	O
Adverse	O
reactions	O
that	O
occurred	O
in	O
less	O
than	O
1%	O
of	O
Patients	B-D010361

Body	O
as	O
a	O
Whole	O
:	O
Allergic	O
reaction,	O
Fever	B-D005334

Patients	B-D010361
with	O
high	O
frequency	O
Hearing	B-D034381
Loss	I-D034381

In	O
these	O
Patients	B-D010361

6.2	O
Post-Marketing	O
Experience	O
The	O
following	O
is	O
a	O
list	O
of	O
additional	O
adverse	O
reactions	O
that	O
have	O
been	O
reported	O
either	O
in	O
the	O
Literature	B-D008091

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Decisions	O
to	O
include	O
these	O
reactions	O
in	O
labeling	O
are	O
typically	O
based	O
on	O
one	O
or	O
more	O
of	O
the	O
following	O
factors:	O
(1)	O
seriousness	O
of	O
the	O
reaction,	O
(2)	O
frequency	O
of	O
reporting,	O
or	O
(3)	O
strength	O
of	O
causal	O
connection	O
to	O
AGGRENOX	O

Body	O
as	O
a	O
Whole	O
:	O
Hypothermia	B-D007035
,	O
Chest	B-D002637
Pain	I-D002637

WARNING:	O
ADDICTION,	O
ABUSE,	O
AND	O
MISUSE;	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938

Assess	O
each	O
patient’s	O
Risk	B-D012306

Opioid	O
Analgesic	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
Analgesics	B-D000700

Under	O
the	O
requirements	O
of	O
the	O
REMS,	O
drug	O
companies	O
with	O
approved	O
opioid	O
analgesic	O
products	O
must	O
make	O
REMS-compliant	O
Education	B-D004493

Health	B-D006262
care	O
providers	O
are	O
strongly	O
encouraged	O
to	O
complete	O
a	O
REMS-compliant	O
Education	B-D004493

Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Serious,	O
Life	B-D019369

Monitor	O
for	O
respiratory	O
Depression	B-D003863

Accidental	O
Ingestion	O
Accidental	O
ingestion	O
of	O
even	O
one	O
dose	O
of	O
butalbital	B-C004470

Risk	B-D012306
s	O
From	O
Concomitant	O
Use	O
With	O
Benzodiazepines	B-D001569
Or	O
Other	O
CNS	O
Depressants	O
Concomitant	O
use	O
of	O
opioids	O
with	O
Benzodiazepines	B-D001569

Reserve	O
concomitant	O
prescribing	O
of	O
butalbital	B-C004470

Limit	O
dosages	O
and	O
durations	O
to	O
the	O
minimum	O
required	O

Follow	O
Patients	B-D010361

Ultra-Rapid	O
Metabolism	B-D008660
of	O
Codeine	B-D003061
and	O
Other	O
Risk	B-D012307
Factors	I-D012307
for	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Child	B-D002648
ren	O
Life	B-D019369
-threatening	O
respiratory	O
Depression	B-D003863

Most	O
of	O
the	O
reported	O
cases	O
occurred	O
following	O
Tonsillectomy	B-D014068

butalbital	B-C004470

Avoid	O
the	O
use	O
of	O
butalbital	B-C004470

Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Prolonged	O
use	O
of	O
butalbital	B-C004470

If	O
opioid	O
use	O
is	O
required	O
for	O
a	O
prolonged	O
period	O
in	O
a	O
pregnant	O
woman,	O
advise	O
the	O
patient	O
of	O
the	O
Risk	B-D012306

Interactions	O
with	O
Drugs	O
Affect	B-D000339
ing	O
Cytochrome	O
P450	O
Isoenzymes	B-D007527
The	O
effects	O
of	O
concomitant	O
use	O
or	O
discontinuation	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
Codeine	B-D003061

Use	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
butalbital	B-C004470

WARNING:	O
ADDICTION,	O
ABUSE,	O
AND	O
MISUSE;	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938

butalbital	B-C004470

Assess	O
patient’s	O
Risk	B-D012306

(	O
5.1	O
)	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opio	O
i	O
d	O
Analgesics	B-D000700

(	O
5.2	O
)	O
Serious,	O
Life	B-D019369

Monitor	O
closely,	O
especially	O
upon	O
initiation	O
or	O
following	O
a	O
dose	O
increase	O
	O

(	O
5.3	O
)	O
Accidental	O
ingestion	O
of	O
butalbital	B-C004470

(	O
5.3	O
)	O
Concomitant	O
use	O
of	O
opioids	O
or	O
a	O
barbiturate	O
with	O
Benzodiazepines	B-D001569

Reserve	O
concomitant	O
prescribing	O
for	O
use	O
in	O
Patients	B-D010361

(	O
5.4	O
,	O
5.8	O
,	O
7	O
)	O
Life	B-D019369
-threatening	O
respiratory	O
Depression	B-D003863

(	O
5.5	O
)	O
butalbital	B-C004470

(	O
4	O
)	O
Avoid	O
the	O
use	O
of	O
butalbital	B-C004470

Prolonged	O
use	O
during	O
Pregnancy	B-D011247

If	O
prolonged	O
opioid	O
use	O
is	O
required	O
in	O
a	O
pregnant	O
woman,	O
advise	O
the	O
patient	O
of	O
the	O
Risk	B-D012306

(	O
5.6	O
)	O
The	O
effects	O
of	O
concomitant	O
use	O
or	O
discontinuation	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibi	O
tors	O
with	O
Codeine	B-D003061

Use	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
butalbital	B-C004470

(	O
5.7	O
,	O
5.8	O
,	O
7	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Patients	B-D010361
with	O
Chronic	O
Pulmonary	O
Disease	B-D004194
or	O
in	O
Elderly,	O
Cachectic,	O
or	O
Debilitated	O
Patients	B-D010361
:	O
Monitor	O
closely,	O
particularly	O
during	O
initiation	O
and	O
titration	O

(5.8)	O
Adrenal	B-D000309
Insufficiency	I-D000309
:	O
If	O
diagnosed,	O
treat	O
with	O
physiologic	O
replacement	O
of	O
corticosteroids,	O
and	O
wean	O
patient	O
off	O
the	O
opioid	O

(5.10)	O
Severe	O
Hypotensi	O
on:	O
Monitor	O
during	O
dose	O
initiation	O
and	O
titration	O

Avoid	O
use	O
of	O
butalbital	B-C004470

(5.11)	O
Risk	B-D012306
s	O
of	O
Use	O
in	O
Patients	B-D010361
with	O
Increased	O
Intracranial	B-D007427
Pressure	I-D007427
,	O
Brain	B-D001921
Tumors,	O
Head	B-D006257
Injury,	O
or	O
Impaired	O
Consciousness	B-D003243
:	O
Monitor	O
for	O
sedation	O
and	O
respiratory	O
Depression	B-D003863

Avoid	O
use	O
of	O
butalbital	B-C004470

(5.12)	O
5	O

1	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
butalbital	B-C004470

Codeine	B-D003061
in	O
combination	O
with	O
butalbital	B-C004470
,	O
Aspirin	B-D001241

As	O
butalbital	B-C004470
and	O
Codeine	B-D003061

Although	O
the	O
Risk	B-D012306

Addiction	O
can	O
occur	O
at	O
recommended	O
dosages	O
and	O
if	O
the	O
drug	O
is	O
misused	O
or	O
abused	O

Assess	O
each	O
patient’s	O
Risk	B-D012306

Risk	B-D012306
s	O
are	O
increased	O
in	O
Patients	B-D010361

The	O
potential	O
for	O
these	O
Risk	B-D012306

Patients	B-D010361
at	O
increased	O
Risk	B-D012306

Opioids	O
and	O
Barbiturates	B-D001463

Consider	O
these	O
Risk	B-D012306

Strategies	O
to	O
reduce	O
these	O
Risk	B-D012306

Contact	O
local	O
state	O
professional	O
licensing	O
board	O
or	O
state	O
Controlled	B-D061891
Substances	I-D061891

5.2	O
Opio	O
i	O
d	O
Analgesic	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
Analgesics	B-D000700

Under	O
the	O
requirements	O
of	O
the	O
REMS,	O
drug	O
companies	O
with	O
approved	O
opioid	O
analgesic	O
products	O
must	O
make	O
REMS-compliant	O
Education	B-D004493

Health	B-D006262
care	O
providers	O
are	O
strongly	O
encouraged	O
to	O
do	O
all	O
of	O
the	O
following:	O
•	O
Complete	O
a	O
REMS-compliant	O
Education	B-D004493
Blueprint	O
for	O
Health	B-D006262
care	O
Providers	O
Involved	O
in	O
the	O
Management	O
or	O
Support	O
of	O
Patients	B-D010361
with	O
Pain	B-D010146
	O

•	O
Discuss	O
the	O
safe	O
use,	O
serious	O
Risk	B-D012306

The	O
Patient	O
Counseling	B-D003376
Guide	O
(PCG)	O
can	O
be	O
obtained	O
at	O
this	O
link:	O
www.fda.gov/OpioidAnalgesicREMSPCG	O

•	O
Emphasize	O
to	O
Patients	B-D010361

•	O
Consider	O
using	O
other	O
tools	O
to	O
ImProv	B-C413303

To	O
obtain	O
further	O
information	O
on	O
the	O
opioid	O
analgesic	O
REMS	O
and	O
for	O
a	O
list	O
of	O
accredited	O
REMS	O
CME/CE,	O
call	O
1-800-503-0784,	O
or	O
log	O
on	O
to	O
www.opioidanalgesicrems.com	O

The	O
FDA	O
Blueprint	O
can	O
be	O
found	O
at	O
www.fda.gov/OpioidAnalgesicREMSBlueprint	O

5	O

3	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Serious,	O
Life	B-D019369

Respiratory	O
Depression	B-D003863

Management	O
of	O
respiratory	O
Depression	B-D003863

Carbon	B-D002245
Dioxide	I-D002245

While	O
serious,	O
Life	B-D019369

Monitor	O
Patients	B-D010361

To	O
reduce	O
the	O
Risk	B-D012306

Overestimating	O
the	O
butalbital	B-C004470

Accidental	O
ingestion	O
of	O
butalbital	B-C004470
	O

Opioids	O
can	O
cause	O
Sleep	B-D012890

Opioid	O
use	O
increases	O
the	O
Risk	B-D012306

In	O
Patients	B-D010361

5	O

4	O
Risk	B-D012306
s	O
from	O
Concomitant	O
Use	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants	O
Profound	O
sedation,	O
respiratory	O
Depression	B-D003863

Because	O
of	O
these	O
Risk	B-D012306

Observation	B-D019370
al	O
studies	O
have	O
demonstrated	O
that	O
concomitant	O
use	O
of	O
opioid	O
Analgesics	B-D000700

Because	O
of	O
similar	O
pharmacological	O
properties,	O
it	O
is	O
reasonable	O
to	O
expect	O
similar	O
Risk	B-D012306

If	O
the	O
decision	O
is	O
made	O
to	O
prescribe	O
a	O
benzodiazepine	O
or	O
other	O
CNS	O
depressant	O
concomitantly	O
with	O
an	O
opioid	O
analgesic,	O
prescribe	O
the	O
lowest	O
effective	O
dosages	O
and	O
minimum	O
durations	O
of	O
concomitant	O
use	O

In	O
Patients	B-D010361

If	O
an	O
opioid	O
analgesic	O
is	O
initiated	O
in	O
a	O
patient	O
already	O
taking	O
a	O
benzodiazepine	O
or	O
other	O
CNS	O
depressant,	O
prescribe	O
a	O
lower	O
initial	O
dose	O
of	O
the	O
opioid	O
analgesic,	O
and	O
titrate	O
based	O
on	O
clinical	O
response	O

Follow	O
Patients	B-D010361

Advise	O
both	O
Patients	B-D010361

Advise	O
Patients	B-D010361

Screen	O
Patients	B-D010361

5	O

5	O
Ultra-Rapid	O
Metabolism	B-D008660
of	O
Codeine	B-D003061
and	O
Other	O
Risk	B-D012307
Factors	I-D012307
for	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Child	B-D002648
ren	O
Life	B-D019369
-threatening	O
respiratory	O
Depression	B-D003863

Codeine	B-D003061
is	O
subject	O
to	O
variability	O
in	O
Metabolism	B-D008660

Based	O
upon	O
postmarketing	O
reports,	O
Child	B-D002648

For	O
example,	O
many	O
reported	O
cases	O
of	O
Death	B-D003643

Furthermore,	O
Child	B-D002648

Because	O
of	O
the	O
Risk	B-D012306

butalbital	B-C004470

Avoid	O
the	O
use	O
of	O
butalbital	B-C004470

Risk	B-D012307
Factors	I-D012307

As	O
with	O
Adult	B-D000328

N	O
ursing	O
M	O
oth	O
e	O
rs	O
At	O
least	O
one	O
Death	B-D003643

Breast	B-D001940
feeding	O
is	O
not	O
recommended	O
during	O
treatment	O
with	O
butalbital	B-C004470

C	O
Y	O
P2D6	O
G	O
e	O
n	O
e	O
tic	O
Variabilit	O
y	O
:	O
Ultra	O
-	O
rapid	O
m	O
e	O
taboliz	O
e	O
r	O
Some	O
individuals	O
may	O
be	O
ultra-rapid	O
metabolizers	O
because	O
of	O
a	O
specific	O
CYP2D6	O
Genotype	B-D005838

The	O
Prevalence	B-D015995

These	O
individuals	O
convert	O
Codeine	B-D003061

This	O
rapid	O
conversion	O
results	O
in	O
higher	O
than	O
expected	O
Serum	B-D044967

Even	O
at	O
labeled	O
dosage	O
regimens,	O
individuals	O
who	O
are	O
ultra-rapid	O
metabolizers	O
may	O
have	O
Life	B-D019369

Therefore,	O
individuals	O
who	O
are	O
ultra-rapid	O
metabolizers	O
should	O
not	O
use	O
butalbital	B-C004470

5	O

6	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Prolonged	O
use	O
of	O
butalbital	B-C004470

Neon	B-D009356
atal	O
opioid	O
withdrawal	O
Syndrome	B-D013577

Observe	O
newborns	O
for	O
signs	O
of	O
Neon	B-D009356

Advise	O
Pregnant	B-D037841
Women	I-D037841

5	O

7	O
Risk	B-D012306
s	O
of	O
Interactions	O
with	O
Drugs	O
Affect	B-D000339
ing	O
Cytochrome	O
P450	O
Isoenzymes	B-D007527
The	O
effects	O
of	O
concomitant	O
use	O
or	O
discontinuation	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
Codeine	B-D003061

Use	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
butalbital	B-C004470

Cytochrome	O
P450	O
3A4	O
Interaction	O
The	O
concomitant	O
use	O
of	O
butalbital	B-C004470

The	O
concomitant	O
use	O
of	O
butalbital	B-C004470

This	O
may	O
be	O
associated	O
with	O
a	O
decrease	O
in	O
efficacy,	O
and	O
in	O
some	O
Patients	B-D010361

Follow	O
Patients	B-D010361

If	O
concomitant	O
use	O
of	O
a	O
CYP3A4	O
inhibitor	O
is	O
necessary	O
or	O
if	O
a	O
CYP3A4	O
inducer	O
is	O
discontinued,	O
consider	O
dosage	O
reduction	O
of	O
butalbital	B-C004470

Monitor	O
Patients	B-D010361

If	O
concomitant	O
use	O
of	O
a	O
CYP3A4	O
inducer	O
is	O
necessary	O
or	O
if	O
a	O
CYP3A4	O
inhibitor	O
is	O
discontinued,	O
consider	O
increasing	O
the	O
butalbital	B-C004470

Monitor	O
for	O
signs	O
of	O
opioid	O
withdrawal	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)]	O

Risk	B-D012306
s	O
of	O
Concomitant	O
Use	O
or	O
Discontinuation	O
of	O
Cytochrome	O
P450	O
2D6	O
Inhibitors	O
The	O
concomitant	O
use	O
of	O
butalbital	B-C004470

Discontinuation	O
of	O
a	O
concomitantly	O
used	O
cytochrome	O
P450	O
2D6	O
inhibitor	O
may	O
result	O
in	O
a	O
decrease	O
in	O
Codeine	B-D003061

Follow	O
Patients	B-D010361

If	O
concomitant	O
use	O
with	O
a	O
CYP2D6	O
inhibitor	O
is	O
necessary,	O
follow	O
the	O
patient	O
for	O
signs	O
of	O
reduced	O
efficacy	O
or	O
opioid	O
withdrawal	O
and	O
consider	O
increasing	O
the	O
butalbital	B-C004470

After	O
stopping	O
use	O
of	O
a	O
CYP2D6	O
inhibitor,	O
consider	O
reducing	O
the	O
butalbital	B-C004470

5	O

8	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Patients	B-D010361
with	O
Chronic	O
Pulmonary	O
Disease	B-D004194
or	O
in	O
Elderly,	O
Cachectic,	O
or	O
Debilitated	O
Patients	B-D010361
The	O
use	O
of	O
butalbital	B-C004470

Patients	B-D010361
with	O
Chronic	O
Pulmonary	O
Disease	B-D004194
:	O
butalbital	B-C004470

Elderly,	O
Cachectic	O
,	O
or	O
Debilitated	O
Patients	B-D010361
:	O
Life	B-D019369
-threatening	O
respiratory	O
Depression	B-D003863

Monitor	O
such	O
Patients	B-D010361

Alternatively,	O
consider	O
the	O
use	O
of	O
non-opioid	O
Analgesics	B-D000700

5	O

9	O
Interaction	O
with	O
Monoamine	B-D008996
Oxidase	I-D008996
Inhibitors	I-D008996
Monoamine	B-D008996
Oxidase	I-D008996
Inhibitors	I-D008996

butalbital	B-C004470

5	O

10	O
Adrenal	B-D000309
Insufficiency	I-D000309
Cases	O
of	O
Adrenal	B-D000309
Insufficiency	I-D000309

Presentation	O
of	O
Adrenal	B-D000309
Insufficiency	I-D000309

If	O
Adrenal	B-D000309
Insufficiency	I-D000309

If	O
Adrenal	B-D000309
Insufficiency	I-D000309

Wean	O
the	O
patient	O
off	O
of	O
the	O
opioid	O
to	O
allow	O
adrenal	O
function	O
to	O
recover	O
and	O
continue	O
corticosteroid	O
treatment	O
until	O
adrenal	O
function	O
recovers	O

Other	O
opioids	O
may	O
be	O
tried	O
as	O
some	O
cases	O
reported	O
use	O
of	O
a	O
different	O
opioid	O
without	O
Recurrence	B-D012008

The	O
information	O
available	O
does	O
not	O
Id	B-D007060

5	O

1	O
1	O
Severe	O
Hypotension	B-D007022
butalbital	B-C004470

There	O
is	O
increased	O
Risk	B-D012306

Monitor	O
these	O
Patients	B-D010361

In	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
butalbital	B-C004470

5	O

1	O
2	O
Risk	B-D012306
s	O
of	O
Use	O
in	O
Patients	B-D010361
with	O
Increased	O
Intracranial	B-D007427
Pressure	I-D007427
,	O
Brain	B-D001921
Tumors,	O
Head	B-D006257
Injury,	O
or	O
Impaired	O
Consciousness	B-D003243
In	O
Patients	B-D010361

Monitor	O
such	O
Patients	B-D010361

Opioids	O
may	O
also	O
obscure	O
the	O
clinical	O
course	O
in	O
a	O
patient	O
with	O
a	O
Head	B-D006257

Avoid	O
the	O
use	O
of	O
butalbital	B-C004470

5	O

1	O
3	O
Risk	B-D012306
s	O
of	O
Use	O
in	O
Patients	B-D010361
with	O
Gastrointestinal	O
Conditions	O
Including	O
Peptic	B-D010437
Ulcer	I-D010437
Disease	B-D004194
butalbital	B-C004470

The	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
may	O
cause	O
Spasm	B-D013035

Opioids	O
may	O
cause	O
increases	O
in	O
Serum	B-D044967

Monitor	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
History	B-D006664

The	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
can	O
cause	O
GI	O
side	O
effects	O
including	O
Stomach	B-D013270

Although	O
minor	O
upper	O
GI	O
symptoms,	O
such	O
as	O
Dyspepsia	B-D004415

Physicians	B-D010820
should	O
inform	O
Patients	B-D010361

5	O

1	O
4	O
Increased	O
Risk	B-D012306
of	O
Seizures	B-D012640
in	O
Patients	B-D010361
with	O
Seizure	O
Disorders	O
The	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
may	O
increase	O
the	O
frequency	O
of	O
Seizures	B-D012640

Monitor	O
Patients	B-D010361

5	O

1	O
5	O
Withdrawal	O
Do	O
not	O
abruptly	O
discontinue	O
butalbital	B-C004470

Rapid	O
tapering	O
of	O
butalbital	B-C004470
,	O
Aspirin	B-D001241

Additionally,	O
avoid	O
the	O
use	O
of	O
mixed	O
agonist/antagonist	O
(e.g.,	O
Pentazocine	B-D010423

In	O
these	O
Patients	B-D010361

When	O
discontinuing	O
butalbital	B-C004470

Abrupt	O
discontinuation	O
of	O
butalbital	B-C004470
can	O
cause	O
Seizures	B-D012640

5	O

1	O
6	O
Risk	B-D012306
s	O
of	O
Driving	O
and	O
Operating	O
Machinery	O
butalbital	B-C004470

Warn	O
Patients	B-D010361

5.1	O
7	O
Coagulation	O
Abnormalities	O
and	O
Bleeding	O
Risk	B-D012306
s	O
Even	O
low	O
doses	O
of	O
Aspirin	B-D001241

This	O
can	O
adversely	O
Affect	B-D000339

hemophilia)	O
or	O
acquired	O
(i.e	O

Liver	B-D008099

Aspirin	B-D001241
is	O
contraindicated	O
in	O
Patients	B-D010361

Aspirin	B-D001241
administered	O
pre-operatively	O
may	O
prolong	O
the	O
Bleeding	B-D001760
Time	I-D001760

Patients	B-D010361
who	O
consume	O
three	O
or	O
more	O
alcoholic	O
drinks	O
every	O
day	O
should	O
be	O
counseled	O
about	O
the	O
bleeding	O
Risk	B-D012306

5.1	O
8	O
Reye’s	O
Syndrome	B-D013577
Aspirin	B-D001241
should	O
not	O
be	O
used	O
in	O
Child	B-D002648

5.1	O
9	O
Allergy	O
Aspirin	B-D001241
is	O
contraindicated	O
in	O
Patients	B-D010361

Aspirin	B-D001241
may	O
cause	O
severe	O
Urticaria	B-D014581

5	O

20	O
Drug/Laboratory	O
TES	B-C004551

Aspirin	B-D001241
may	O
interfere	O
with	O
the	O
following	O
laboratory	O
determinations	O
in	O
Urine	B-D014556

Codeine	B-D003061
:	O
Codeine	B-D003061
may	O
increase	O
Serum	B-D044967

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described,	O
or	O
described	O
in	O
greater	O
detail,	O
in	O
other	O
sections:	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)]	O
Interactions	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
Ultra-Rapid	O
Metabolism	B-D008660
of	O
Codeine	B-D003061
and	O
Other	O
Risk	B-D012307
Factors	I-D012307
for	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Child	B-D002648
ren	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)]	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)]	O
Adrenal	B-D000309
Insufficiency	I-D000309
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.10	O
)]	O
Severe	O
Hypotension	B-D007022
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.11	O
)]	O
Gastrointestinal	O
Adverse	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.13	O
)]	O
Seizures	B-D012640
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.14	O
)]	O
Withdrawal	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.15	O
)]	O
Coagulation	O
Abnormalities	O
and	O
Bleeding	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.17	O
)]	O
Reye’s	O
Syndrome	B-D013577
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.18	O
)]	O
Allergy	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.19	O
)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>	O
1%)	O
are	O
Nausea	B-D009325

(6)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Actavis	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

Incidence	B-D015994
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848
s	O
The	O
following	O
table	O
summarizes	O
the	O
Incidence	B-D015994

The	O
prescriber	O
should	O
be	O
aware	O
that	O
these	O
figures	O
cannot	O
be	O
used	O
to	O
predict	O
the	O
Incidence	B-D015994

Similarly,	O
the	O
cited	O
frequencies	O
cannot	O
be	O
compared	O
with	O
figures	O
obtained	O
from	O
other	O
clinical	O
investigations	O
involving	O
different	O
treatments,	O
uses,	O
and	O
investigators	O

Adverse	O
Events	O
Reported	O
by	O
at	O
Least	O
1%	O
of	O
butalbital	B-C004470

All	O
reported	O
adverse	O
events,	O
except	O
those	O
already	O
presented	O
in	O
the	O
previous	O
table,	O
are	O
included	O

It	O
is	O
important	O
to	O
emphasize	O
that,	O
although	O
the	O
adverse	O
events	O
reported	O
did	O
occur	O
while	O
the	O
patient	O
was	O
receiving	O
butalbital	B-C004470

Adverse	O
events	O
are	O
classified	O
by	O
body	O
system	O
and	O
frequency	O

“Frequent”	O
is	O
defined	O
as	O
an	O
adverse	O
event	O
which	O
occurred	O
in	O
at	O
least	O
1/100	O
(1%)	O
of	O
the	O
Patients	B-D010361

“Infrequent”	O
is	O
defined	O
as	O
an	O
adverse	O
event	O
that	O
occurred	O
in	O
less	O
than	O
1/100	O
Patients	B-D010361

All	O
adverse	O
events	O
tabulated	O
below	O
are	O
classified	O
as	O
infrequent	O

Centra	O
l	O
Nervous:	O
Headache	B-D006261

Autonomic	O
Nervous:	O
dry	O
Mouth	B-D009055

Gastrointestinal:	O
Vomiting	B-D014839

Cardiovascular:	O
Tachycardia	B-D013610

Musculoskeletal:	O
Leg	B-D007866

Genitourinary:	O
Diuresis	B-D004231

Miscellaneous:	O
Pruritus	B-D011537

The	O
following	O
adverse	O
drug	O
reactions	O
have	O
been	O
reported	O
with	O
the	O
components	O
of	O
butalbital	B-C004470

Potential	O
effects	O
of	O
high	O
dosage	O
are	O
listed	O
in	O
the	O
[	O
O	O
verdosage	O
(	O
10	O
)]	O
section	O
of	O
this	O
insert	O

Aspirin	B-D001241
:	O
Occult	B-D009780
Blood	I-D009780

Caffeine	B-D002110
:	O
Cardia	B-D002299

Codeine	B-D003061
:	O
Nausea	B-D009325

6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Centra	O
l	O
Nervous:	O
abuse,	O
addiction,	O
Anxiety	B-D001007

Autonomic	O
Nervous:	O
Epistaxis	B-D004844

Gastrointestinal:	O
Anorexia	B-D000855

Cardiovascular:	O
Chest	B-D002637
Pain	I-D002637

Skin	B-D012867
:	O
Erythema	B-D004890

Urinary:	O
Kidney	B-D007668

Miscellaneous:	O
allergic	O
reaction,	O
anaphylactic	O
Shock	B-D012769

Serotonin	B-D020230
Syndrome	I-D020230

Adrenal	B-D000309
Insufficiency	I-D000309

Anaphylaxis	B-D000707
:	O
Anaphylaxis	B-D000707
has	O
been	O
reported	O
with	O
ingredients	O
contained	O
in	O
butalbital	B-C004470

Androgen	O
deficiency:	O
Cases	O
of	O
androgen	O
deficiency	O
have	O
occurred	O
with	O
chronic	O
use	O
of	O
opioids	O
[see	O
Clinical	O
Pharmacology	B-D010600
(	O
12.2	O
)]	O

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

•	O
Naproxen	B-D009288

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS	O
)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS	O
)	O
Hepatotoxicity	O
(see	O
WARNINGS	O
)	O
Hypertension	B-D006973
(see	O
WARNINGS	O
)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS	O
)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS	O
)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS	O
)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS	O
)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS	O
)	O
Adverse	O
reactions	O
reported	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

In	O
general,	O
reactions	O
in	O
Patients	B-D010361

The	O
most	O
frequent	O
complaints	O
reported	O
related	O
to	O
the	O
Gastrointestinal	B-D041981
Tract	I-D041981

A	O
Clinical	B-D000068397
Study	I-D000068397

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

In	O
Patients	B-D010361

Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
Patients	B-D010361

In	O
Patients	B-D010361

Gastrointestinal	O
(GI)	O
Experiences	O
,	O
i	O
ncluding:	O
Flatulence	B-D005414

Those	O
adverse	O
reactions	O
observed	O
through	O
postmarketing	O
reports	O
are	O
italicized	O

Body	O
as	O
a	O
Whole:	O
anaphylactoid	O
reactions,	O
angioneurotic	O
Edema	B-D004487

E	O
sophagitis	O
,	O
Stomatitis	B-D013280

Hepatobiliary:	O
Jaundice	B-D007565

If	O
Skin	B-D012867

Special	O
Senses:	O
Hearing	B-D006309

Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS	O
)	O
Hepatotoxicity	O
(see	O
WARNINGS	O
)	O
Hypertension	B-D006973
(see	O
WARNINGS	O
)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS	O
)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS	O
)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS	O
)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS	O
)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS	O
)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS	O
)	O
Hepatotoxicity	O
(see	O
WARNINGS	O
)	O
Hypertension	B-D006973
(see	O
WARNINGS	O
)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS	O
)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS	O
)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS	O
)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS	O
)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS	O
)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Etodolac	B-D017308
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse-reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
to	O
1,000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064

Nervous	B-D009420
System	I-D009420

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566

*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
Death	B-D003643

The	O
Overall	B-D016424

Sulfite	O
sensitivity	O
is	O
seen	O
more	O
frequently	O
in	O
Asthma	B-D001249

5.2	O
Slow	O
or	O
Delayed	O
Healing	O
All	O
topical	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
slow	O
or	O
delay	O
healing	O

Topical	O
corticosteroids	O
are	O
also	O
known	O
to	O
slow	O
or	O
delay	O
healing	O

Concomitant	O
use	O
of	O
topical	O
NSAIDs	O
and	O
topical	O
Steroids	B-D013256

Therefore,	O
caution	O
should	O
be	O
used	O
when	O
treating	O
individuals	O
who	O
have	O
previously	O
exhibited	O
sensitivities	O
to	O
these	O
drugs	O

5.4	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
With	O
some	O
NSAIDs,	O
there	O
exists	O
the	O
potential	O
for	O
increased	O
Bleeding	B-D001760
Time	I-D001760

There	O
have	O
been	O
reports	O
that	O
ocularly	O
applied	O
NSAIDs	O
may	O
cause	O
increased	O
bleeding	O
of	O
ocular	O
Tissues	B-D014024

It	O
is	O
recommended	O
that	O
Bromday	O
ophthalmic	O
solution	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.5	O
Keratitis	B-D007634
and	O
Cornea	B-D003315
l	O
Reactions	O
Use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
Keratitis	B-D007634

In	O
some	O
susceptible	O
Patients	B-D010361

These	O
events	O
may	O
be	O
sight	O
threatening	O

Patients	B-D010361
with	O
evidence	O
of	O
Cornea	B-D003315

Post-marketing	O
experience	O
with	O
topical	O
NSAIDs	O
suggests	O
that	O
Patients	B-D010361

Topical	O
NSAIDs	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

Post-marketing	O
experience	O
with	O
topical	O
NSAIDs	O
also	O
suggests	O
that	O
use	O
more	O
than	O
24	O
hours	O
prior	O
to	O
surgery	O
or	O
use	O
beyond	O
14	O
days	O
post	O
surgery	O
may	O
increase	O
patient	O
Risk	B-D012306

5.6	O
Contact	O
Lens	O
Wear	O
Bromday	O
should	O
not	O
be	O
administered	O
while	O
wearing	O
Contact	B-D003261
Lenses	I-D003261

6	O
ADVERSE	O
REACTIONS	O
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
in	O
2-7%	O
of	O
Patients	B-D010361

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
ISTA	O
Pharmaceuticals,	O
Inc	O

at	O
1-877-788-2020,	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
Experience	O
The	O
most	O
commonly	O
reported	O
adverse	O
experiences	O
reported	O
following	O
use	O
of	O
bromfenac	B-C053083
after	O
Cataract	B-D002386

These	O
events	O
were	O
reported	O
in	O
2-7%	O
of	O
Patients	B-D010361

6.2	O
Post-Marketing	O
Experience	O
The	O
following	O
events	O
have	O
been	O
Id	B-D007060

Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

The	O
events,	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
bromfenac	B-C053083
ophthalmic	O
solution	O
0.09%	O
or	O
a	O
combination	O
of	O
these	O
factors,	O
include	O
Cornea	B-D003315

[see	O
Warnings	O
and	O
Precautions	O
(5)]	O
BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs	O
1)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

•	O
Etodolac	B-D017308
Capsules	B-D002214

Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS)	O

1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
nonsteroidal	O
anti-inflammatory	O
drug	O

Adverse	O
Reactions	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse-reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
to	O
1000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
or	O
Equal	O
to	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064

Nervous	B-D009420
System	I-D009420

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566

Musculoskeletal	O
-	O
Arthralgia	B-D018771
	O

*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566

Musculoskeletal	O
-	O
Muscle	O
Pain	B-D010146

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
Death	B-D003643

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Urogenital	B-D014566
System	I-D014566

WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

This	O
Risk	B-D012306

Piroxicam	B-D010894
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Piroxicam	B-D010894
is	O
contraindicated	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Piroxicam	B-D010894

If	O
Piroxicam	B-D010894

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Piroxicam	B-D010894

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Piroxicam	B-D010894

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
Alanine	B-D000409

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Piroxicam	B-D010894

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Piroxicam	B-D010894

Avoid	O
the	O
use	O
of	O
Piroxicam	B-D010894

If	O
Piroxicam	B-D010894

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Piroxicam	B-D010894

The	O
renal	O
effects	O
of	O
Piroxicam	B-D010894

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Piroxicam	B-D010894

If	O
Piroxicam	B-D010894

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Piroxicam	B-D010894
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Piroxicam	B-D010894

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Piroxicam	B-D010894

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Piroxicam	B-D010894

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Piroxicam	B-D010894
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Piroxicam	B-D010894

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Piroxicam	B-D010894

NSAIDs,	O
including	O
Piroxicam	B-D010894

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Piroxicam	B-D010894

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Ophthalmologic	O
Effects	O
Because	O
of	O
reports	O
of	O
adverse	O
Eye	B-D005123

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>2%	O
from	O
Clinical	B-D016430
Trial	I-D016430

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Greenstone	O
LLC	O
Professional	O
Information	B-D007255
Services	I-D007255
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Body	O
As	O
a	O
Whole:	O
Fever	B-D005334
,	O
infection,	O
Sepsis	B-D018805

This	O
Risk	B-D012306

(	O
5.1)	O
•	O
NALFON	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

This	O
Risk	B-D012306

[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O

•	O
NALFON	O
®	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
NALFON	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
NALFON	O
in	O
Patients	B-D010361

If	O
NALFON	O
is	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
NALFON,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
Inflammation	B-D007249

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361
:	O
•Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

•Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

•Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

•Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

•If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
NALFON	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

•In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
NALFON,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Fenoprofen	B-D005279

Avoid	O
the	O
use	O
of	O
NALFON	O
in	O
Patients	B-D010361

If	O
NALFON	O
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
NALFON	O
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
NALFON	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
NALFON	O
in	O
Patients	B-D010361

If	O
NALFON	O
is	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Fenoprofen	B-D005279
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
NALFON	O
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
fenoprop	B-C009264
fen,	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

NALFON	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Fenoprofen	B-D005279
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
NALFON,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
NALFON	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

NSAIDs,	O
including	O
NALFON,	O
may	O
increase	O
the	O
Risk	B-D012306

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
NALFON	O
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Ocular	O
Effects	O
Studies	O
to	O
date	O
have	O
not	O
shown	O
changes	O
in	O
the	O
Eye	B-D005123

However,	O
adverse	O
ocular	O
effects	O
have	O
been	O
observed	O
with	O
other	O
anti-inflammatory	O
drugs	O

Eye	B-D005123
examinations,	O
therefore,	O
should	O
be	O
performed	O
if	O
visual	O
disturbances	O
occur	O
in	O
Patients	B-D010361

5.15	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects	O
Caution	O
should	O
be	O
Exercise	B-D015444

5.16	O
Impact	O
on	O
Hearing	B-D006309
Since	O
the	O
Safety	B-D012449

6	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O
•Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3)	O
]	O
•Hypertension	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)	O
]	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5)	O
]	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6)	O
]	O
•Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7)	O
]	O
•Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9)	O
]	O
•Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥	O
5%)	O
are	O
Dyspepsia	B-D004415
,	O
Headache	B-D006261

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Xspire	O
Pharma	O
at	O
1-601-990-9497	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

During	O
clinical	O
studies	O
for	O
Rheum	B-D012250

These	O
encompass	O
Observation	B-D019370

For	O
comparison,	O
data	O
are	O
also	O
presented	O
from	O
complaints	O
received	O
from	O
the	O
266	O
Patients	B-D010361

During	O
short-term	O
studies	O
for	O
Analgesia	B-D000698

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
>1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—	O
During	O
Clinical	B-D016430
Trial	I-D016430

In	O
descending	O
order	O
of	O
frequency,	O
these	O
reactions	O
included	O
Dyspepsia	B-D004415

2.3%	O
placebo),	O
Nausea	B-D009325

7.1%),	O
Constipation	B-D003248

1.5%),	O
Vomiting	B-D014839

1.9%),	O
Abdominal	B-D015746
Pain	I-D015746

1.1%),	O
and	O
Diarrhea	B-D003967

4.1%)	O

The	O
drug	O
was	O
discontinued	O
because	O
of	O
adverse	O
gastrointestinal	O
reactions	O
in	O
less	O
than	O
2%	O
of	O
Patients	B-D010361

Nervous	B-D009420
System	I-D009420
—	O
The	O
most	O
frequent	O
adverse	O
neurologic	O
reactions	O
were	O
Headache	B-D006261

7.5%)	O
and	O
somnolence	O
(8.5%	O
vs	O

6.4%)	O

Dizziness	B-D004244
(6.5%	O
vs	O

5.6%),	O
Tremor	B-D014202

0.4%),	O
and	O
Confusion	B-D003221

none)	O
were	O
noted	O
less	O
frequently	O

Nalfon	O
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Skin	B-D012867
and	O
Appendages—	O
Increased	O
Sweating	B-D013546

0.4%),	O
Pruritus	B-D011537

0.8%),	O
and	O
rash	O
(3.7%	O
vs	O

0.4%)	O
were	O
reported	O

Nalfon	O
was	O
discontinued	O
in	O
about	O
1%	O
of	O
Patients	B-D010361

Special	O
Senses	O
—	O
Tinnitus	B-D014012
(4.5%	O
vs	O

0.4%),	O
blurred	O
vision	O
(2.2%	O
vs	O

none),	O
and	O
decreased	O
Hearing	B-D006309

none)	O
were	O
reported	O

Nalfon	O
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Cardiovascular	O
—	O
Palpitations	O
(2.5%	O
vs	O

0.4%)	O

Nalfon	O
was	O
discontinued	O
in	O
about	O
0.5%	O
of	O
Patients	B-D010361

Miscellaneous	O
—	O
Nervousness	O
(5.7%	O
vs	O

1.5%),	O
Asthenia	B-D001247

0.4%),	O
peripheral	O
Edema	B-D004487

0.4%),	O
Dyspnea	B-D004417

none),	O
Fatigue	B-D005221

1.5%),	O
upper	O
respiratory	O
infection	O
(1.5%	O
vs	O

5.6%),	O
and	O
nas	B-C015378
opharyngitis	O
(1.2%	O
vs	O

none)	O

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
<1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—Gastritis,	O
Peptic	B-D010437
Ulcer	I-D010437

Increases	O
in	O
Alkaline	B-D000469
Phosphatase	I-D000469

Cardiovascular—Atrial	O
fibrillation,	O
Pulmonary	B-D011654
Edema	I-D011654

Genitourinary	O
Tract—Renal	O
failure,	O
Dysuria	B-D053159

Hypersensitivity	B-D006967
—Angioedema	O
(angioneurotic	O
Edema	B-D004487

Hematologic—Purpura,	O
bruising,	O
Hemorrhage	B-D006470

Nervous	B-D009420
System	I-D009420
—Depression,	O
disorientation,	O
Seizures	B-D012640

Special	O
Senses—Burning	O
Tongue	B-D014059

Skin	B-D012867
and	O
Appendages—Exfoliative	O
Dermatitis	B-D003872

Miscellaneous—Anaphylaxis,	O
Urticaria	B-D014581

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,	O
14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
knownCV	O
Disease	B-D004194

•	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
Risk	B-D012306

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
thesepatients	O
(5.4,	O
8.5,	O
14.6,	O
17.3)	O

•	O
Elevated	O
Liver	B-D008099

Discontinue	O
use	O
of	O
Celecoxib	B-D000068579

•	O
New	O
onset	O
or	O
worsening	O
of	O
Hypertension	B-D006973

Blood	B-D001794
Pressure	I-D001794

•	O
Fluid	O
retention	O
and	O
Edema	B-D004487

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

•	O
Renal	O
papillary	O
Necrosis	B-D009336

Use	O
Celecoxib	B-D000068579

•	O
Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
Celecoxib	B-D000068579

•	O
Serious	O
Skin	B-D012867

Discontinue	O
Celecoxib	B-D000068579

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovasculardeath,	O
MI,	O
or	O
Stroke	B-D020521

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

Therefore,	O
treatment	O
with	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
postmarketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9	O
Pregnancy	B-D011247
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

Celecoxib	B-D000068579
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
Patients	B-D010361

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
Celecoxib	B-D000068579

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sydon	O
Labs,	O
LLC	O
at	O
1	O
866-487-4695	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
>2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4,	O
146	O
Placebo	O
N=1,	O
864	O
NAP	O
N=1,	O
366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
Diarrhea	B-D003967
Dyspepsia	B-D004415
Flatulence	B-D005414
Nausea	B-D009325
4.1%5.6%8.8%2.2%3.5%	O
2.8%3.8%6.2%1%4.2%	O
7.7%5.3%12.2%3.6%6%	O
9%9.3%10.9%4.1%3.4%	O
9%5.8%12.8%3.5%6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
Peripheral	O
Edema	B-D004487
Injury-Accidental	O
2.8%2.1%2.9%	O
3.6%1.1%2.3%	O
2.2%2.1%3%	O
2.6%1%2.6%	O
0.9%3.5%3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

In	O
placebo-	O
or	O
active-controlled	O
Clinical	B-D016430
Trial	I-D016430

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(>5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(>5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
>5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
postdental	O
extraction	O
alveolar	O
Osteitis	B-D010000

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(	O
5.1)	O
Diclofenac	B-D004008
Sodium	B-D012964

(	O
4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(	O
5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964

Monitor	O
Patients	B-D010361

(	O
5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
Hematocrit	B-D006400

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Diclofenac	B-D004008

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatic	O
Effects	O
In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
Diclofenac	B-D004008

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008

The	O
renal	O
effects	O
of	O
Diclofenac	B-D004008

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactoid	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Diclofenac	B-D004008

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Diclofenac	B-D004008

NSAIDs,	O
including	O
Diclofenac	B-D004008

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
Art	B-D001154

The	O
potential	O
effects	O
of	O
Diclofenac	B-D004008

5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
Diclofenac	B-D004008

Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
Eye	B-D005123

5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
and	O
topical	O
NSAIDs	O
may	O
result	O
in	O
a	O
higher	O
rate	O
of	O
Hemorrhage	B-D006470

Do	O
not	O
use	O
combination	O
therapy	O
with	O
Diclofenac	B-D004008

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>2%	O
of	O
Patients	B-D010361

(	O
6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
GlaxoSmithKline	O
Consumer	O
Health	B-D006262
care	O
at	O
1	O
-855-297-3031	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

During	O
clinical	O
development,	O
913	O
Patients	B-D010361

Of	O
these,	O
513	O
Patients	B-D010361

Additionally,	O
583	O
Patients	B-D010361

Of	O
these,	O
355	O
Patients	B-D010361

Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
Safety	B-D012449

Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
Patients	B-D010361

These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>1%	O
of	O
treated	O
Patients	B-D010361

Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported	O

Application	O
site	O
Dermatitis	B-D003872

Table	O
1	O

Non-serious	O
Application	O
Site	O
Adverse	O
Reactions	O
(≥1%	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Gel	O
Patients	B-D010361
)	O
–	O
Short-term	O
Controlled	O
Trials	O
†	O
Preferred	O
Term	O
according	O
to	O
MedDRA	O
9.1	O

Adverse	O
Reaction	O
†	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Gel	O
N=913	O
Placebo	O
(vehicle)	O
N=876	O
N	O
(%)	O
N	O
(%)	O
Any	O
application	O
site	O
reaction	O
62	O
(7)	O
19	O
(2)	O
Application	O
site	O
Dermatitis	B-D003872

Application	O
site	O
reactions,	O
including	O
application	O
site	O
Dermatitis	B-D003872

Long-Term	O
Open-Label	O
Safety	B-D012449
Trial:	O
In	O
the	O
open-label,	O
long-term	O
Safety	B-D012449

In	O
this	O
study,	O
where	O
Patients	B-D010361

Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
Patients	B-D010361

The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
Dermatitis	B-D003872

WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

(4	O
,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Celecoxib	B-D000068579
Capsules	B-D002214

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
Risk	B-D012306

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

A	O
Randomized	B-D016449
Controlled	I-D016449
Trial	I-D016449

Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
Risk	B-D012306

Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
Naproxen	B-D009288

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Celecoxib	B-D000068579

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

See	O
Clinical	O
Studies	O
(14.6,	O
14.7)	O
for	O
additional	O
Blood	B-D001794
Pressure	I-D001794

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.7)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

The	O
renal	O
effects	O
of	O
Celecoxib	B-D000068579

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Celecoxib	B-D000068579

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Celecoxib	B-D000068579

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
Risk	B-D012306

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp	O

at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

In	O
placebo-	O
or	O
active-controlled	O
Clinical	B-D016430
Trial	I-D016430

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Vertigo	B-D014717

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-	O
controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

ADMINISTRATION	O
OF	O
Misoprostol	B-D016595

Uterine	B-D014597
Rupture	I-D014597

Arthrotec	B-C078133

Patients	B-D010361

Arthrotec	B-C078133

In	O
such	O
Patients	B-D010361

is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures	O

has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
Misoprostol	B-D016595

will	O
begin	O
Arthrotec	B-C078133

Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Arthrotec	B-C078133

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
Adverse	O
reactions	O
associated	O
with	O
Arthrotec	B-C078133

Gastrointestinal	O
GI	O
disorders	O
had	O
the	O
highest	O
reported	O
Incidence	B-D015994

These	O
events	O
were	O
generally	O
minor,	O
but	O
led	O
to	O
discontinuation	O
of	O
therapy	O
in	O
9%	O
of	O
Patients	B-D010361

For	O
GI	O
Ulcer	B-D014456

GI	O
disorder	O
Arthrotec	B-C078133

Diarrhea	B-D003967
and	O
Abdominal	B-D015746
Pain	I-D015746

Rare	O
instances	O
of	O
profound	O
Diarrhea	B-D003967

Patients	B-D010361
with	O
an	O
underlying	O
condition	O
such	O
as	O
inflammatory	O
bowel	O
Disease	B-D004194

The	O
Incidence	B-D015994

Gynecological	O
Gynecological	O
disorders	O
previously	O
reported	O
with	O
Misoprostol	B-D016595

Postmenopausal	O
Vagina	B-D014621

If	O
it	O
occurs,	O
diagnostic	O
Work	B-D014937

Elderly	O
Overall	B-D016424
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
Safety	B-D012449

Other	O
adverse	O
experiences	O
reported	O
occasionally	O
or	O
rarely	O
with	O
Arthrotec	B-C078133

Cardiovascular	B-D002319
System	I-D002319

Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Digestive:	O
Anorexia	B-D000855
,	O
Appetite	B-D001066

Female	B-D005260
reproductive	O
disorders:	O
Breast	B-D001940
Pain	B-D010146

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Hypersensitivity	B-D006967
:	O
Angioedema	B-D000799
,	O
laryngeal/pharyngeal	O
Edema	B-D004487

Liver	B-D008099
and	O
biliary	O
system:	O
Abnormal	O
hepatic	O
function,	O
Bilirubin	B-D001663

Male	B-D008297
reproductive	O
disorders:	O
Impotence,	O
perineal	O
Pain	B-D010146

Metabolic	O
and	O
nutritional:	O
Alanine	B-D000409
aminotransferase	O
increased,	O
Alkaline	B-D000469
Phosphatase	I-D000469

Musculoskeletal	B-D009141
System	I-D009141

Psychiatric:	O
Anxiety	B-D001007
,	O
concentration	O
impaired,	O
Confusion	B-D003221

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages:	O
Acne,	O
Alopecia	B-D000505

Special	O
senses:	O
Hearing	B-D006309
impairment,	O
Taste	B-D013649

Urinary	O
system:	O
Cystitis	B-D003556
,	O
Dysuria	B-D053159

Vision:	O
Amblyopia	B-D000550
,	O
blurred	O
vision,	O
Conjunctivitis	B-D003231

BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
·	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

·	O
Ibuprofen	B-D007052
Tablets	B-D013607
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
Ibuprofen	B-D007052

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052

Adverse	O
reactions	O
observed	O
during	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
Observation	B-D019370

More	O
than	O
500	O
of	O
these	O
Patients	B-D010361

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
Clinical	B-D016430
Trial	I-D016430

The	O
increases	O
in	O
Incidence	B-D015994

Incidence	B-D015994
Greater	O
than	O
1%(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINAL	O
Nausea	B-D009325
*,	O
epigastric	O
Pain	B-D010146

Henoch-Schonlein	O
Vasculitis	B-D014657

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
Patients	B-D010361

**Reactions	O
are	O
classified	O
under	O
“Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“CausalRelationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Indomethacin	B-D007213
may	O
mask	O
the	O
usual	O
signs	O
of	O
infection	O

(5.1)	O
Monitor	O
for	O
signs	O
of	O
hepatic	O
reactions	O

Indomethacin	B-D007213
for	O
Injection	O
may	O
need	O
to	O
be	O
discontinued	O

(5.2)	O
Indomethacin	B-D007213
for	O
Injection	O
may	O
inhibit	O
Platelet	B-D010974
Aggregation	I-D010974

(5.3)	O
Gastrointestinal	O
Effects:	O
Monitor	O
Neon	B-D009356

(5.4)	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects:	O
Monitor	O
Neon	B-D009356

(5.5)	O
Renal	O
Effects:	O
Monitor	O
renal	O
function	O
and	O
Serum	B-D044967

(5.6)	O
5.1	O
Infection	O
Indomethacin	B-D007213
may	O
mask	O
the	O
usual	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

Therefore,	O
the	O
physician	O
must	O
be	O
continually	O
on	O
the	O
alert	O
for	O
this	O
and	O
should	O
use	O
the	O
drug	O
with	O
extra	O
care	O
in	O
the	O
presence	O
of	O
existing	O
controlled	O
infection	O

5.2	O
Hepatic	O
Reactions	O
Severe	O
hepatic	O
reactions	O
have	O
been	O
reported	O
in	O
Adult	B-D000328

[For	O
further	O
information,	O
see	O
package	O
insert	O
for	O
oral	O
Indomethacin	B-D007213

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.3	O
Platelet	B-D010974
Aggregation	I-D010974
Indomethacin	B-D007213
for	O
Injection	O
may	O
inhibit	O
Platelet	B-D010974
Aggregation	I-D010974

In	O
one	O
small	O
study,	O
Platelet	B-D010974
Aggregation	I-D010974

Platelet	B-D010974
Aggregation	I-D010974

Observe	O
Prema	B-C070504

5.4	O
Gastrointestinal	O
Effects	O
In	O
the	O
collaborative	O
study,	O
major	O
gastrointestinal	O
bleeding	O
was	O
no	O
more	O
common	O
in	O
Neon	B-D009356

However,	O
minor	O
gastrointestinal	O
bleeding	O
(i.e.,	O
chemical	O
detection	O
of	O
Blood	B-D001769

Severe	O
gastrointestinal	O
effects	O
have	O
been	O
reported	O
in	O
Adult	B-D000328

[For	O
further	O
information,	O
see	O
package	O
insert	O
for	O
oral	O
Indomethacin	B-D007213

5.5	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects	O
Prema	B-C070504
turity	O
per	O
se	O
is	O
associated	O
with	O
an	O
increased	O
Incidence	B-D015994

Because	O
Indomethacin	B-D007213

However,	O
in	O
the	O
large	O
Multicenter	B-D016448
Study	I-D016448

5.6	O
Renal	O
Effects	O
Indomethacin	B-D007213
for	O
Injection	O
may	O
cause	O
significant	O
reduction	O
in	O
Urine	B-D014556

These	O
effects	O
in	O
most	O
Neon	B-D009356

However,	O
because	O
adequate	O
renal	O
function	O
can	O
depend	O
upon	O
renal	O
prostaglandin	O
synthesis,	O
Indomethacin	B-D007213
for	O
Injection	O
may	O
precipitate	O
Renal	B-D051437
Insufficiency	I-D051437

When	O
significant	O
suppression	O
of	O
Urine	B-D014556

Indomethacin	B-D007213
for	O
Injection	O
in	O
pre-term	O
Infant	B-D007223

When	O
this	O
occurs,	O
a	O
significant	O
reduction	O
in	O
Serum	B-D044967

Monitor	O
renal	O
function	O
and	O
Serum	B-D044967

5.7	O
Administration	O
Administer	O
Indomethacin	B-D007213
for	O
Injection	O
carefully	O
to	O
avoid	O
extravascular	O
injection	O
or	O
leakage	O
as	O
the	O
solution	O
may	O
be	O
irritating	O
to	O
tissue	O

6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
adverse	O
reactions	O
are	O
bleeding	O
problems,	O
higher	O
Incidence	B-D015994

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Fresenius	O
Kabi	O
USA,	O
LLC	O
at	O
1-800-551-7176	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
In	O
a	O
double-blind,	O
placebo-controlled	O
trial	O
of	O
405	O
Prema	B-C070504

There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
treatment	O
groups	O
in	O
intracranial	O
Hemorrhage	B-D006470

The	O
Neon	B-D009356

The	O
Incidence	B-D015994

The	O
following	O
additional	O
adverse	O
reactions	O
in	O
Neon	B-D009356

The	O
rates	O
are	O
calculated	O
from	O
a	O
Database	B-D019991

One	O
year	O
follow-up	O
is	O
available	O
on	O
175	O
Neon	B-D009356

In	O
controlled	O
clinical	O
studies,	O
only	O
electrolyte	O
imbalance	O
and	O
renal	O
dysfunction	O
(of	O
the	O
reactions	O
listed	O
below)	O
occurred	O
statistically	O
significantly	O
more	O
frequently	O
after	O
Indomethacin	B-D007213
for	O
Injection	O
than	O
after	O
placebo	O

Reactions	O
marked	O
with	O
a	O
single	O
asterisk	O
(*)	O
occurred	O
in	O
3	O
to	O
9	O
percent	O
of	O
Indomethacin	B-D007213

Unmarked	O
reactions	O
occurred	O
in	O
less	O
than	O
3	O
percent	O
of	O
Neon	B-D009356

Renal:	O
renal	O
failure,	O
renal	O
dysfunction	O
in	O
41	O
percent	O
of	O
Neon	B-D009356

Cardiovascular:	O
intracranial	O
bleeding**,	O
pulmonary	O
Hypertension	B-D006973

Gastrointestinal:	O
gastrointestinal	O
bleeding*,	O
Vomiting	B-D014839

Metabolic:	O
Hyponatremia	B-D007010

Coagulation:	O
decreased	O
Platelet	B-D010974
Aggregation	I-D010974

The	O
following	O
adverse	O
reactions	O
have	O
also	O
been	O
reported	O
in	O
Neon	B-D009356

Respiratory:	O
Apnea	B-D001049

Metabolic:	O
Acidosis	B-D000138

Hematologic:	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211

Ophthalmic:	O
retrolental	O
fibroplasia.**	O
A	O
variety	O
of	O
additional	O
adverse	O
experiences	O
have	O
been	O
reported	O
in	O
Adult	B-D000328

Their	O
relevance	O
to	O
the	O
pre-term	O
Infant	B-D007223

BOXED	O
WARNING	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
As	O
A	O
Whole:fever,	O
infection,	O
Sepsis	B-D018805

4	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
5	O

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

(4	O
,	O
5.1)	O
6	O

NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
1	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

2	O

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
1	O

NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
10	O

Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
Celecoxib	B-D000068579

Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
use	O
of	O
Celecoxib	B-D000068579

Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
15	O

Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Celecoxib	B-D000068579
Capsules	B-D002214

Monitor	O
Patients	B-D010361

Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
Celecoxib	B-D000068579

Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
Pregnant	B-D037841
Women	I-D037841

Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
Hematocrit	B-D006400

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
Risk	B-D012306

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

A	O
Randomized	B-D016449
Controlled	I-D016449
Trial	I-D016449

Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
Risk	B-D012306

Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
Naproxen	B-D009288

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

2.Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

3.Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

4.Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Celecoxib	B-D000068579

6.In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

See	O
Clinical	O
Studies	O
(14.6,	O
14.7)	O
for	O
additional	O
Blood	B-D001794
Pressure	I-D001794

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.7)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

The	O
renal	O
effects	O
of	O
Celecoxib	B-D000068579

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Celecoxib	B-D000068579

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Celecoxib	B-D000068579

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
Risk	B-D012306

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
1.Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
2.GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
3.Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
4.Hypertension	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
5.Heart	O
Failure	O
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
6.Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
7.Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
8.Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
9.Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp	O

at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

In	O
placebo-	O
or	O
active-controlled	O
Clinical	B-D016430
Trial	I-D016430

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
%	O
to	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-	O
controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

In	O
Cataract	B-D002386

Elevated	O
Intraocular	B-D007429
Pressure	I-D007429

Lacrimation	O
complaints	O
were	O
reported	O
in	O
approximately	O
30%	O
of	O
case	O
studies	O
undergoing	O
incisional	O
refractive	O
surgery	O

The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
approximately	O
10%	O
or	O
less	O
of	O
Patients	B-D010361

Systemic	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
3%	O
or	O
less	O
of	O
Patients	B-D010361

Clinical	O
Practice	O
The	O
following	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

The	O
reactions,	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
Diclofenac	B-D004008

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

•	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
is	O
contraindicated	O
in	O
the	O
perioperative	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306

Cardiovascular	O
Risk	B-D012306
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1)	O
•	O
Diclofenac	B-D004008
Sodium	B-D012964

(4)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Use	O
the	O
lowest	O
effective	O
dose	O
of	O
Diclofenac	B-D004008

(5.1)	O
•NSAIDs	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
Inflammation	B-D007249

Prescribe	O
Diclofenac	B-D004008

(5.2)	O
•Elevation	O
of	O
one	O
or	O
more	O
Liver	B-D008099

Discontinue	O
Diclofenac	B-D004008

(5.3)	O
•Hypertension	O
can	O
occur	O
with	O
NSAID	O
treatment	O

Monitor	O
Blood	B-D001794
Pressure	I-D001794

(5.4)	O
•Use	O
Diclofenac	B-D004008

(5.5)	O
•Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Use	O
Diclofenac	B-D004008

(5.6)	O
•Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

(5.7)	O
•NSAIDs	O
can	O
cause	O
serious	O
Skin	B-D012867

(5.8)	O
•Not	O
for	O
use	O
during	O
Pregnancy	B-D011247

(5.9)	O
•Do	O
not	O
administer	O
to	O
Patients	B-D010361

(5.10)	O
•Avoid	O
exposure	O
of	O
treated	O
Knee	B-D007717

(5.11)	O
•Avoid	O
contact	O
of	O
Diclofenac	B-D004008

(5.12)	O
•Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs	O

(5.13)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

All	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Inform	O
Patients	B-D010361

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Prescribe	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

For	O
high-risk	O
Patients	B-D010361

5.3	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
(less	O
than	O
3	O
Time	B-D013995

Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
Liver	B-D008099

In	O
Clinical	B-D016430
Trial	I-D016430

In	O
an	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
Patients	B-D010361

In	O
this	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
NSAID	O
therapy	O

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
inform	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
Diclofenac	B-D004008

Caution	O
Patients	B-D010361

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008

Use	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Patients	B-D010361
taking	O
ACE-inhibitors,	O
Thiazides	B-D049971

5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
Diclofenac	B-D004008

5.6	O
Renal	O
Effects	O
Use	O
caution	O
when	O
initiating	O
treatment	O
with	O
Diclofenac	B-D004008

Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008

Therefore,	O
treatment	O
with	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

Do	O
not	O
prescribe	O
Diclofenac	B-D004008

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Seek	O
emergency	O
help	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Do	O
not	O
apply	O
Diclofenac	B-D004008

NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

5.9	O
Pregnancy	B-D011247
Diclofenac	B-D004008
Sodium	B-D012964

5.10	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross-reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.11	O
Sun	O
Exposure	O
Instruct	O
Patients	B-D010361

The	O
potential	O
effects	O
of	O
Diclofenac	B-D004008

5.12	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
Diclofenac	B-D004008

Advise	O
Patients	B-D010361

5.13	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
Diclofenac	B-D004008

Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
Diclofenac	B-D004008

5.14	O
Corticosteroid	O
Treatment	O
Diclofenac	B-D004008
Sodium	B-D012964

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

For	O
Patients	B-D010361

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.16	O
Hematological	O
Effects	O
The	O
effects	O
of	O
Diclofenac	B-D004008

There	O
was	O
no	O
significant	O
change	O
in	O
Platelet	B-D010974
Aggregation	I-D010974

Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
Blood	B-D001769

Check	O
hemoglobin	O
or	O
Hematocrit	B-D006400

NSAIDs	O
inhibit	O
Platelet	B-D010974
Aggregation	I-D010974

Unlike	O
Aspirin	B-D001241

Carefully	O
monitor	O
Patients	B-D010361

5.17	O
Monitoring	O
Because	O
serious	O
GI	O
tract	O
Ulcer	B-D014456

Check	O
CBC	O
and	O
a	O
Chemistry	B-D002621

Discontinue	O
Diclofenac	B-D004008

6	O
ADVERSE	O
REACTIONS	O
The	O
most	O
common	O
adverse	O
events	O
with	O
Diclofenac	B-D004008

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
the	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
Diclofenac	B-D004008

The	O
Population	B-D011153

The	O
most	O
common	O
adverse	O
events	O
with	O
Diclofenac	B-D004008

These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies	O

Application	O
Site	O
Reactions	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment-related	O
adverse	O
events	O
in	O
Patients	B-D010361

Application	O
site	O
reactions	O
were	O
Character	B-D002605

The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
Skin	B-D012867

In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
Dermatitis	B-D003872

In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
Safety	B-D012449

Adverse	O
Events	O
Common	O
to	O
the	O
NSAID	O
Class	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
Diclofenac	B-D004008

The	O
combination	O
of	O
Diclofenac	B-D004008

less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
Creatinine	B-D003404

7%),	O
Urea	B-D014508

12%),	O
and	O
hemoglobin	O
(13%	O
vs	O

9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
Liver	B-D008099

Table	O
1	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
Patients	B-D010361

Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
Patients	B-D010361

Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
N=911	O
Topical	O
Placebo	O
N=332	O
Adverse	O
Reaction	O
Preferred	O
Term	O
according	O
to	O
COSTART	O
N	O
(%)	O
N	O
(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non-U.S	O

postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
Diclofenac	B-D004008

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Body	O
as	O
a	O
Whole:	O
Abdominal	B-D015746
Pain	I-D015746

This	O
Risk	B-D012306

•Diclofenac	O
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS	O
)	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS	O
)	O
•Hepatotoxicity	O
(see	O
WARNINGS	O
)	O
•Hypertension	O
(see	O
WARNINGS	O
)	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
(see	O
WARNINGS	O
)	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS	O
)	O
•Anaphylactic	O
Reactions	O
(see	O
WARNINGS	O
)	O
•Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS	O
)	O
•Hematologic	O
Toxicity	O
(see	O
WARNINGS	O
)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
Fever	B-D005334

1-866-562-4597	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
5.1	O
General	O
There	O
are	O
no	O
long-term	O
evaluations	O
of	O
the	O
Infant	B-D007223

Ibuprofen	B-D007052
’s	O
effects	O
on	O
neurodevelopmental	O
outcome	O
and	O
Growth	B-D006128

5.2	O
Infection	O
NeoProfen	O
may	O
alter	O
the	O
usual	O
signs	O
of	O
infection	O

The	O
physician	O
must	O
be	O
continually	O
on	O
the	O
alert	O
and	O
should	O
use	O
the	O
drug	O
with	O
extra	O
care	O
in	O
the	O
presence	O
of	O
controlled	O
infection	O
and	O
in	O
Infant	B-D007223

5.3	O
Platelet	B-D010974
Aggregation	I-D010974
NeoProfen,	O
like	O
other	O
non-steroidal	O
Anti-Inflammatory	B-D000893
Agents	I-D000893

Preterm	O
Infant	B-D007223

Ibuprofen	B-D007052
has	O
been	O
shown	O
to	O
prolong	O
Bleeding	B-D001760
Time	I-D001760

This	O
effect	O
may	O
be	O
exaggerated	O
in	O
Patients	B-D010361

5.4	O
Bilirubin	B-D001663
Displacement	O
Ibuprofen	B-D007052
has	O
been	O
shown	O
to	O
displace	O
Bilirubin	B-D001663

5.5	O
Administration	O
NeoProfen	O
should	O
be	O
administered	O
carefully	O
to	O
avoid	O
extravascular	O
injection	O
or	O
leakage,	O
as	O
solution	O
may	O
be	O
irritating	O
to	O
tissue	O

NeoProfen	O
has	O
not	O
been	O
assessed	O
for	O
neurodevelopmental	O
outcome	O
and	O
Growth	B-D006128

6.2	O
Renal	O
Function	O
Compared	O
to	O
placebo,	O
there	O
was	O
a	O
small	O
decrease	O
in	O
urinary	O
output	O
in	O
the	O
Ibuprofen	B-D007052

In	O
other	O
studies,	O
adverse	O
events	O
classified	O
as	O
Renal	B-D051437
Insufficiency	I-D051437

6.3	O
Additional	O
Adverse	O
Events	O
The	O
adverse	O
events	O
reported	O
in	O
the	O
Multicenter	B-D016448
Study	I-D016448

6.4	O
Post-marketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Most	O
common	O
adverse	O
reactions	O
(≥10%)	O
are	O
Sepsis	B-D018805

(6)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Recordati	O
Rare	B-D035583
Diseases	I-D035583
at	O
1-888-575-8344,	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

Table	O
1	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

•	O
Etodolac	B-D017308
Tablets	B-D013607

Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse-reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
to	O
1000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064

Nervous	B-D009420
System	I-D009420

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566

Musculoskeletal—Arthralgia	O

________________________________	O
1	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566

Musculoskeletal—Muscle	O
Pain	B-D010146

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
Death	B-D003643

Do	O
not	O
exceed	O
a	O
total	O
combined	O
duration	O
of	O
use	O
of	O
SPRIX	O
and	O
other	O
Ketorolac	B-D020910

SPRIX	O
is	O
not	O
indicated	O
for	O
use	O
in	O
pediatric	O
Patients	B-D010361

Gastrointestinal	O
Risk	B-D012306
Ketorolac	B-D020911
Tromethamine	I-D020911

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Therefore,	O
SPRIX	O
is	O
contraindicated	O
in	O
Patients	B-D010361

Elderly	O
Patients	B-D010361

Bleeding	O
Risk	B-D012306
Ketorolac	B-D020911
Tromethamine	I-D020911

Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

SPRIX	O
nas	B-C015378

Renal	O
Risk	B-D012306
SPRIX	O
is	O
contraindicated	O
in	O
Patients	B-D010361

WARNING:	O
LIMITATIONS	O
OF	O
USE,	O
GASTROINTESTINAL,	O
BLEEDING,	O
CARDIOVASCULAR,	O
and	O
RENAL	O
Risk	B-D012306

Limitations	O
of	O
Use	O
–	O
The	O
total	O
duration	O
of	O
use	O
of	O
SPRIX	O
and	O
other	O
Ketorolac	B-D020910

(2.1)	O
Gastrointestinal	O
(GI)	O
Risk	B-D012306
–	O
Ketorolac	B-D020910
can	O
cause	O
Peptic	B-D010437
Ulcer	I-D010437

SPRIX	O
is	O
CONTRAINDICATED	O
in	O
Patients	B-D010361

(4)	O
Bleeding	O
Risk	B-D012306
–	O
SPRIX	O
inhibits	O
platelet	O
function	O
and	O
is	O
CONTRAINDICATED	O
in	O
Patients	B-D010361

(4)	O
Cardiovascular	O
(CV)	O
Risk	B-D012306
–	O
NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
CV	O
Disease	B-D004194

(5.6)	O
SPRIX	O
is	O
CONTRAINDICATED	O
for	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4)	O
Renal	O
Risk	B-D012306

(4)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
SPRIX	O
should	O
not	O
be	O
used	O
concomitantly	O
with	O
IM/IV	O
or	O
oral	O
Ketorolac	B-D020910

(5.1)	O
Ketorolac	B-D020910
can	O
cause	O
serious	O
GI	O
adverse	O
events	O
including	O
bleeding,	O
Ulcer	B-D014456

SPRIX	O
should	O
be	O
prescribed	O
with	O
caution	O
in	O
Patients	B-D010361

Elderly	O
Patients	B-D010361

(4,	O
5.2)	O
NSAIDs	O
Affect	B-D000339

SPRIX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Do	O
not	O
use	O
SPRIX	O
in	O
Patients	B-D010361

(4,	O
5.3)	O
Ketorolac	B-D020910
can	O
cause	O
renal	O
injury	O

SPRIX	O
should	O
not	O
be	O
used	O
in	O
Patients	B-D010361

(4,	O
5.4,	O
12.4)	O
Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

SPRIX	O
should	O
be	O
discontinued	O
immediately	O
in	O
Patients	B-D010361

(4,	O
5.5,	O
5.7,	O
5.11)	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

(5.6)	O
Fluid	O
retention	O
and	O
Edema	B-D004487

SPRIX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

(5.4,	O
5.6)	O
NSAIDs	O
can	O
cause	O
serious	O
dermatologic	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
Dermatitis	B-D003872

SPRIX	O
should	O
be	O
discontinued	O
immediately	O
in	O
Patients	B-D010361

(4,	O
5.7)	O
During	O
Pregnancy	B-D011247

(5.8)	O
5.1	O
Limitations	O
of	O
Use	O
The	O
total	O
duration	O
of	O
use	O
of	O
SPRIX	O
alone	O
or	O
sequentially	O
with	O
other	O
Form	B-D020478

SPRIX	O
must	O
not	O
be	O
used	O
concomitantly	O
with	O
other	O
Form	B-D020478

5.2	O
Gastrointestinal	O
(GI)	O
Effects	O
-	O
Risk	B-D012306
of	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
SPRIX	O
is	O
contraindicated	O
in	O
Patients	B-D010361

Ketorolac	B-D020911
Tromethamine	I-D020911

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Minor	O
upper	O
GI	O
problems,	O
such	O
as	O
Dyspepsia	B-D004415

The	O
Incidence	B-D015994

Even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

In	O
addition	O
to	O
past	O
History	B-D006664

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

This	O
should	O
include	O
discontinuation	O
of	O
SPRIX	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

For	O
high	O
Risk	B-D012306

Use	O
great	O
care	O
when	O
giving	O
SPRIX	O
to	O
Patients	B-D010361

5.3	O
Hematological	O
Effects	O
Because	O
Prostaglandins	B-D011453

The	O
effects	O
of	O
NSAIDs	O
other	O
than	O
Aspirin	B-D001241

Patients	B-D010361
on	O
therapeutic	O
doses	O
of	O
Anticoagulants	B-D000925

The	O
concurrent	O
use	O
of	O
Ketorolac	B-D020911
Tromethamine	I-D020911

Until	O
data	O
from	O
such	O
studies	O
are	O
available,	O
carefully	O
weigh	O
the	O
benefits	O
against	O
the	O
Risk	B-D012306

Monitor	O
Patients	B-D010361

In	O
Clinical	B-D016430
Trial	I-D016430

In	O
Clinical	B-D016430
Trial	I-D016430

Therefore,	O
use	O
SPRIX	O
with	O
caution	O
in	O
the	O
postoperative	O
setting	O
when	O
Hemostasis	B-D006487

Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
Blood	B-D001769

Do	O
not	O
use	O
SPRIX	O
in	O
Patients	B-D010361

5.4	O
Renal	O
Effects	O
Ketorolac	B-D020910
and	O
its	O
metabolites	O
are	O
eliminated	O
primarily	O
by	O
the	O
Kidney	B-D007668

Patients	B-D010361
with	O
reduced	O
Creatinine	B-D003404

SPRIX	O
is	O
contraindicated	O
in	O
Patients	B-D010361

In	O
Patients	B-D010361

Decreased	O
intravascular	O
volume	O
such	O
as	O
when	O
oral	O
intake	O
is	O
poor	O
increases	O
the	O
Risk	B-D012306

Therefore,	O
Patients	B-D010361

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Use	O
SPRIX	O
with	O
caution	O
in	O
Patients	B-D010361

Assess	O
the	O
Risk	B-D012306

Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

5.5	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

SPRIX	O
should	O
be	O
discontinued	O
immediately	O
in	O
Patients	B-D010361

SPRIX	O
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.6	O
Cardiovascular	O
Effects	O
Cardiovascular	O
(CV)	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Hypertension	B-D006973
NSAIDs	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
Thiazides	B-D049971

Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention,	O
Edema	B-D004487

Therefore,	O
only	O
use	O
SPRIX	O
very	O
cautiously	O
in	O
Patients	B-D010361

5.7	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Ketorolac	B-D020910

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

5.8	O
Pregnancy	B-D011247
Starting	O
at	O
30	O
weeks	O
gestation,	O
SPRIX	O
can	O
cause	O
fetal	O
harm	O
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
due	O
to	O
an	O
increased	O
Risk	B-D012306

If	O
SPRIX	O
is	O
used	O
at	O
or	O
after	O
30	O
weeks	O
gestation,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
a	O
Fetus	B-D005333

5.9	O
Hepatic	O
Effects	O
Use	O
SPRIX	O
with	O
caution	O
in	O
Patients	B-D010361

Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

Evaluate	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.10	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
SPRIX	O
in	O
reducing	O
Inflammation	B-D007249

5.11	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.12	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
SPRIX	O
with	O
the	O
Eye	B-D005123

If	O
Eye	B-D005123

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling:	O
Gastrointestinal	O
effects	O
[see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hemorrhage	B-D006470
[see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Renal	O
effects	O
[see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Anaphylactoid	O
reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Cardiovascular	O
thrombotic	O
events	O
[see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Congestive	O
Heart	B-D006333
Failure	I-D006333

These	O
reactions	O
were	O
generally	O
mild	O
and	O
transient	O
in	O
Nature	B-D019368

The	O
most	O
common	O
drug-related	O
adverse	O
events	O
Lead	B-D007854

The	O
most	O
common	O
adverse	O
reactions	O
(incidence	O
>	O
2%)	O
in	O
Patients	B-D010361

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
American	O
Regent,	O
Inc	O

at	O
1-800-734-9236	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Experience	O
from	O
SPRIX	O
Clinical	O
Studies	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
SPRIX	O
in	O
Patients	B-D010361

The	O
studies	O
enrolled	O
828	O
Patients	B-D010361

The	O
Patients	B-D010361

Most	O
Patients	B-D010361

Table	O
1	O

Post-operative	O
Patients	B-D010361
with	O
Adverse	O
Reactions	O
Observed	O
at	O
a	O
rate	O
of	O
2%	O
or	O
more	O
and	O
at	O
least	O
twice	O
the	O
Incidence	B-D015994

SPRIX	O
(N=455)	O
Placebo	O
(N=	O
245)	O
nas	B-C015378

Six	O
of	O
the	O
seven	O
Patients	B-D010361

6.2	O
Adverse	O
Reactions	O
Reported	O
in	O
Clinical	B-D016430
Trial	I-D016430
s	O
with	O
Other	O
Dosage	B-D004304
Forms	I-D004304
of	O
Ketorolac	B-D020910
or	O
Other	O
NSAIDs	O
Adverse	O
reaction	O
rates	O
increase	O
with	O
higher	O
doses	O
of	O
Ketorolac	B-D020910

It	O
is	O
necessary	O
to	O
remain	O
alert	O
for	O
the	O
severe	O
complications	O
of	O
treatment	O
with	O
Ketorolac	B-D020910

These	O
complications	O
can	O
be	O
serious	O
in	O
certain	O
Patients	B-D010361

In	O
Patients	B-D010361

Other	O
adverse	O
reactions	O
reported	O
with	O
the	O
use	O
of	O
Flurbiprofen	B-D005480
Sodium	B-D012964
Ophthalmic	O
Solution	O
include:	O
Fibrosis	B-D005355

Increased	O
bleeding	O
tendency	O
of	O
ocular	O
Tissues	B-D014024

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Bausch	O
+	O
Lomb,	O
a	O
division	O
of	O
Valeant	O
Pharmaceuticals	O
North	B-D009656
America	I-D009656
LLC,	O
at	O
1-800-321-4576	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

Cardiovascular	O
Risk	B-D012306
•	O
NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS)	O

•	O
Diclofenac	B-D004008
Potassium	B-D011188

Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
In	O
718	O
Patients	B-D010361

In	O
a	O
6-month,	O
double-blind	O
trial	O
comparing	O
Diclofenac	B-D004008

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
Diclofenac	B-D004008
Sodium	B-D012964

(4,	O
5.1)	O
NSAIDs,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity	O
:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964

Monitor	O
Patients	B-D010361

(5.14)	O
Eye	B-D005123
Contact	O
:	O
Avoid	O
contact	O
of	O
Diclofenac	B-D004008

(5.15)	O
Oral	O
Nonsteroidal	O
Anti-inflammatory	O
Drugs	O
:	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs	O

(5.16)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Diclofenac	B-D004008

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
Diclofenac	B-D004008

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
was	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008

The	O
renal	O
effects	O
of	O
Diclofenac	B-D004008

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Diclofenac	B-D004008

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

Do	O
not	O
apply	O
Diclofenac	B-D004008

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Diclofenac	B-D004008

NSAIDs,	O
including	O
Diclofenac	B-D004008

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

The	O
effects	O
of	O
Diclofenac	B-D004008

There	O
was	O
no	O
significant	O
change	O
in	O
Platelet	B-D010974
Aggregation	I-D010974

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Sun	O
Exposure	O
Instruct	O
Patients	B-D010361

The	O
potential	O
effects	O
of	O
Diclofenac	B-D004008

5.15	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
Diclofenac	B-D004008

Advise	O
Patients	B-D010361

5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
Diclofenac	B-D004008

Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
Diclofenac	B-D004008

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)]	O
Hepatotoxicity	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.3)]	O
Hypertension	B-D006973
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(	O
)	O
with	O
Diclofenac	B-D004008

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Lupin	O
Pharmaceuticals	O
Inc	O

at	O
1-800-399-2561	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
Diclofenac	B-D004008

The	O
Population	B-D011153

The	O
most	O
common	O
adverse	O
events	O
with	O
Diclofenac	B-D004008

These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies	O

Application	O
Site	O
Reactions	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment-related	O
adverse	O
events	O
in	O
Patients	B-D010361

Application	O
site	O
reactions	O
were	O
Character	B-D002605

The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
Skin	B-D012867

In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
Dermatitis	B-D003872

In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
Safety	B-D012449

Adverse	O
Events	O
Common	O
to	O
the	O
NSAID	O
Class	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
Diclofenac	B-D004008

The	O
combination	O
of	O
Diclofenac	B-D004008

less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
Creatinine	B-D003404

7%),	O
Urea	B-D014508

12%),	O
and	O
hemoglobin	O
(13%	O
vs	O

9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
Liver	B-D008099

Table	O
1	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
Patients	B-D010361

Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
≥1%	O
of	O
Patients	B-D010361

Treatment	O
Group	O
:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
,	O
1	O
	O

5	O
%	O
w	O
/	O
w	O
Topical	O
Placebo	O
N	O
=	O
911	O
N	O
=	O
332	O
Adverse	O
Reaction	O
Preferred	O
Term	O
according	O
to	O
COSTART	O
N	O
(%)	O
N	O
(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non-U.S	O

postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
Diclofenac	B-D004008

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Body	O
as	O
a	O
Whole	O
Abdominal	B-D015746
Pain	I-D015746

Other	O
adverse	O
reactions	O
reported	O
with	O
the	O
use	O
of	O
Flurbiprofen	B-D005480

Increased	O
bleeding	O
tendency	O
of	O
ocular	O
Tissues	B-D014024

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Delayed	O
healing	O
(5.1)	O
Cross-sensitivity	O
or	O
Hypersensitivity	B-D006967

Topical	O
corticosteroids	O
are	O
also	O
known	O
to	O
slow	O
or	O
delay	O
healing	O

Concomitant	O
use	O
of	O
topical	O
NSAIDs	O
and	O
topical	O
Steroids	B-D013256

5.2	O
Cross-Sensitivity	O
or	O
Hypersensitivity	B-D006967
There	O
is	O
the	O
potential	O
for	O
cross-sensitivity	O
to	O
acetylsalicylic	O
acid,	O
phenylacetic	B-C025136
acid	I-C025136
derivatives,	O
and	O
other	O
NSAIDs	O

There	O
have	O
been	O
reports	O
of	O
bronchospasm	O
or	O
exacerbation	O
of	O
Asthma	B-D001249

Therefore,	O
caution	O
should	O
be	O
used	O
when	O
treating	O
individuals	O
who	O
have	O
previously	O
exhibited	O
sensitivities	O
to	O
these	O
drugs	O

5.3	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
With	O
some	O
NSAIDs,	O
there	O
exists	O
the	O
potential	O
for	O
increased	O
Bleeding	B-D001760
Time	I-D001760

There	O
have	O
been	O
reports	O
that	O
ocularly	O
applied	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
may	O
cause	O
increased	O
bleeding	O
of	O
ocular	O
Tissues	B-D014024

It	O
is	O
recommended	O
that	O
ACULAR	O
LS	O
®	O
ophthalmic	O
solution	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4	O
Cornea	B-D003315
l	O
Effects	O
Use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
Keratitis	B-D007634

In	O
some	O
susceptible	O
Patients	B-D010361

These	O
events	O
may	O
be	O
sight	O
threatening	O

Patients	B-D010361
with	O
evidence	O
of	O
Cornea	B-D003315

Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
suggests	O
that	O
Patients	B-D010361

Topical	O
NSAIDs	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
also	O
suggests	O
that	O
use	O
more	O
than	O
1	O
day	O
prior	O
to	O
surgery	O
or	O
use	O
beyond	O
14	O
days	O
post-surgery	O
may	O
increase	O
patient	O
Risk	B-D012306

5.5	O
Contact	O
Lens	O
Wear	O
ACULAR	O
LS	O
®	O
should	O
not	O
be	O
administered	O
while	O
wearing	O
Contact	B-D003261
Lenses	I-D003261

6	O
A	O
DVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described	O
elsewhere	O
in	O
the	O
labeling:	O
Delayed	O
Healing	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Cross-Sensitivity	O
or	O
Hypersensitivity	B-D006967
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Cornea	B-D003315
l	O
Effects[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
The	O
most	O
common	O
adverse	O
reactions	O
occurring	O
in	O
1	O
-	O
5%	O
of	O
Patients	B-D010361

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Allergan	O
at	O
1-800-433-8871	O
or	O
the	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
for	O
ACULAR	O
LS	O
®	O
ophthalmic	O
solution	O
occurring	O
in	O
approximately	O
1	O
to	O
5%	O
of	O
the	O
Overall	B-D016424

The	O
most	O
frequent	O
adverse	O
reactions	O
reported	O
with	O
the	O
use	O
of	O
Ketorolac	B-D020911
Tromethamine	I-D020911

These	O
reactions	O
were	O
reported	O
by	O
up	O
to	O
40%	O
of	O
Patients	B-D010361

Other	O
adverse	O
reactions	O
occurring	O
approximately	O
in	O
1	O
to	O
10%	O
of	O
the	O
Time	B-D013995

Other	O
adverse	O
reactions	O
reported	O
rarely	O
with	O
the	O
use	O
of	O
Ketorolac	B-D020911
Tromethamine	I-D020911

6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

The	O
reactions,	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
Ketorolac	B-D020911
Tromethamine	I-D020911

WARNING:	O
Risk	B-D012306

4	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
5	O

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

(4	O
,	O
5.1)	O
6	O

NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
1	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

2	O

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
1	O

NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
10	O

Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
Celecoxib	B-D000068579

Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
use	O
of	O
Celecoxib	B-D000068579

Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
15	O

Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Celecoxib	B-D000068579
Capsules	B-D002214

Monitor	O
Patients	B-D010361

Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
Celecoxib	B-D000068579

Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
Pregnant	B-D037841
Women	I-D037841

Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
Hematocrit	B-D006400

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
Risk	B-D012306

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

A	O
Randomized	B-D016449
Controlled	I-D016449
Trial	I-D016449

Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
Risk	B-D012306

Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
Naproxen	B-D009288

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

2.Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

3.Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

4.Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Celecoxib	B-D000068579

6.In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

See	O
Clinical	O
Studies	O
(14.6,	O
14.7)	O
for	O
additional	O
Blood	B-D001794
Pressure	I-D001794

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.7)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

The	O
renal	O
effects	O
of	O
Celecoxib	B-D000068579

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Celecoxib	B-D000068579

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Celecoxib	B-D000068579

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
Risk	B-D012306

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
1.Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
2.GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
3.Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
4.Hypertension	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
5.Heart	O
Failure	O
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
6.Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
7.Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
8.Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
9.Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp	O

at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

In	O
placebo-	O
or	O
active-controlled	O
Clinical	B-D016430
Trial	I-D016430

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
%	O
to	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-	O
controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

This	O
Risk	B-D012306

•Etodolac	O
Tablets	B-D013607

Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse	O
reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
mg/day	O
to	O
1000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
Whole:	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064
:	O
Dyspepsia	B-D004415
(10%),	O
Abdominal	B-D015746
Pain	I-D015746

Nervous	B-D009420
System	I-D009420
:	O
Asthenia	B-D001247
/malaise5,	O
Dizziness	B-D004244

Skin	B-D012867
and	O
Appendages:	O
Pruritus	B-D011537
,	O
rash	O

Special	O
Senses:	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566
:	O
Dysuria	B-D053159
,	O
urinary	O
frequency	O

Musculoskeletal:	O
Arthralgia	B-D018771
1Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

2Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

3Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

4Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

5Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

6Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
post-marketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319
:	O
Hypertension	B-D006973
,	O
congestive	O
Heart	B-D006333
Failure	I-D006333

Digestive	B-D004064
System	I-D004064
:	O
Thirst	B-D013894
,	O
dry	O
Mouth	B-D009055

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
Ecchymosis	B-D004438
,	O
Anemia	B-D000740

Metabolic	O
and	O
Nutritional:	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420
:	O
Insomnia,	O
somnolence	O

Respiratory	B-D012137
System	I-D012137
:	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
Eosinophilia	B-D004802

Skin	B-D012867
and	O
Appendages:	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
Senses:	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566
:	O
Elevated	O
BUN,	O
renal	O
failure,	O
Renal	B-D051437
Insufficiency	I-D051437

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319
:	O
Arrhythmias,	O
Myocardial	B-D009203
Infarction	I-D009203

Digestive	B-D004064
System	I-D004064
:	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
Colitis	B-D003092

Metabolic	O
and	O
Nutritional:	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420
:	O
Paresthesia	B-D010292
,	O
Confusion	B-D003221

Respiratory	B-D012137
System	I-D012137
:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
Dyspnea	B-D004417

Skin	B-D012867
and	O
Appendages:	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
Senses:	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566
:	O
Cystitis	B-D003556
,	O
Hematuria	B-D006417

Musculoskeletal:	O
Muscle	O
Pain	B-D010146

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
Whole:	O
Sepsis	B-D018805
,	O
Death	B-D003643

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
Risk	B-D012306

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

Elevated	O
Liver	B-D008099

Discontinue	O
use	O
of	O
Celecoxib	B-D000068579

New	O
onset	O
or	O
worsening	O
of	O
Hypertension	B-D006973

Blood	B-D001794
Pressure	I-D001794

Fluid	O
retention	O
and	O
Edema	B-D004487

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Renal	O
papillary	O
Necrosis	B-D009336

Use	O
Celecoxib	B-D000068579

Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
Celecoxib	B-D000068579

Serious	O
Skin	B-D012867

Discontinue	O
Celecoxib	B-D000068579

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
Patients	B-D010361

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

Therefore,	O
treatment	O
with	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9	O
Pregnancy	B-D011247
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

Celecoxib	B-D000068579
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
Patients	B-D010361

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
Celecoxib	B-D000068579

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Lupin	O
Pharmaceuticals,	O
Inc	O

at	O
1-800-399-2561	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS	O
)	O

•Etodolac	O
Capsules	B-D002214

Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse-reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
to	O
1000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064

Nervous	B-D009420
System	I-D009420

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566

Musculoskeletal—Arthralgia	O

Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566

Musculoskeletal—Muscle	O
Pain	B-D010146

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
Death	B-D003643

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

This	O
Risk	B-D012306

ZORVOLEX	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
ZORVOLEX	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
ZORVOLEX	O
in	O
Patients	B-D010361

If	O
ZORVOLEX	O
is	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
ZORVOLEX	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
ZORVOLEX	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
Acetaminophen	B-D000082

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
ZORVOLEX,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
ZORVOLEX	O
in	O
Patients	B-D010361

If	O
ZORVOLEX	O
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
ZORVOLEX	O
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
ZORVOLEX	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
ZORVOLEX	O
in	O
Patients	B-D010361

If	O
ZORVOLEX	O
is	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
ZORVOLEX	O
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

ZORVOLEX	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
ZORVOLEX,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
ZORVOLEX	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

NSAIDs,	O
including	O
ZORVOLEX,	O
may	O
increase	O
the	O
Risk	B-D012306

Co-morbid	O
conditions,	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
ZORVOLEX	O
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥2%)	O
are	O
Edema	B-D004487

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Iroko	O
Pharmaceuticals,	O
LLC	O
at	O
1-877-757-0676	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

Adverse	O
Reactions	O
in	O
Patients	B-D010361
with	O
Acute	B-D059787
Pain	I-D059787
Two-hundred	O
sixteen	O
(216)	O
Patients	B-D010361

The	O
most	O
frequent	O
adverse	O
reactions	O
in	O
this	O
study	O
are	O
summarized	O
in	O
Table	O
1	O

Table	O
1	O
Summary	O
of	O
Adverse	O
Reactions	O
(≥2%	O
in	O
ZORVOLEX	O
18	O
mg	O
or	O
35	O
mg	O
group)	O
–	O
Phase	O
3	O
Study	O
in	O
Patients	B-D010361
With	O
Postsurgical	O
Pain	B-D010146
Adverse	O
Reactions	O
ZORVOLEX	O
18	O
mg	O
or	O
35	O
mg	O
three	O
Time	B-D013995

There	O
was	O
a	O
greater	O
use	O
of	O
concomitant	O
opioid	O
rescue	O
medication	O
in	O
placebo-treated	O
Patients	B-D010361

About	O
82%	O
of	O
Patients	B-D010361

N	O
=	O
216	O
Placebo	O
N	O
=	O
106	O
Edema	B-D004487
33%	O
32%	O
Nausea	B-D009325
27%	O
37%	O
Headache	B-D006261
13%	O
15%	O
Dizziness	B-D004244
10%	O
16%	O
Vomiting	B-D014839
9%	O
12%	O
Constipation	B-D003248
8%	O
4%	O
Pruritus	B-D011537
7%	O
6%	O
Flatulence	B-D005414
3%	O
2%	O
Pain	B-D010146
in	O
Extremity	O
3%	O
1%	O
Dyspepsia	B-D004415
2%	O
1%	O
Adverse	O
Reactions	O
in	O
Patients	B-D010361
with	O
Osteoarthritis	B-D010003
Pain	B-D010146
Two-hundred	O
two	O
(202)	O
Patients	B-D010361

The	O
most	O
frequent	O
adverse	O
reactions	O
in	O
this	O
study	O
are	O
summarized	O
in	O
Table	O
2	O

Table	O
2	O
Summary	O
of	O
Adverse	O
Reactions	O
(≥2%)	O
–	O
12-week	O
Phase	O
3	O
Study	O
in	O
Patients	B-D010361
With	O
Osteoarthritis	B-D010003
Pain	B-D010146
Adverse	O
reactions	O
that	O
occurred	O
in	O
≥2%	O
of	O
Patients	B-D010361

Of	O
those,	O
360	O
(60%)	O
Patients	B-D010361

The	O
most	O
frequent	O
adverse	O
reactions	O
in	O
this	O
study	O
are	O
summarized	O
in	O
Table	O
3	O

Table	O
3	O
Summary	O
of	O
Adverse	O
Reactions	O
(≥2%)	O
–	O
52-week	O
Open-label	O
Study	O
in	O
Patients	B-D010361
with	O
Osteoarthritis	B-D010003
Pain	B-D010146
Adverse	O
Reactions	O
ZORVOLEX	O
35	O
mgN=601	O
Upper	O
respiratory	O
tract	O
infection	O
8%	O
Headache	B-D006261
8%	O
Urinary	B-D014551
Tract	I-D014551

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
reactions	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS:	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS	O
)	O
Hepatotoxicity	O
(see	O
WARNINGS	O
)	O
Hypertension	B-D006973
(see	O
WARNINGS	O
)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS	O
)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS	O
)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS	O
)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS	O
)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS	O
)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
•	O
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
•	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
Cardiovascular	O
Risk	B-D012306
•	O
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
•	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
•Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

•Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
Risk	B-D012306

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

•Elevated	O
Liver	B-D008099

Discontinue	O
use	O
of	O
Celecoxib	B-D000068579

•New	O
onset	O
or	O
worsening	O
of	O
Hypertension	B-D006973

Blood	B-D001794
Pressure	I-D001794

•Fluid	O
retention	O
and	O
Edema	B-D004487

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

•Renal	O
papillary	O
Necrosis	B-D009336

Use	O
Celecoxib	B-D000068579

•Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
Celecoxib	B-D000068579

•Serious	O
Skin	B-D012867

Discontinue	O
Celecoxib	B-D000068579

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

Therefore,	O
treatment	O
with	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9	O
Pregnancy	B-D011247
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

Celecoxib	B-D000068579
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
Patients	B-D010361

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
Celecoxib	B-D000068579

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp	O

at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CXB	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
CXB	O
=	O
Celecoxib	B-D000068579

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS).Etodolac	O
Capsules	B-D002214

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse-reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
to	O
1000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064

Nervous	B-D009420
System	I-D009420

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566

Musculoskeletal—Arthralgia	O

Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

1Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566

Musculoskeletal—Muscle	O
Pain	B-D010146

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
Death	B-D003643

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

1.IBU	O
Tablets	B-D013607

Gastrointestinal	O
Risk	B-D012306
1.NSAIDS	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
eventscan	O
occur	O
at	O
any	O
Time	B-D013995

(See	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
withIbuprofen	O
Tablets	B-D013607

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052
Tablets	B-D013607

Adverse	O
reactions	O
observed	O
during	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Those	O
reactions	O
listedin	O
Column	O
one	O
encompass	O
Observation	B-D019370

More	O
than	O
500	O
of	O
these	O
Patients	B-D010361

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
werereported	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
thanat	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
Clinical	B-D016430
Trial	I-D016430

The	O
increases	O
in	O
Incidence	B-D015994

table	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Wholefever,	O
infection,	O
Sepsis	B-D018805

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Ibuprofen	B-D007052
Tablets	B-D013607

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
Ibuprofen	B-D007052

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052

Adverse	O
reactions	O
observed	O
during	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
Observation	B-D019370

More	O
than	O
500	O
of	O
these	O
Patients	B-D010361

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
Clinical	B-D016430
Trial	I-D016430

The	O
increases	O
in	O
Incidence	B-D015994

Incidence	B-D015994
Greater	O
than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship*	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown*	O
GASTROINTESTINAL	O
Nausea	B-D009325
†,	O
epigastric	O
Pain	B-D010146
,	O
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
Flatulence	B-D005414

Henoch-Schonlein	O
Vasculitis	B-D014657

Reactions	O
are	O
classified	O
under	O
"Causal	O
Relationship	O
Unknown"	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O

†Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
Patients	B-D010361

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

(	O
5.1)	O
NALFON	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

This	O
Risk	B-D012306

[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O

NALFON	O
®	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
NALFON	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
NALFON	O
in	O
Patients	B-D010361

If	O
NALFON	O
is	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
NALFON,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
Inflammation	B-D007249

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361
:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
NALFON	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
NALFON,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Fenoprofen	B-D005279

Avoid	O
the	O
use	O
of	O
NALFON	O
in	O
Patients	B-D010361

If	O
NALFON	O
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
NALFON	O
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
NALFON	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
NALFON	O
in	O
Patients	B-D010361

If	O
NALFON	O
is	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Fenoprofen	B-D005279
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
NALFON	O
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
fenoprop	B-C009264
fen,	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

NALFON	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Fenoprofen	B-D005279
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
NALFON,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
NALFON	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

NSAIDs,	O
including	O
NALFON,	O
may	O
increase	O
the	O
Risk	B-D012306

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
NALFON	O
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Ocular	O
Effects	O
Studies	O
to	O
date	O
have	O
not	O
shown	O
changes	O
in	O
the	O
Eye	B-D005123

However,	O
adverse	O
ocular	O
effects	O
have	O
been	O
observed	O
with	O
other	O
anti-inflammatory	O
drugs	O

Eye	B-D005123
examinations,	O
therefore,	O
should	O
be	O
performed	O
if	O
visual	O
disturbances	O
occur	O
in	O
Patients	B-D010361

5.15	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects	O
Caution	O
should	O
be	O
Exercise	B-D015444

5.16	O
Impact	O
on	O
Hearing	B-D006309
Since	O
the	O
Safety	B-D012449

6	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥	O
5%)	O
are	O
Dyspepsia	B-D004415
,	O
Headache	B-D006261

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Xspire	O
Pharma	O
at	O
1-601-990-9497	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

During	O
clinical	O
studies	O
for	O
Rheum	B-D012250

These	O
encompass	O
Observation	B-D019370

For	O
comparison,	O
data	O
are	O
also	O
presented	O
from	O
complaints	O
received	O
from	O
the	O
266	O
Patients	B-D010361

During	O
short-term	O
studies	O
for	O
Analgesia	B-D000698

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
>1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—	O
During	O
Clinical	B-D016430
Trial	I-D016430

In	O
descending	O
order	O
of	O
frequency,	O
these	O
reactions	O
included	O
Dyspepsia	B-D004415

2.3%	O
placebo),	O
Nausea	B-D009325

7.1%),	O
Constipation	B-D003248

1.5%),	O
Vomiting	B-D014839

1.9%),	O
Abdominal	B-D015746
Pain	I-D015746

1.1%),	O
and	O
Diarrhea	B-D003967

4.1%)	O

The	O
drug	O
was	O
discontinued	O
because	O
of	O
adverse	O
gastrointestinal	O
reactions	O
in	O
less	O
than	O
2%	O
of	O
Patients	B-D010361

Nervous	B-D009420
System	I-D009420
—	O
The	O
most	O
frequent	O
adverse	O
neurologic	O
reactions	O
were	O
Headache	B-D006261

7.5%)	O
and	O
somnolence	O
(8.5%	O
vs	O

6.4%)	O

Dizziness	B-D004244
(6.5%	O
vs	O

5.6%),	O
Tremor	B-D014202

0.4%),	O
and	O
Confusion	B-D003221

none)	O
were	O
noted	O
less	O
frequently	O

Nalfon	O
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Skin	B-D012867
and	O
Appendages—	O
Increased	O
Sweating	B-D013546

0.4%),	O
Pruritus	B-D011537

0.8%),	O
and	O
rash	O
(3.7%	O
vs	O

0.4%)	O
were	O
reported	O

Nalfon	O
was	O
discontinued	O
in	O
about	O
1%	O
of	O
Patients	B-D010361

Special	O
Senses	O
—	O
Tinnitus	B-D014012
(4.5%	O
vs	O

0.4%),	O
blurred	O
vision	O
(2.2%	O
vs	O

none),	O
and	O
decreased	O
Hearing	B-D006309

none)	O
were	O
reported	O

Nalfon	O
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Cardiovascular	O
—	O
Palpitations	O
(2.5%	O
vs	O

0.4%)	O

Nalfon	O
was	O
discontinued	O
in	O
about	O
0.5%	O
of	O
Patients	B-D010361

Miscellaneous	O
—	O
Nervousness	O
(5.7%	O
vs	O

1.5%),	O
Asthenia	B-D001247

0.4%),	O
peripheral	O
Edema	B-D004487

0.4%),	O
Dyspnea	B-D004417

none),	O
Fatigue	B-D005221

1.5%),	O
upper	O
respiratory	O
infection	O
(1.5%	O
vs	O

5.6%),	O
and	O
nas	B-C015378
opharyngitis	O
(1.2%	O
vs	O

none)	O

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
<1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—Gastritis,	O
Peptic	B-D010437
Ulcer	I-D010437

Increases	O
in	O
Alkaline	B-D000469
Phosphatase	I-D000469

Cardiovascular—Atrial	O
fibrillation,	O
Pulmonary	B-D011654
Edema	I-D011654

Genitourinary	O
Tract—Renal	O
failure,	O
Dysuria	B-D053159

Hypersensitivity	B-D006967
—Angioedema	O
(angioneurotic	O
Edema	B-D004487

Hematologic—Purpura,	O
bruising,	O
Hemorrhage	B-D006470

Nervous	B-D009420
System	I-D009420
—Depression,	O
disorientation,	O
Seizures	B-D012640

Special	O
Senses—Burning	O
Tongue	B-D014059

Skin	B-D012867
and	O
Appendages—Exfoliative	O
Dermatitis	B-D003872

Miscellaneous—Anaphylaxis,	O
Urticaria	B-D014581

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

(	O
5.1)	O
Fenoprofen	B-D005279
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

This	O
Risk	B-D012306

[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O

Fenoprofen	B-D005279
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Fenoprofen	B-D005279
is	O
contraindicated	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Fenoprofen	B-D005279

If	O
Fenoprofen	B-D005279

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Fenoprofen	B-D005279

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361
:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Fenoprofen	B-D005279

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Fenoprofen	B-D005279

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Fenoprofen	B-D005279

Avoid	O
the	O
use	O
of	O
Fenoprofen	B-D005279

If	O
Fenoprofen	B-D005279

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Fenoprofen	B-D005279

The	O
renal	O
effects	O
of	O
Fenoprofen	B-D005279

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Fenoprofen	B-D005279

If	O
Fenoprofen	B-D005279

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Fenoprofen	B-D005279
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Fenoprofen	B-D005279

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
fenoprop	B-C009264
fen,	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Fenoprofen	B-D005279
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Fenoprofen	B-D005279
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Fenoprofen	B-D005279

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Fenoprofen	B-D005279

NSAIDs,	O
including	O
Fenoprofen	B-D005279

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Fenoprofen	B-D005279

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Ocular	O
Effects	O
Studies	O
to	O
date	O
have	O
not	O
shown	O
changes	O
in	O
the	O
Eye	B-D005123

However,	O
adverse	O
ocular	O
effects	O
have	O
been	O
observed	O
with	O
other	O
anti-inflammatory	O
drugs	O

Eye	B-D005123
examinations,	O
therefore,	O
should	O
be	O
performed	O
if	O
visual	O
disturbances	O
occur	O
in	O
Patients	B-D010361

5.15	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects	O
Caution	O
should	O
be	O
Exercise	B-D015444

5.16	O
Impact	O
on	O
Hearing	B-D006309
Since	O
the	O
Safety	B-D012449

6	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥	O
5%)	O
are	O
Dyspepsia	B-D004415
,	O
Headache	B-D006261

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Xspire	O
Pharma	O
at	O
1-601-990-9497	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

During	O
clinical	O
studies	O
for	O
Rheum	B-D012250

These	O
encompass	O
Observation	B-D019370

For	O
comparison,	O
data	O
are	O
also	O
presented	O
from	O
complaints	O
received	O
from	O
the	O
266	O
Patients	B-D010361

During	O
short-term	O
studies	O
for	O
Analgesia	B-D000698

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
>1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—	O
During	O
Clinical	B-D016430
Trial	I-D016430

In	O
descending	O
order	O
of	O
frequency,	O
these	O
reactions	O
included	O
Dyspepsia	B-D004415

2.3%	O
placebo),	O
Nausea	B-D009325

7.1%),	O
Constipation	B-D003248

1.5%),	O
Vomiting	B-D014839

1.9%),	O
Abdominal	B-D015746
Pain	I-D015746

1.1%),	O
and	O
Diarrhea	B-D003967

4.1%)	O

The	O
drug	O
was	O
discontinued	O
because	O
of	O
adverse	O
gastrointestinal	O
reactions	O
in	O
less	O
than	O
2%	O
of	O
Patients	B-D010361

Nervous	B-D009420
System	I-D009420
—	O
The	O
most	O
frequent	O
adverse	O
neurologic	O
reactions	O
were	O
Headache	B-D006261

7.5%)	O
and	O
somnolence	O
(8.5%	O
vs	O

6.4%)	O

Dizziness	B-D004244
(6.5%	O
vs	O

5.6%),	O
Tremor	B-D014202

0.4%),	O
and	O
Confusion	B-D003221

none)	O
were	O
noted	O
less	O
frequently	O

Fenoprofen	B-D005279
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Skin	B-D012867
and	O
Appendages—	O
Increased	O
Sweating	B-D013546

0.4%),	O
Pruritus	B-D011537

0.8%),	O
and	O
rash	O
(3.7%	O
vs	O

0.4%)	O
were	O
reported	O

Fenoprofen	B-D005279
was	O
discontinued	O
in	O
about	O
1%	O
of	O
Patients	B-D010361

Special	O
Senses	O
—	O
Tinnitus	B-D014012
(4.5%	O
vs	O

0.4%),	O
blurred	O
vision	O
(2.2%	O
vs	O

none),	O
and	O
decreased	O
Hearing	B-D006309

none)	O
were	O
reported	O

Fenoprofen	B-D005279
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Cardiovascular	O
—	O
Palpitations	O
(2.5%	O
vs	O

0.4%)	O

Fenoprofen	B-D005279
was	O
discontinued	O
in	O
about	O
0.5%	O
of	O
Patients	B-D010361

Miscellaneous	O
—	O
Nervousness	O
(5.7%	O
vs	O

1.5%),	O
Asthenia	B-D001247

0.4%),	O
peripheral	O
Edema	B-D004487

0.4%),	O
Dyspnea	B-D004417

none),	O
Fatigue	B-D005221

1.5%),	O
upper	O
respiratory	O
infection	O
(1.5%	O
vs	O

5.6%),	O
and	O
nas	B-C015378
opharyngitis	O
(1.2%	O
vs	O

none)	O

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
<1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—Gastritis,	O
Peptic	B-D010437
Ulcer	I-D010437

Increases	O
in	O
Alkaline	B-D000469
Phosphatase	I-D000469

Cardiovascular—Atrial	O
fibrillation,	O
Pulmonary	B-D011654
Edema	I-D011654

Genitourinary	O
Tract—Renal	O
failure,	O
Dysuria	B-D053159

Hypersensitivity	B-D006967
—Angioedema	O
(angioneurotic	O
Edema	B-D004487

Hematologic—Purpura,	O
bruising,	O
Hemorrhage	B-D006470

Nervous	B-D009420
System	I-D009420
—Depression,	O
disorientation,	O
Seizures	B-D012640

Special	O
Senses—Burning	O
Tongue	B-D014059

Skin	B-D012867
and	O
Appendages—Exfoliative	O
Dermatitis	B-D003872

Miscellaneous—Anaphylaxis,	O
Urticaria	B-D014581

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
•Celecoxib	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
•Celecoxib	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•NSAIDs,	O
including	O
Celecoxib	B-D000068579
,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
•	O
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
•	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579
,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

•Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
Risk	B-D012306

Celecoxib	B-D000068579
Capsules	B-D002214
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

•Elevated	O
Liver	B-D008099

Discontinue	O
use	O
of	O
Celecoxib	B-D000068579
Capsules	B-D002214
immediately	O
if	O
abnormal	O
Liver	B-D008099

•New	O
onset	O
or	O
worsening	O
of	O
Hypertension	B-D006973

Blood	B-D001794
Pressure	I-D001794

•Fluid	O
retention	O
and	O
Edema	B-D004487

Celecoxib	B-D000068579
Capsules	B-D002214
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

•Renal	O
papillary	O
Necrosis	B-D009336

Use	O
Celecoxib	B-D000068579
Capsules	B-D002214
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
Heart	B-D006333
Failure	I-D006333

•Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
Celecoxib	B-D000068579
Capsules	B-D002214
in	O
Patients	B-D010361

•Serious	O
Skin	B-D012867

Discontinue	O
Celecoxib	B-D000068579
Capsules	B-D002214
at	O
first	O
appearance	O
of	O
rash	O
or	O
Skin	B-D012867

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
Celecoxib	B-D000068579
Capsules	B-D002214
may	O
cause	O
an	O
increased	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

Therefore,	O
treatment	O
with	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

Celecoxib	B-D000068579
Capsules	B-D002214
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9	O
Pregnancy	B-D011247
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579
Capsules	B-D002214
should	O
have	O
their	O
hemoglobin	O
or	O
Hematocrit	B-D006400

Celecoxib	B-D000068579
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
Capsules	B-D002214
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
Patients	B-D010361

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
Celecoxib	B-D000068579

6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Cipla	O
Ltd,	O
at	O
1-866-604-3268	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
Of	O
the	O
Celecoxib	B-D000068579
Capsules	B-D002214
-treated	O
Patients	B-D010361

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Celecoxib	B-D000068579
=	O
Celecoxib	B-D000068579
Capsules	B-D002214
100	O
-	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

Celecoxib	B-D000068579
(N=4146)	O
Placebo	O
(N=1864)	O
NAP	O
(N=1366)	O
DCF	O
(N=387)	O
IBU	O
(N=345)	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
-	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579
,	O
Diclofenac	B-D004008

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579
treated	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579
Capsules	B-D002214
were	O
studied	O
in	O
primary	O
Dysmenorrhea	B-D004412

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579
Capsules	B-D002214
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

This	O
Risk	B-D012306

[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Celecoxib	B-D000068579

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

The	O
rates	O
of	O
Hypertension	B-D006973

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

The	O
renal	O
effects	O
of	O
Celecoxib	B-D000068579

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
Sulfonamides	B-D013449

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Celecoxib	B-D000068579

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
Patients	B-D010361

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Celecoxib	B-D000068579

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
Risk	B-D012306

6	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Cambridge	O
Therapeutic	O
Technologies	O
at	O
1-844-810-0004	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
>2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
Diarrhea	B-D003967
Dyspepsia	B-D004415
Flatulence	B-D005414
Nausea	B-D009325
4.1%5.6%	O
8.8%	O
2.2%	O
3.5%	O
2.8%	O
3.8%	O
6.2%	O
1%	O
4.2%	O
7.7%	O
5.3%	O
12.2%	O
3.6%6%	O
9%9.3%10.9%4.1%3.4%	O
9%5.8%12.8%3.5%6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
Peripheral	O
Edema	B-D004487
Injury-Accidental	O
2.8%2.1%2.9%	O
3.6%1.1%2.3%	O
2.2%2.1%3%	O
2.6%1%2.6%	O
0.9%3.5%3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
Diclofenac	B-D004008

(4,	O
5.1)	O
NSAIDs,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

(5.14)	O
Eye	B-D005123
Contact:	O
Avoid	O
contact	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
with	O
Eye	B-D005123

(5.15)	O
Oral	O
Nonsteroidal	O
Anti-inflammatory	O
Drugs:	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs	O

(5.16)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
Patients	B-D010361

If	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
is	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
Acetaminophen	B-D000082

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
Patients	B-D010361

If	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
was	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
Patients	B-D010361

If	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
is	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

NSAIDs,	O
including	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
,	O
may	O
increase	O
the	O
Risk	B-D012306

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

The	O
effects	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
on	O
platelet	O
function	O
were	O
studied	O
in	O
10	O
Health	B-D006262

There	O
was	O
no	O
significant	O
change	O
in	O
Platelet	B-D010974
Aggregation	I-D010974

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Sun	O
Exposure	O
Instruct	O
Patients	B-D010361

The	O
potential	O
effects	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
on	O
Skin	B-D012867

5.15	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
with	O
Eye	B-D005123

Advise	O
Patients	B-D010361

5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
Hemorrhage	B-D006470

Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
Risk	B-D012306

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
are	O
application	O
site	O
reactions	O

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Teligent	O
Pharma,	O
Inc	O

at	O
1-856-697-1441	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
of	O
911	O
Patients	B-D010361

The	O
Population	B-D011153

The	O
most	O
common	O
adverse	O
events	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
were	O
application	O
site	O
Skin	B-D012867

These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies	O

Application	O
Site	O
Reactions	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment-related	O
adverse	O
events	O
in	O
Patients	B-D010361

Application	O
site	O
reactions	O
were	O
Character	B-D002605

The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
Skin	B-D012867

In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
Dermatitis	B-D003872

In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
Safety	B-D012449

Adverse	O
Events	O
Common	O
to	O
the	O
NSAID	O
Class	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
Diarrhea	B-D003967

The	O
combination	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
and	O
oral	O
Diclofenac	B-D004008

less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
Creatinine	B-D003404

7%),	O
Urea	B-D014508

12%),	O
and	O
hemoglobin	O
(13%	O
vs	O

9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
Liver	B-D008099

Table	O
1	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
Patients	B-D010361

Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
≥1%	O
of	O
Patients	B-D010361

†Preferred	O
Term	O
according	O
to	O
COSTART	O
Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
N=911	O
Topical	O
Placebo	O
N=332	O
Adverse	O
Reaction†	O
N	O
(%)	O
N	O
(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non-US	O
postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Body	O
as	O
a	O
Whole:	O
Abdominal	B-D015746
Pain	I-D015746

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
Fever	B-D005334

This	O
Risk	B-D012306

Diflunisal	B-D004061
Tablets	B-D013607

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
adverse	O
reactions	O
observed	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Listed	O
below	O
are	O
the	O
adverse	O
reactions	O
reported	O
in	O
the	O
1,314	O
of	O
these	O
Patients	B-D010361

Five	O
hundred	O
thirteen	O
Patients	B-D010361

In	O
general,	O
the	O
adverse	O
reactions	O
listed	O
below	O
were	O
2	O
to	O
14	O
Time	B-D013995

Incidence	B-D015994
Greater	O
Than	O
1%	O
Gastrointestinal	O
The	O
most	O
frequent	O
types	O
of	O
adverse	O
reactions	O
occurring	O
with	O
Diflunisal	B-D004061

Psychiatric	O
Somnolence,	O
insomnia	O

Central	B-D002490
Nervous	I-D002490
System	I-D002490
Dizziness	B-D004244
	O

Special	O
Senses	O
Tinnitus	B-D014012
	O

Dermatologic	O
Rash*	O

Miscellaneous	O
Headache	B-D006261
*,	O
Fatigue	B-D005221

*	O
Incidence	B-D015994
between	O
3%	O
and	O
9%	O

Those	O
reactions	O
occurring	O
in	O
1%	O
to	O
3%	O
are	O
not	O
marked	O
with	O
an	O
asterisk	O

Incidence	B-D015994
Less	O
Than	O
1	O
in	O
100	O
The	O
following	O
adverse	O
reactions,	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100,	O
were	O
reported	O
in	O
Clinical	B-D016430
Trial	I-D016430

The	O
Probability	B-D011336

Dermatologic	O
Erythema	B-D004892
Multiforme	I-D004892

Gastrointestinal	O
Peptic	B-D010437
Ulcer	I-D010437

Liver	B-D008099
function	O
abnormalities;	O
Jaundice	B-D007565

Hematologic	O
Thrombocytopenia	B-D013921
;	O
Agranulocytosis	B-D000380

Genitourinary	O
Dysuria	B-D053159
;	O
renal	O
impairment,	O
including	O
renal	O
failure;	O
interstitial	O
Nephritis	B-D009393

Psychiatric	O
Nervousness,	O
Depression	B-D003863

Central	B-D002490
Nervous	I-D002490
System	I-D002490
Vertigo	B-D014717
;	O
Light	B-D008027

Special	O
Senses	O
Transient	O
visual	O
disturbances	O
including	O
blurred	O
vision	O

Hypersensitivity	B-D006967
Reactions	O
Acute	O
anaphylactic	O
reaction	O
with	O
bronchospasm;	O
Angioedema	B-D000799

Hypersensitivity	B-D006967
Vasculitis	B-D014657

Hypersensitivity	B-D006967
Syndrome	B-D013577

Miscellaneous	O
Asthenia	B-D001247
,	O
Edema	B-D004487

Causal	O
Relationship	O
Unknown	O
Other	O
reactions	O
have	O
been	O
reported	O
in	O
Clinical	B-D016430
Trial	I-D016430

However,	O
in	O
these	O
rarely	O
reported	O
events,	O
that	O
possibility	O
cannot	O
be	O
excluded	O

Therefore,	O
these	O
Observation	B-D019370

Respiratory	O
Dyspnea	B-D004417
	O

Cardiovascular	O
Palpitation,	O
Syncope	B-D013575

Musculoskeletal	O
Muscle	B-D009120
Cramp	I-D009120

Genitourinary	O
Nephrotic	B-D009404
Syndrome	I-D009404

Special	O
Senses	O
Hearing	B-D034381
Loss	I-D034381

Miscellaneous	O
Chest	B-D002637
Pain	I-D002637

A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
Fasciitis	B-D005208

Potential	O
Adverse	O
Effects	O
In	O
addition,	O
a	O
variety	O
of	O
adverse	O
effects	O
not	O
observed	O
with	O
Diflunisal	B-D004061

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
Fever	B-D005334

at	O
1-855-361-3993;	O
email	O
drugsafety@avkare.com;	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

WARNING:	O
ADDICTION,	O
ABUSE,	O
AND	O
MISUSE;	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938

ASCOMP	O
with	O
Codeine	B-D003061
exposes	O
users	O
to	O
the	O
Risk	B-D012306

Assess	O
patient's	O
Risk	B-D012306

(5.1)	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
Analgesics	B-D000700

(5.2)	O
Serious,	O
Life	B-D019369

Monitor	O
closely,	O
especially	O
upon	O
initiation	O
or	O
following	O
a	O
dose	O
increase	O

(5.3)	O
Accidental	O
ingestion	O
of	O
ASCOMP	O
with	O
Codeine	B-D003061
,	O
especially	O
by	O
Child	B-D002648

(5.3)	O
Concomitant	O
use	O
of	O
opioids	O
or	O
a	O
barbiturate	O
with	O
Benzodiazepines	B-D001569

Reserve	O
concomitant	O
prescribing	O
for	O
use	O
in	O
Patients	B-D010361

(5.4,	O
5.8,	O
7)	O
Life	B-D019369
-threatening	O
respiratory	O
Depression	B-D003863

(5.5)	O
ASCOMP	O
with	O
Codeine	B-D003061
is	O
contraindicated	O
in	O
Child	B-D002648

Avoid	O
the	O
use	O
of	O
ASCOMP	O
with	O
Codeine	B-D003061
in	O
Adolescent	B-D000293

Prolonged	O
use	O
during	O
Pregnancy	B-D011247

If	O
prolonged	O
opioid	O
use	O
is	O
required	O
in	O
a	O
pregnant	O
woman,	O
advise	O
the	O
patient	O
of	O
the	O
Risk	B-D012306

(5.6)	O
The	O
effects	O
of	O
concomitant	O
use	O
or	O
discontinuation	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
Codeine	B-D003061

Use	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
ASCOMP	O
with	O
Codeine	B-D003061
requires	O
careful	O
consideration	O
of	O
the	O
effects	O
on	O
Codeine	B-D003061

(5.7,	O
5.8,	O
7)	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
ASCOMP	O
with	O
Codeine	B-D003061
exposes	O
Patients	B-D010361

Assess	O
each	O
patient's	O
Risk	B-D012306

Opioid	O
Analgesic	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
Analgesics	B-D000700

Under	O
the	O
requirements	O
of	O
the	O
REMS,	O
drug	O
companies	O
with	O
approved	O
opioid	O
analgesic	O
products	O
must	O
make	O
REMS-compliant	O
Education	B-D004493

Health	B-D006262
care	O
providers	O
are	O
strongly	O
encouraged	O
to:	O
complete	O
a	O
REMS-compliant	O
Education	B-D004493

Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Serious,	O
Life	B-D019369

Monitor	O
for	O
respiratory	O
Depression	B-D003863

Accidental	O
Ingestion	O
Accidental	O
ingestion	O
of	O
even	O
one	O
dose	O
of	O
ASCOMP	O
with	O
Codeine	B-D003061
,	O
especially	O
by	O
Child	B-D002648

Risk	B-D012306
s	O
From	O
Concomitant	O
Use	O
With	O
Benzodiazepines	B-D001569
Or	O
Other	O
CNS	O
Depressants	O
Concomitant	O
use	O
of	O
opioids	O
with	O
Benzodiazepines	B-D001569

Reserve	O
concomitant	O
prescribing	O
of	O
ASCOMP	O
with	O
Codeine	B-D003061
and	O
Benzodiazepines	B-D001569

Limit	O
dosages	O
and	O
durations	O
to	O
the	O
minimum	O
required	O

Follow	O
Patients	B-D010361

Ultra-Rapid	O
Metabolism	B-D008660
of	O
Codeine	B-D003061
and	O
Other	O
Risk	B-D012307
Factors	I-D012307
for	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Child	B-D002648
ren	O
Life	B-D019369
-threatening	O
respiratory	O
Depression	B-D003863

Most	O
of	O
the	O
reported	O
cases	O
occurred	O
following	O
Tonsillectomy	B-D014068

[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O

ASCOMP	O
with	O
Codeine	B-D003061
is	O
contraindicated	O
in	O
Child	B-D002648

Avoid	O
the	O
use	O
of	O
ASCOMP	O
with	O
Codeine	B-D003061
in	O
Adolescent	B-D000293

Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Prolonged	O
use	O
of	O
ASCOMP	O
with	O
Codeine	B-D003061
during	O
Pregnancy	B-D011247

If	O
opioid	O
use	O
is	O
required	O
for	O
a	O
prolonged	O
period	O
in	O
a	O
pregnant	O
woman,	O
advise	O
the	O
patient	O
of	O
the	O
Risk	B-D012306

Interactions	O
with	O
Drugs	O
Affect	B-D000339
ing	O
Cytochrome	O
P450	O
Isoenzymes	B-D007527
The	O
effects	O
of	O
concomitant	O
use	O
or	O
discontinuation	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
Codeine	B-D003061

Use	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
ASCOMP	O
with	O
Codeine	B-D003061
requires	O
careful	O
consideration	O
of	O
the	O
effects	O
on	O
Codeine	B-D003061

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Patients	B-D010361
with	O
Chronic	O
Pulmonary	O
Disease	B-D004194
or	O
in	O
Elderly,	O
Cachectic,	O
or	O
Debilitated	O
Patients	B-D010361
:	O
Monitor	O
closely,	O
particularly	O
during	O
initiation	O
and	O
titration	O

(5.8)	O
Adrenal	B-D000309
Insufficiency	I-D000309
:	O
If	O
diagnosed,	O
treat	O
with	O
physiologic	O
replacement	O
of	O
corticosteroids,	O
and	O
wean	O
patient	O
off	O
the	O
opioid	O

(5.10)	O
Severe	O
Hypotension	B-D007022
:	O
Monitor	O
during	O
dose	O
initiation	O
and	O
titration	O

Avoid	O
use	O
of	O
ASCOMP	O
with	O
Codeine	B-D003061
in	O
Patients	B-D010361

(5.11)	O
Risk	B-D012306
s	O
of	O
Use	O
in	O
Patients	B-D010361
with	O
Increased	O
Intracranial	B-D007427
Pressure	I-D007427
,	O
Brain	B-D001921
Tumors,	O
Head	B-D006257
Injury,	O
or	O
Impaired	O
Consciousness	B-D003243
:	O
Monitor	O
for	O
sedation	O
and	O
respiratory	O
Depression	B-D003863

Avoid	O
use	O
of	O
ASCOMP	O
with	O
Codeine	B-D003061
in	O
Patients	B-D010361

(5.12)	O
5.1	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
ASCOMP	O
with	O
Codeine	B-D003061
contains	O
Codeine	B-D003061

Codeine	B-D003061
in	O
combination	O
with	O
butalbital	B-C004470
,	O
Aspirin	B-D001241

As	O
ASCOMP	O
with	O
Codeine	B-D003061
contains	O
butalbital	B-C004470
and	O
Codeine	B-D003061

Although	O
the	O
Risk	B-D012306

Addiction	O
can	O
occur	O
at	O
recommended	O
dosages	O
and	O
if	O
the	O
drug	O
is	O
misused	O
or	O
abused	O

Assess	O
each	O
patient's	O
Risk	B-D012306

Risk	B-D012306
s	O
are	O
increased	O
in	O
Patients	B-D010361

The	O
potential	O
for	O
these	O
Risk	B-D012306

Patients	B-D010361
at	O
increased	O
Risk	B-D012306

Opioids	O
and	O
Barbiturates	B-D001463

Consider	O
these	O
Risk	B-D012306

Strategies	O
to	O
reduce	O
these	O
Risk	B-D012306

Contact	O
local	O
state	O
professional	O
licensing	O
board	O
or	O
state	O
Controlled	B-D061891
Substances	I-D061891

5.2	O
Opioid	O
Analgesic	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
Analgesics	B-D000700

Under	O
the	O
requirements	O
of	O
the	O
REMS,	O
drug	O
companies	O
with	O
approved	O
opioid	O
analgesic	O
products	O
must	O
make	O
REMS-compliant	O
Education	B-D004493

Health	B-D006262
care	O
providers	O
are	O
strongly	O
encouraged	O
to	O
do	O
all	O
of	O
the	O
following:	O
Complete	O
a	O
REMS-compliant	O
Education	B-D004493
Blueprint	O
for	O
Health	B-D006262
Care	O
Providers	O
Involved	O
in	O
the	O
Management	O
or	O
Support	O
of	O
Patients	B-D010361
with	O
Pain	B-D010146
	O

Discuss	O
the	O
safe	O
use,	O
serious	O
Risk	B-D012306

The	O
Patient	O
Counseling	B-D003376
Guide	O
(PCG)	O
can	O
be	O
obtained	O
at	O
this	O
link:	O
www.fda.gov/OpioidAnalgesicREMSPCG	O

Emphasize	O
to	O
Patients	B-D010361

Consider	O
using	O
other	O
tools	O
to	O
ImProv	B-C413303

To	O
obtain	O
further	O
information	O
on	O
the	O
opioid	O
analgesic	O
REMS	O
and	O
for	O
a	O
list	O
of	O
accredited	O
REMS	O
CME/CE,	O
call	O
1-800-503-0784,	O
or	O
log	O
on	O
to	O
www.opioidanalgesicrems.com	O

The	O
FDA	O
Blueprint	O
can	O
be	O
found	O
at	O
www.fda.gov/OpioidAnalgesicREMSBlueprint	O

5.3	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Serious,	O
Life	B-D019369

Respiratory	O
Depression	B-D003863

Management	O
of	O
respiratory	O
Depression	B-D003863

Carbon	B-D002245
Dioxide	I-D002245

While	O
serious,	O
Life	B-D019369

Monitor	O
Patients	B-D010361

To	O
reduce	O
the	O
Risk	B-D012306

Overestimating	O
the	O
ASCOMP	O
with	O
Codeine	B-D003061
dosage	O
when	O
converting	O
Patients	B-D010361

Accidental	O
ingestion	O
of	O
ASCOMP	O
with	O
Codeine	B-D003061
,	O
especially	O
by	O
Child	B-D002648

Opioids	O
can	O
cause	O
Sleep	B-D012890

Opioid	O
use	O
increases	O
the	O
Risk	B-D012306

In	O
Patients	B-D010361

5.4	O
Risk	B-D012306
s	O
from	O
Concomitant	O
Use	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants	O
Profound	O
sedation,	O
respiratory	O
Depression	B-D003863

Because	O
of	O
these	O
Risk	B-D012306

Observation	B-D019370
al	O
studies	O
have	O
demonstrated	O
that	O
concomitant	O
use	O
of	O
opioid	O
Analgesics	B-D000700

Because	O
of	O
similar	O
pharmacological	O
properties,	O
it	O
is	O
reasonable	O
to	O
expect	O
similar	O
Risk	B-D012306

If	O
the	O
decision	O
is	O
made	O
to	O
prescribe	O
a	O
benzodiazepine	O
or	O
other	O
CNS	O
depressant	O
concomitantly	O
with	O
an	O
opioid	O
analgesic,	O
prescribe	O
the	O
lowest	O
effective	O
dosages	O
and	O
minimum	O
durations	O
of	O
concomitant	O
use	O

In	O
Patients	B-D010361

If	O
an	O
opioid	O
analgesic	O
is	O
initiated	O
in	O
a	O
patient	O
already	O
taking	O
a	O
benzodiazepine	O
or	O
other	O
CNS	O
depressant,	O
prescribe	O
a	O
lower	O
initial	O
dose	O
of	O
the	O
opioid	O
analgesic,	O
and	O
titrate	O
based	O
on	O
clinical	O
response	O

Follow	O
Patients	B-D010361

Advise	O
both	O
Patients	B-D010361

Advise	O
Patients	B-D010361

Screen	O
Patients	B-D010361

5.5	O
Ultra-Rapid	O
Metabolism	B-D008660
of	O
Codeine	B-D003061
and	O
Other	O
Risk	B-D012307
Factors	I-D012307
for	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Child	B-D002648
ren	O
Life	B-D019369
-threatening	O
respiratory	O
Depression	B-D003863

Codeine	B-D003061
is	O
subject	O
to	O
variability	O
in	O
Metabolism	B-D008660

Based	O
upon	O
postmarketing	O
reports,	O
Child	B-D002648

For	O
example,	O
many	O
reported	O
cases	O
of	O
Death	B-D003643

Furthermore,	O
Child	B-D002648

Because	O
of	O
the	O
Risk	B-D012306

ASCOMP	O
with	O
Codeine	B-D003061
is	O
contraindicated	O
for	O
post-operative	O
management	O
in	O
pediatric	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
ASCOMP	O
with	O
Codeine	B-D003061
in	O
Adolescent	B-D000293

Risk	B-D012307
Factors	I-D012307

As	O
with	O
Adult	B-D000328

Nursing	B-D009729
Mothers	B-D009035
At	O
least	O
one	O
Death	B-D003643

Breast	B-D001940
feeding	O
is	O
not	O
recommended	O
during	O
treatment	O
with	O
ASCOMP	O
with	O
Codeine	B-D003061
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.2)]	O

CYP2D6	O
Genetic	O
Variability:	O
Ultra-rapid	O
metabolizer	O
Some	O
individuals	O
may	O
be	O
ultra-rapid	O
metabolizers	O
because	O
of	O
a	O
specific	O
CYP2D6	O
Genotype	B-D005838

The	O
Prevalence	B-D015995

These	O
individuals	O
convert	O
Codeine	B-D003061

This	O
rapid	O
conversion	O
results	O
in	O
higher	O
than	O
expected	O
Serum	B-D044967

Even	O
at	O
labeled	O
dosage	O
regimens,	O
individuals	O
who	O
are	O
ultra-rapid	O
metabolizers	O
may	O
have	O
Life	B-D019369

Therefore,	O
individuals	O
who	O
are	O
ultra-rapid	O
metabolizers	O
should	O
not	O
use	O
ASCOMP	O
with	O
Codeine	B-D003061
	O

5.6	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Prolonged	O
use	O
of	O
ASCOMP	O
with	O
Codeine	B-D003061
during	O
Pregnancy	B-D011247

Neon	B-D009356
atal	O
opioid	O
withdrawal	O
Syndrome	B-D013577

Observe	O
newborns	O
for	O
signs	O
of	O
Neon	B-D009356

Advise	O
Pregnant	B-D037841
Women	I-D037841

5.7	O
Risk	B-D012306
s	O
of	O
Interactions	O
with	O
Drugs	O
Affect	B-D000339
ing	O
Cytochrome	O
P450	O
Isoenzymes	B-D007527
The	O
effects	O
of	O
concomitant	O
use	O
or	O
discontinuation	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
Codeine	B-D003061

Use	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
ASCOMP	O
with	O
Codeine	B-D003061
requires	O
careful	O
consideration	O
of	O
the	O
effects	O
on	O
Codeine	B-D003061

Cytochrome	O
P450	O
3A4	O
Interaction	O
The	O
concomitant	O
use	O
of	O
ASCOMP	O
with	O
Codeine	B-D003061
with	O
all	O
cytochrome	O
P450	O
3A4	O
inhibitors,	O
such	O
as	O
macrolide	O
antibiotics	O
(e.g.,	O
Erythromycin	B-D004917

The	O
concomitant	O
use	O
of	O
ASCOMP	O
with	O
Codeine	B-D003061
with	O
all	O
cytochrome	O
P450	O
3A4	O
inducers	O
or	O
discontinuation	O
of	O
a	O
cytochrome	O
P450	O
3A4	O
inhibitor	O
may	O
result	O
in	O
lower	O
Codeine	B-D003061

This	O
may	O
be	O
associated	O
with	O
a	O
decrease	O
in	O
efficacy,	O
and	O
in	O
some	O
Patients	B-D010361

Follow	O
Patients	B-D010361

If	O
concomitant	O
use	O
of	O
a	O
CYP3A4	O
inhibitor	O
is	O
necessary	O
or	O
if	O
a	O
CYP3A4	O
inducer	O
is	O
discontinued,	O
consider	O
dosage	O
reduction	O
of	O
ASCOMP	O
with	O
Codeine	B-D003061
until	O
stable	O
drug	O
effects	O
are	O
achieved	O

Monitor	O
Patients	B-D010361

If	O
concomitant	O
use	O
of	O
a	O
CYP3A4	O
inducer	O
is	O
necessary	O
or	O
if	O
a	O
CYP3A4	O
inhibitor	O
is	O
discontinued,	O
consider	O
increasing	O
the	O
ASCOMP	O
with	O
Codeine	B-D003061
dosage	O
until	O
stable	O
drug	O
effects	O
are	O
achieved	O

Monitor	O
for	O
signs	O
of	O
opioid	O
withdrawal	O

[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

Risk	B-D012306
s	O
of	O
Concomitant	O
Use	O
or	O
Discontinuation	O
of	O
Cytochrome	O
P450	O
2D6	O
Inhibitors	O
The	O
concomitant	O
use	O
of	O
ASCOMP	O
with	O
Codeine	B-D003061
with	O
all	O
cytochrome	O
P450	O
2D6	O
inhibitors	O
(e.g.,	O
Amiodarone	B-D000638

Discontinuation	O
of	O
a	O
concomitantly	O
used	O
cytochrome	O
P450	O
2D6	O
inhibitor	O
may	O
result	O
in	O
a	O
decrease	O
in	O
Codeine	B-D003061

Follow	O
Patients	B-D010361

If	O
concomitant	O
use	O
with	O
a	O
CYP2D6	O
inhibitor	O
is	O
necessary,	O
follow	O
the	O
patient	O
for	O
signs	O
of	O
reduced	O
efficacy	O
or	O
opioid	O
withdrawal	O
and	O
consider	O
increasing	O
the	O
ASCOMP	O
with	O
Codeine	B-D003061
dosage	O

After	O
stopping	O
use	O
of	O
a	O
CYP2D6	O
inhibitor,	O
consider	O
reducing	O
the	O
ASCOMP	O
with	O
Codeine	B-D003061
dosage	O
and	O
follow	O
the	O
patient	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

5.8	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Patients	B-D010361
with	O
Chronic	O
Pulmonary	O
Disease	B-D004194
or	O
in	O
Elderly,	O
Cachectic,	O
or	O
Debilitated	O
Patients	B-D010361
The	O
use	O
of	O
ASCOMP	O
with	O
Codeine	B-D003061
in	O
Patients	B-D010361

Patients	B-D010361
with	O
Chronic	O
Pulmonary	O
Disease	B-D004194
:	O
ASCOMP	O
with	O
Codeine	B-D003061
-treated	O
Patients	B-D010361

Elderly,	O
Cachectic,	O
or	O
Debilitated	O
Patients	B-D010361
:	O
Life	B-D019369
-threatening	O
respiratory	O
Depression	B-D003863

Monitor	O
such	O
Patients	B-D010361

Alternatively,	O
consider	O
the	O
use	O
of	O
non-opioid	O
Analgesics	B-D000700

5.9	O
Interaction	O
with	O
Monoamine	B-D008996
Oxidase	I-D008996
Inhibitors	I-D008996
Monoamine	B-D008996
Oxidase	I-D008996
Inhibitors	I-D008996

ASCOMP	O
with	O
Codeine	B-D003061
should	O
not	O
be	O
used	O
in	O
Patients	B-D010361

5.10	O
Adrenal	B-D000309
Insufficiency	I-D000309
Cases	O
of	O
Adrenal	B-D000309
Insufficiency	I-D000309

Presentation	O
of	O
Adrenal	B-D000309
Insufficiency	I-D000309

If	O
Adrenal	B-D000309
Insufficiency	I-D000309

If	O
Adrenal	B-D000309
Insufficiency	I-D000309

Wean	O
the	O
patient	O
off	O
of	O
the	O
opioid	O
to	O
allow	O
adrenal	O
function	O
to	O
recover	O
and	O
continue	O
corticosteroid	O
treatment	O
until	O
adrenal	O
function	O
recovers	O

Other	O
opioids	O
may	O
be	O
tried	O
as	O
some	O
cases	O
reported	O
use	O
of	O
a	O
different	O
opioid	O
without	O
Recurrence	B-D012008

The	O
information	O
available	O
does	O
not	O
Id	B-D007060

5.11	O
Severe	O
Hypotension	B-D007022
ASCOMP	O
with	O
Codeine	B-D003061
may	O
cause	O
severe	O
Hypotension	B-D007022

There	O
is	O
increased	O
Risk	B-D012306

Monitor	O
these	O
Patients	B-D010361

In	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
ASCOMP	O
with	O
Codeine	B-D003061
in	O
Patients	B-D010361

5.12	O
Risk	B-D012306
s	O
of	O
Use	O
in	O
Patients	B-D010361
with	O
Increased	O
Intracranial	B-D007427
Pressure	I-D007427
,	O
Brain	B-D001921
Tumors,	O
Head	B-D006257
Injury,	O
or	O
Impaired	O
Consciousness	B-D003243
In	O
Patients	B-D010361

Monitor	O
such	O
Patients	B-D010361

Opioids	O
may	O
also	O
obscure	O
the	O
clinical	O
course	O
in	O
a	O
patient	O
with	O
a	O
Head	B-D006257

Avoid	O
the	O
use	O
of	O
ASCOMP	O
with	O
Codeine	B-D003061
in	O
Patients	B-D010361

5.13	O
Risk	B-D012306
s	O
of	O
Use	O
in	O
Patients	B-D010361
with	O
Gastrointestinal	O
Conditions	O
Including	O
Peptic	B-D010437
Ulcer	I-D010437
Disease	B-D004194
ASCOMP	O
with	O
Codeine	B-D003061
is	O
contraindicated	O
in	O
Patients	B-D010361

The	O
Codeine	B-D003061
may	O
cause	O
Spasm	B-D013035

Opioids	O
may	O
cause	O
increases	O
in	O
Serum	B-D044967

Monitor	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
History	B-D006664

The	O
Aspirin	B-D001241

Although	O
minor	O
upper	O
GI	O
symptoms,	O
such	O
as	O
Dyspepsia	B-D004415

Physicians	B-D010820
should	O
inform	O
Patients	B-D010361

5.14	O
Increased	O
Risk	B-D012306
of	O
Seizures	B-D012640
in	O
Patients	B-D010361
with	O
Seizure	O
Disorders	O
The	O
Codeine	B-D003061
may	O
increase	O
the	O
frequency	O
of	O
Seizures	B-D012640

Monitor	O
Patients	B-D010361

5.15	O
Withdrawal	O
Do	O
not	O
abruptly	O
discontinue	O
ASCOMP	O
with	O
Codeine	B-D003061
in	O
a	O
patient	O
physically	O
dependent	O
on	O
opioids	O

Rapid	O
tapering	O
of	O
butalbital	B-C004470
,	O
Aspirin	B-D001241

Additionally,	O
avoid	O
the	O
use	O
of	O
mixed	O
agonist/antagonist	O
(e.g.,	O
Pentazocine	B-D010423

In	O
these	O
Patients	B-D010361

When	O
discontinuing	O
ASCOMP	O
with	O
Codeine	B-D003061
in	O
a	O
physically-dependent	O
patient,	O
gradually	O
taper	O
the	O
dosage	O
[see	O
Dosage	O
and	O
Administration	O
(2.3)]	O

Abrupt	O
discontinuation	O
of	O
butalbital	B-C004470
can	O
cause	O
Seizures	B-D012640

5.16	O
Risk	B-D012306
s	O
of	O
Driving	O
and	O
Operating	O
Machinery	O
ASCOMP	O
with	O
Codeine	B-D003061
may	O
impair	O
the	O
Men	B-D008571

Warn	O
Patients	B-D010361

5.17	O
Coagulation	O
Abnormalities	O
and	O
Bleeding	O
Risk	B-D012306
s	O
Even	O
low	O
doses	O
of	O
Aspirin	B-D001241

This	O
can	O
adversely	O
Affect	B-D000339

hemophilia)	O
or	O
acquired	O
(i.e	O

Liver	B-D008099

Aspirin	B-D001241
is	O
contraindicated	O
in	O
Patients	B-D010361

Aspirin	B-D001241
administered	O
pre-operatively	O
may	O
prolong	O
the	O
Bleeding	B-D001760
Time	I-D001760

Patients	B-D010361
who	O
consume	O
three	O
or	O
more	O
alcoholic	O
drinks	O
every	O
day	O
should	O
be	O
counseled	O
about	O
the	O
bleeding	O
Risk	B-D012306

5.18	O
Reye's	O
Syndrome	B-D013577
Aspirin	B-D001241
should	O
not	O
be	O
used	O
in	O
Child	B-D002648

5.19	O
Allergy	O
Aspirin	B-D001241
is	O
contraindicated	O
in	O
Patients	B-D010361

Aspirin	B-D001241
may	O
cause	O
severe	O
Urticaria	B-D014581

5.20	O
Drug/Laboratory	O
TES	B-C004551

Aspirin	B-D001241
may	O
interfere	O
with	O
the	O
following	O
laboratory	O
determinations	O
in	O
Urine	B-D014556

Codeine	B-D003061
:	O
Codeine	B-D003061
may	O
increase	O
Serum	B-D044967

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described,	O
or	O
described	O
in	O
greater	O
detail,	O
in	O
other	O
sections:	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Interactions	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Ultra-Rapid	O
Metabolism	B-D008660
of	O
Codeine	B-D003061
and	O
Other	O
Risk	B-D012307
Factors	I-D012307
for	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Child	B-D002648
ren	O
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Adrenal	B-D000309
Insufficiency	I-D000309
[see	O
Warnings	O
and	O
Precautions	O
(5.10)]	O
Severe	O
Hypotension	B-D007022
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Gastrointestinal	O
Adverse	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.13)]	O
Seizures	B-D012640
[see	O
Warnings	O
and	O
Precautions	O
(5.14)]	O
Withdrawal	O
[see	O
Warnings	O
and	O
Precautions	O
(5.15)]	O
Coagulation	O
Abnormalities	O
and	O
Bleeding	O
[see	O
Warnings	O
and	O
Precautions	O
(5.17)]	O
Reye's	O
Syndrome	B-D013577
[see	O
Warnings	O
and	O
Precautions	O
(5.18)]	O
Allergy	O
[see	O
Warnings	O
and	O
Precautions	O
(5.19)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>	O
1%)	O
are	O
Nausea	B-D009325

(6)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Breckenridge	O
Pharmaceutical,	O
Inc	O

at	O
1-800-367-3395	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

Incidence	B-D015994
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848
s	O
The	O
following	O
table	O
summarizes	O
the	O
Incidence	B-D015994

The	O
prescriber	O
should	O
be	O
aware	O
that	O
these	O
figures	O
cannot	O
be	O
used	O
to	O
predict	O
the	O
Incidence	B-D015994

Similarly,	O
the	O
cited	O
frequencies	O
cannot	O
be	O
compared	O
with	O
figures	O
obtained	O
from	O
other	O
clinical	O
investigations	O
involving	O
different	O
treatments,	O
uses,	O
and	O
investigators	O

Adverse	O
Events	O
Reported	O
by	O
at	O
Least	O
1%	O
of	O
butalbital	B-C004470

All	O
reported	O
adverse	O
events,	O
except	O
those	O
already	O
presented	O
in	O
the	O
previous	O
table,	O
are	O
included	O

It	O
is	O
important	O
to	O
emphasize	O
that,	O
although	O
the	O
adverse	O
events	O
reported	O
did	O
occur	O
while	O
the	O
patient	O
was	O
receiving	O
butalbital	B-C004470

Adverse	O
events	O
are	O
classified	O
by	O
body	O
system	O
and	O
frequency	O

"Frequent"	O
is	O
defined	O
as	O
an	O
adverse	O
event	O
which	O
occurred	O
in	O
at	O
least	O
1/100	O
(1%)	O
of	O
the	O
Patients	B-D010361

"Infrequent"	O
is	O
defined	O
as	O
an	O
adverse	O
event	O
that	O
occurred	O
in	O
less	O
than	O
1/100	O
Patients	B-D010361

All	O
adverse	O
events	O
tabulated	O
below	O
are	O
classified	O
as	O
infrequent	O

Central	O
Nervous:	O
Headache	B-D006261

Autonomic	O
Nervous:	O
dry	O
Mouth	B-D009055

Gastrointestinal:	O
Vomiting	B-D014839

Cardiovascular:	O
Tachycardia	B-D013610

Musculoskeletal:	O
Leg	B-D007866

Genitourinary:	O
Diuresis	B-D004231

Miscellaneous:	O
Pruritus	B-D011537

The	O
following	O
adverse	O
drug	O
reactions	O
have	O
been	O
reported	O
with	O
the	O
components	O
of	O
ASCOMP	O
with	O
Codeine	B-D003061
	O

Potential	O
effects	O
of	O
high	O
dosage	O
are	O
listed	O
in	O
the	O
[see	O
Overdosage	O
(10)]	O
section	O
of	O
this	O
insert	O

Aspirin	B-D001241
:	O
Occult	B-D009780
Blood	I-D009780

Caffeine	B-D002110
:	O
Cardia	B-D002299

Codeine	B-D003061
:	O
Nausea	B-D009325

6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Central	O
Nervous:	O
abuse,	O
addiction,	O
Anxiety	B-D001007

Autonomic	O
Nervous:	O
Epistaxis	B-D004844

Gastrointestinal:	O
Anorexia	B-D000855

Cardiovascular:	O
Chest	B-D002637
Pain	I-D002637

Skin	B-D012867
:	O
Erythema	B-D004890

Urinary:	O
Kidney	B-D007668

Miscellaneous:	O
allergic	O
reaction,	O
anaphylactic	O
Shock	B-D012769

Serotonin	B-D020230
Syndrome	I-D020230

Adrenal	B-D000309
Insufficiency	I-D000309

Anaphylaxis	B-D000707
:	O
Anaphylaxis	B-D000707
has	O
been	O
reported	O
with	O
ingredients	O
contained	O
in	O
ASCOMP	O
with	O
Codeine	B-D003061
	O

Androgen	O
deficiency:	O
Cases	O
of	O
androgen	O
deficiency	O
have	O
occurred	O
with	O
chronic	O
use	O
of	O
opioids	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)]	O

ADVERSE	O
REACTIONS	O
Transient	O
burning	O
and	O
stinging	O
upon	O
instillation	O
and	O
other	O
minor	O
symptoms	O
of	O
ocular	O
irritation	O
have	O
been	O
reported	O
with	O
the	O
use	O
of	O
Flurbiprofen	B-D005480
Sodium	B-D012964
Ophthalmic	O
Solution	O

Other	O
adverse	O
reactions	O
reported	O
with	O
the	O
use	O
of	O
Flurbiprofen	B-D005480
Sodium	B-D012964
Ophthalmic	O
Solution	O
include:	O
Fibrosis	B-D005355

Increased	O
bleeding	O
tendency	O
of	O
ocular	O
Tissues	B-D014024

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Bausch	O
+	O
Lomb,	O
a	O
division	O
of	O
Valeant	O
Pharmaceuticals	O
North	B-D009656
America	I-D009656
LLC,	O
at	O
1-800-321-4576	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
VIMOVO	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

(4,	O
5.1)	O
NSAIDs,	O
including	O
Naproxen	B-D009288

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Non-Steroidal	O
Anti-inflammatory	O
Drugs	O
(NSAIDs),	O
a	O
component	O
of	O
VIMOVO,	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

VIMOVO	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
a	O
component	O
of	O
VIMOVO	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
Blood	B-D001794
Pressure	I-D001794

(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
VIMOVO	O
in	O
Patients	B-D010361

(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
use	O
of	O
VIMOVO	O
in	O
Patients	B-D010361

(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
VIMOVO	O
is	O
contraindicated	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
VIMOVO	O
at	O
first	O
appearance	O
of	O
Skin	B-D012867

(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
Pregnant	B-D037841
Women	I-D037841

(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
Hematocrit	B-D006400

(5.11,	O
7)	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
:	O
Potential	O
for	O
diminished	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
Infections	B-D007239

(5.12)	O
Laboratory	O
Monitoring:	O
Obtain	O
CBC	O
and	O
Chemistry	B-D002621

Monitor	O
hemoglobin	B-C036602
P	I-C036602

(5.13)	O
Active	O
Bleeding:	O
Withdraw	O
treatment	O
in	O
Patients	B-D010361

(5.14)	O
Concomitant	O
NSAID	O
Use:	O
Do	O
not	O
use	O
VIMOVO	O
with	O
other	O
Naproxen	B-D009288

(5.15)	O
Gastric	O
Mali	B-D008302
gnancy:	O
In	O
Adult	B-D000328

Consider	O
additional	O
follow-up	O
and	O
diagnostic	O
TES	B-C004551

(5.16)	O
Acute	O
Interstitial	O
Nephritis	B-D009393
:	O
Observed	O
in	O
Patients	B-D010361

(5.17)	O
Clostridium	B-D016360
difficile	I-D016360
-Associated	O
Diarrhea	B-D003967
:	O
PPI	O
therapy	O
may	O
be	O
associated	O
with	O
increased	O
Risk	B-D012306

(5.18)	O
Bone	O
Fracture:	O
Long-term	O
and	O
multiple	O
daily	O
dose	O
PPI	O
therapy	O
may	O
be	O
associated	O
with	O
an	O
increased	O
Risk	B-D012306

(5.19)	O
Cutaneous	O
and	O
Systemic	O
Lupus	O
Erythema	B-D004890
tosus:	O
Mostly	O
cutaneous,	O
new	O
onset	O
or	O
exacerbation	O
of	O
existing	O
Disease	B-D004194

(5.20)	O
Interaction	O
with	O
Clopidogrel	B-D000077144
:	O
Avoid	O
concomitant	O
use	O

(5.21,	O
7)	O
Cyanocobalamin	O
(Vitamin	O
B-12)	O
Deficiency:	O
Daily	O
long-term	O
use	O
(e.g.,	O
longer	O
than	O
3	O
years)	O
may	O
Lead	B-D007854

(5.22)	O
Hypomagnesemia:	O
Reported	O
rarely	O
with	O
prolonged	O
treatment	O
with	O
PPIs	O

(5.23)	O
Interaction	O
with	O
St	O

John's	O
Wort	O
or	O
Rifampin	B-D012293
:	O
Avoid	O
concomitant	O
use	O

(5.24,	O
7)	O
Interactions	O
with	O
Diagnostic	O
Investigations	O
for	O
Neuroendocrine	B-D018358
Tumors	I-D018358
:	O
Increases	O
in	O
intragastric	O
pH	O
may	O
result	O
in	O
hypergastrinemia,	O
enterochromaffin-like	O
cell	O
Hyperplasia	B-D006965

(5.25)	O
Interaction	O
with	O
Methotrexate	B-D008727
:	O
Concomitant	O
use	O
with	O
PPIs	O
may	O
elevate	O
and/or	O
prolong	O
Serum	B-D044967

(5.26,	O
7)	O
Fundic	O
Gland	O
Polyps	B-D011127
:	O
Risk	B-D012306
increases	O
with	O
long-term	O
PPI	O
use,	O
especially	O
beyond	O
one	O
year	O

Use	O
the	O
shortest	O
Duration	B-D000081206
of	I-D000081206
Therapy	I-D000081206

(5.27)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
VIMOVO	O
in	O
Patients	B-D010361

If	O
VIMOVO	O
is	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Naproxen	B-D009288

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
as	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
VIMOVO	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

NSAIDs	O
should	O
be	O
given	O
with	O
care	O
to	O
Patients	B-D010361

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
and	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
Jaundice	B-D007565

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

VIMOVO	O
should	O
be	O
avoided	O
in	O
Patients	B-D010361

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
VIMOVO,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
Thiazides	B-D049971

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Naproxen	B-D009288

Avoid	O
the	O
use	O
of	O
VIMOVO	O
in	O
Patients	B-D010361

If	O
VIMOVO	O
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
was	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
VIMOVO	O
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
VIMOVO	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
VIMOVO	O
in	O
Patients	B-D010361

If	O
VIMOVO	O
is	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Naproxen	B-D009288
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
VIMOVO	O
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Naproxen	B-D009288

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

VIMOVO	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Naproxen	B-D009288
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
VIMOVO,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
VIMOVO	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

NSAIDs,	O
including	O
VIMOVO,	O
may	O
increase	O
the	O
Risk	B-D012306

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
VIMOVO	O
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

Patients	B-D010361
with	O
initial	O
hemoglobin	O
values	O
of	O
10	O
g	O
or	O
less	O
who	O
are	O
to	O
receive	O
long-term	O
therapy	O
should	O
have	O
hemoglobin	O
values	O
determined	O
Periodical	B-D020492

5.14	O
Active	O
Bleeding	O
When	O
active	O
and	O
clinically	O
significant	O
bleeding	O
from	O
any	O
source	O
occurs	O
in	O
Patients	B-D010361

5.15	O
Concomitant	O
NSAID	O
Use	O
VIMOVO	O
contains	O
Naproxen	B-D009288

It	O
should	O
not	O
be	O
used	O
with	O
other	O
Naproxen	B-D009288

The	O
concomitant	O
use	O
of	O
VIMOVO	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
Risk	B-D012306

5.16	O
Presence	O
of	O
Gastric	O
Mali	B-D008302
gnancy	O
In	O
Adult	B-D000328

Consider	O
additional	O
gastrointestinal	O
follow-up	O
and	O
diagnostic	O
TES	B-C004551

In	O
older	O
Patients	B-D010361

5.17	O
Acute	O
Interstitial	O
Nephritis	B-D009393
Acute	O
interstitial	O
Nephritis	B-D009393

Acute	O
interstitial	O
Nephritis	B-D009393

Discontinue	O
VIMOVO	O
if	O
acute	O
interstitial	O
Nephritis	B-D009393

5.18	O
Clostridium	B-D016360
difficile	I-D016360
-Associated	O
Diarrhea	B-D003967
Published	O
Observation	B-D019370

This	O
Diagnosis	B-D003933

Patients	B-D010361
should	O
use	O
the	O
lowest	O
dose	O
and	O
shortest	O
duration	O
of	O
PPI	O
therapy	O
appropriate	O
to	O
the	O
condition	O
being	O
treated	O
[see	O
Dosage	O
and	O
Administration	O
(2)]	O

5.19	O
Bone	O
Fracture	O
Several	O
published	O
Observation	B-D019370

The	O
Risk	B-D012306

Patients	B-D010361
should	O
use	O
the	O
lowest	O
dose	O
and	O
shortest	O
duration	O
of	O
PPI	O
therapy	O
appropriate	O
to	O
the	O
condition	O
being	O
treated	O

Patients	B-D010361
at	O
Risk	B-D012306

VIMOVO	O
(a	O
combination	O
PPI/NSAID)	O
is	O
approved	O
for	O
use	O
twice	O
a	O
day	O
and	O
does	O
not	O
allow	O
for	O
administration	O
of	O
a	O
lower	O
daily	O
dose	O
of	O
the	O
PPI	O
[see	O
Dosage	O
and	O
Administration	O
(2)]	O

5.20	O
Cutaneous	O
and	O
Systemic	O
Lupus	O
Erythema	B-D004890
tosus	O
Cutaneous	O
lupus	O
Erythema	B-D004890

These	O
events	O
have	O
occurred	O
as	O
both	O
new	O
onset	O
and	O
an	O
exacerbation	O
of	O
existing	O
autoimmune	O
Disease	B-D004194

The	O
majority	O
of	O
PPI-induced	O
lupus	O
Erythema	B-D004890

The	O
most	O
common	O
Form	B-D020478

Generally,	O
histological	O
findings	O
were	O
observed	O
without	O
organ	O
involvement	O

SLE	O
is	O
less	O
commonly	O
reported	O
than	O
CLE	O
in	O
Patients	B-D010361

PPI	O
associated	O
SLE	O
is	O
usually	O
milder	O
than	O
non-drug	O
induced	O
SLE	O

Onset	O
of	O
SLE	O
typically	O
occurred	O
within	O
days	O
to	O
years	O
after	O
initiating	O
treatment	O
primarily	O
in	O
Patients	B-D010361

The	O
majority	O
of	O
Patients	B-D010361

Avoid	O
administration	O
of	O
PPIs	O
for	O
longer	O
than	O
medically	O
indicated	O

If	O
signs	O
or	O
symptoms	O
consistent	O
with	O
CLE	O
or	O
SLE	O
are	O
noted	O
in	O
Patients	B-D010361

Most	O
Patients	B-D010361

Serological	O
TES	B-C004551

5.21	O
Interaction	O
with	O
Clopidogrel	B-D000077144
Avoid	O
concomitant	O
use	O
of	O
Esomeprazole	B-D064098

Clopidogrel	B-D000077144
is	O
a	O
prodrug	O

Inhibition	O
of	O
Platelet	B-D010974
Aggregation	I-D010974

The	O
Metabolism	B-D008660

Concomitant	O
use	O
of	O
Clopidogrel	B-D000077144

When	O
using	O
Esomeprazole	B-D064098

5.22	O
Cyanocobalamin	O
(Vitamin	O
B-12)	O
Deficiency	O
Daily	O
treatment	O
with	O
any	O
acid-suppressing	O
medications	O
over	O
a	O
long	O
period	O
of	O
Time	B-D013995

Rare	O
reports	O
of	O
cyanocobalamin	O
deficiency	O
occurring	O
with	O
acid-suppressing	O
therapy	O
have	O
been	O
reported	O
in	O
the	O
Literature	B-D008091

This	O
Diagnosis	B-D003933

5.23	O
Hypomagnesemia	O
Hypomagnesemia,	O
symptomatic	O
and	O
asymptomatic,	O
has	O
been	O
reported	O
rarely	O
in	O
Patients	B-D010361

Serious	O
adverse	O
events	O
include	O
Tetany	B-D013746

In	O
most	O
Patients	B-D010361

For	O
Patients	B-D010361

5.24	O
Concomitant	O
use	O
of	O
St	O

John's	O
Wort	O
or	O
Rifampin	B-D012293
with	O
VIMOVO	O
Drugs	O
that	O
induce	O
CYP2C19	O
or	O
CYP3A4	O
(such	O
as	O
St	O

John's	O
Wort	O
or	O
Rifampin	B-D012293

Avoid	O
concomitant	O
use	O
of	O
VIMOVO	O
with	O
St	O

John's	O
Wort	O
or	O
Rifampin	B-D012293

5.25	O
Interactions	O
with	O
Diagnostic	O
Investigations	O
for	O
Neuroendocrine	B-D018358
Tumors	I-D018358
Serum	B-D044967
Chromogranin	B-D053379
A	I-D053379

The	O
increased	O
CgA	O
level	O
may	O
cause	O
false	O
positive	O
results	O
in	O
diagnostic	O
investigations	O
for	O
Neuroendocrine	B-D018358
Tumors	I-D018358

Providers	O
should	O
TEMPO	B-C003959

If	O
serial	O
TES	B-C004551

for	O
monitoring),	O
the	O
same	O
commercial	O
laboratory	O
should	O
be	O
used	O
for	O
TES	B-C004551

5.26	O
Concomitant	O
Use	O
of	O
VIMOVO	O
with	O
Methotrexate	B-D008727
Literature	B-D008091
suggests	O
that	O
concomitant	O
use	O
of	O
PPIs	O
with	O
Methotrexate	B-D008727

In	O
high-dose	O
Methotrexate	B-D008727

5.27	O
Fundic	O
Gland	O
Polyps	B-D011127
PPI	O
use	O
is	O
associated	O
with	O
an	O
increased	O
Risk	B-D012306

Most	O
PPI	O
users	O
who	O
developed	O
fundic	O
gland	O
Polyps	B-D011127

Use	O
the	O
shortest	O
duration	O
of	O
PPI	O
therapy	O
appropriate	O
to	O
the	O
condition	O
being	O
treated	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforations	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Active	O
Bleeding	O
[see	O
Warnings	O
and	O
Precautions	O
(5.14)]	O
Acute	O
Interstitial	O
Nephritis	B-D009393
[see	O
Warnings	O
and	O
Precautions	O
(5.17)]	O
Clostridium	B-D016360
difficile	I-D016360
-Associated	O
Diarrhea	B-D003967
[see	O
Warnings	O
and	O
Precautions	O
(5.18)]	O
Bone	O
Fracture	O
[see	O
Warnings	O
and	O
Precautions	O
(5.19)]	O
Cutaneous	O
and	O
Systemic	O
Lupus	O
Erythema	B-D004890
tosus	O
[see	O
Warnings	O
and	O
Precautions	O
(5.20)]	O
Cyanocobalamin	O
(Vitamin	O
B-12)	O
Deficiency	O
[see	O
Warnings	O
and	O
Precautions	O
(5.22)]	O
Hypomagnesemia	O
[see	O
Warnings	O
and	O
Precautions	O
(5.23)]	O
Fundic	O
Gland	O
Polyps	B-D011127
[see	O
Warnings	O
and	O
Precautions	O
(5.27)]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Clinical	B-D016430
Trial	I-D016430

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Horizon	O
Pharma	O
USA,	O
Inc	O

at	O
1-866-479-6742	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
with	O
VIMOVO	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reactions	O
reported	O
below	O
are	O
specific	O
to	O
the	O
Clinical	B-D016430
Trial	I-D016430

The	O
Safety	B-D012449

Patients	B-D010361
received	O
either	O
500	O
mg/20	O
mg	O
of	O
VIMOVO	O
twice	O
daily	O
(n=1157),	O
500	O
mg	O
of	O
enteric-coated	O
Naproxen	B-D009288

The	O
average	O
number	O
of	O
VIMOVO	O
doses	O
taken	O
over	O
12	O
months	O
was	O
696±44	O

The	O
table	O
below	O
lists	O
all	O
adverse	O
reactions,	O
regardless	O
of	O
Causality	B-D015984

Both	O
of	O
these	O
studies	O
were	O
randomized,	O
multi-center,	O
double-blind,	O
parallel	O
studies	O

The	O
majority	O
of	O
Patients	B-D010361

The	O
majority	O
of	O
Patients	B-D010361

Approximately	O
one	O
quarter	O
were	O
on	O
low-dose	O
Aspirin	B-D001241

Table	O
1:	O
Adverse	O
Reactionsreported	O
in	O
>2%	O
of	O
Patients	B-D010361

12.5%	O
Respect	B-D000078682

The	O
most	O
common	O
reasons	O
for	O
discontinuations	O
due	O
to	O
adverse	O
events	O
in	O
the	O
VIMOVO	O
treatment	O
group	O
were	O
upper	O
Abdominal	B-D015746
Pain	I-D015746

Among	O
Patients	B-D010361

The	O
proportion	O
of	O
Patients	B-D010361

The	O
table	O
below	O
lists	O
all	O
adverse	O
reactions,	O
regardless	O
of	O
Causality	B-D015984

Table	O
2:	O
Adverse	O
Reactionsreported	O
in	O
>2%	O
of	O
Patients	B-D010361

There	O
were	O
no	O
preferred	O
terms	O
in	O
which	O
more	O
than	O
1%	O
of	O
subjects	O
withdrew	O
from	O
any	O
treatment	O
group	O

The	O
long-term	O
Safety	B-D012449

There	O
were	O
no	O
differences	O
in	O
frequency	O
or	O
types	O
of	O
adverse	O
reactions	O
seen	O
in	O
the	O
long-term	O
Safety	B-D012449

Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
with	O
Naproxen	B-D009288
and	O
Other	O
NSAIDs	O
In	O
Patients	B-D010361

Gastrointestinal:	O
gross	O
bleeding/perforation,	O
GI	O
Ulcer	B-D014456

Gastrointestinal:	O
Pancreatitis	B-D010195

Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

Decreases	O
were	O
seen	O
in	O
hemoglobin,	O
white	O
Blood	B-D001772
Cell	I-D001772
Count	I-D001772

Endoscopic	O
findings	O
that	O
were	O
reported	O
as	O
adverse	O
reactions	O
include:	O
Duodenitis	B-D004382

6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

VIMOVO	O
Body	O
as	O
a	O
Whole:	O
Gait	B-D005684

If	O
Skin	B-D012867

Special	O
Senses:	O
Hearing	B-D006309

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

This	O
Risk	B-D012306

FELDENE	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
FELDENE	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
FELDENE	O
in	O
Patients	B-D010361

If	O
FELDENE	O
is	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
FELDENE,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
Inflammation	B-D007249

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
FELDENE	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
Alanine	B-D000409

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
FELDENE,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Piroxicam	B-D010894

Avoid	O
the	O
use	O
of	O
FELDENE	O
in	O
Patients	B-D010361

If	O
FELDENE	O
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
FELDENE	O
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
FELDENE	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
FELDENE	O
in	O
Patients	B-D010361

If	O
FELDENE	O
is	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Piroxicam	B-D010894
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
FELDENE	O
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Piroxicam	B-D010894

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

FELDENE	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Piroxicam	B-D010894
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
FELDENE,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
FELDENE	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

NSAIDs,	O
including	O
FELDENE,	O
may	O
increase	O
the	O
Risk	B-D012306

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
FELDENE	O
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Ophthalmologic	O
Effects	O
Because	O
of	O
reports	O
of	O
adverse	O
Eye	B-D005123

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>2%	O
from	O
Clinical	B-D016430
Trial	I-D016430

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Body	O
As	O
a	O
Whole:	O
Fever	B-D005334
,	O
infection,	O
Sepsis	B-D018805

ADMINISTRATION	O
OF	O
Misoprostol	B-D016595

Uterine	B-D014597
Rupture	I-D014597

Diclofenac	B-D004008

Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

In	O
such	O
Patients	B-D010361

is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures	O

has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
Misoprostol	B-D016595

will	O
begin	O
Diclofenac	B-D004008

Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

Diclofenac	B-D004008

ADMINISTRATION	O
OF	O
Misoprostol	B-D016595

Uterine	B-D014597
Rupture	I-D014597

Diclofenac	B-D004008

Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

In	O
such	O
Patients	B-D010361

is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures	O

has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
Misoprostol	B-D016595

will	O
begin	O
Diclofenac	B-D004008

Cardiovascular	O
Thrombotic	O
Events	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964

Monitor	O
Patients	B-D010361

Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
Hematocrit	B-D006400

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Diclofenac	B-D004008

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
In	O
Clinical	B-D016430
Trial	I-D016430

These	O
increases	O
were	O
generally	O
transient,	O
and	O
enzyme	O
levels	O
returned	O
to	O
within	O
the	O
normal	O
range	O
upon	O
discontinuation	O
of	O
therapy	O
with	O
Diclofenac	B-D004008

The	O
Misoprostol	B-D016595

In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
Diclofenac	B-D004008

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008

The	O
renal	O
effects	O
of	O
Diclofenac	B-D004008

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
/misoprostol	O
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Diclofenac	B-D004008

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

Diclofenac	B-D004008
Sodium	B-D012964

Advise	O
Pregnant	B-D037841
Women	I-D037841

Verify	O
the	O
Pregnancy	B-D011247

Advise	O
Female	B-D005260

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Diclofenac	B-D004008

NSAIDs,	O
including	O
Diclofenac	B-D004008

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>	O
2%	O
from	O
Clinical	B-D016430
Trial	I-D016430

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

Adverse	O
reaction	O
information	O
for	O
Diclofenac	B-D004008

Gastrointestinal	O
GI	O
disorders	O
had	O
the	O
highest	O
reported	O
Incidence	B-D015994

These	O
events	O
were	O
generally	O
minor,	O
but	O
led	O
to	O
discontinuation	O
of	O
therapy	O
in	O
9%	O
of	O
Patients	B-D010361

For	O
GI	O
Ulcer	B-D014456

GI	O
disorder	O
Diclofenac	B-D004008
Sodium	B-D012964
and	O
Misoprostol	B-D016595
Diclofenac	B-D004008
Abdominal	B-D015746
Pain	I-D015746

Diarrhea	B-D003967
and	O
Abdominal	B-D015746
Pain	I-D015746

Rare	O
instances	O
of	O
profound	O
Diarrhea	B-D003967

Patients	B-D010361
with	O
an	O
underlying	O
condition	O
such	O
as	O
inflammatory	O
bowel	O
Disease	B-D004194

The	O
Incidence	B-D015994

Gynecological	O
Gynecological	O
disorders	O
previously	O
reported	O
with	O
Misoprostol	B-D016595

Postmenopausal	O
Vagina	B-D014621

If	O
it	O
occurs,	O
diagnostic	O
Work	B-D014937

Elderly	O
Overall	B-D016424
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
Safety	B-D012449

Other	O
adverse	O
experiences	O
reported	O
occasionally	O
with	O
Diclofenac	B-D004008

Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Digestive:	O
Anorexia	B-D000855

Female	B-D005260
reproductive	O
disorders:	O
Breast	B-D001940

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional:	O
Alanine	B-D000409

Musculoskeletal	B-D009141
System	I-D009141

Psychiatric:	O
Anxiety	B-D001007

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505

Special	O
senses:	O
Taste	B-D013649

Renal	O
and	O
urinary	O
disorders:	O
Dysuria	B-D053159

Vision:	O
Diplopia	B-D004172

6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Body	O
as	O
a	O
whole:	O
Death	B-D003643

Cardiovascular	B-D002319
System	I-D002319

Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Congenital,	O
familial	O
and	O
genetic	O
disorders:	O
birth	O
defects	O

Digestive:	O
Enteritis	B-D004751

Female	B-D005260
reproductive	O
disorders:	O
intermenstrual	O
bleeding,	O
Leukorrhea	B-D007973

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Hypersensitivity	B-D006967
:	O
Angioedema	B-D000799

Liver	B-D008099
and	O
biliary	O
system:	O
abnormal	O
hepatic	O
function,	O
Bilirubin	B-D001663

Male	B-D008297
reproductive	O
disorders:	O
impotence,	O
perineal	O
Pain	B-D010146

Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
Glycosuria	B-D006029

Pregnancy	B-D011247
,	O
puerperium	O
and	O
perinatal	O
conditions:	O
abnormal	O
Uterine	B-D014590
Contraction	I-D014590

Psychiatric:	O
Confusion	B-D003221

Reproductive	O
system	O
and	O
Breast	B-D001940

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages:	O
acne,	O
bruising,	O
Erythema	B-D004892
Multiforme	I-D004892

Special	O
senses:	O
Hearing	B-D006309

Renal	O
and	O
urinary	O
disorders:	O
Cystitis	B-D003556

Vision:	O
Amblyopia	B-D000550

Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

[see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O

CALDOLOR	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
CALDOLOR	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
CALDOLOR	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
CALDOLOR	O
in	O
Patients	B-D010361

If	O
CALDOLOR	O
is	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Ibuprofen	B-D007052

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
CALDOLOR	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
CALDOLOR,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Ibuprofen	B-D007052

Avoid	O
the	O
use	O
of	O
CALDOLOR	O
in	O
Patients	B-D010361

If	O
CALDOLOR	O
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
CALDOLOR	O
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
CALDOLOR	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
CALDOLOR	O
in	O
Patients	B-D010361

If	O
CALDOLOR	O
is	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Ibuprofen	B-D007052
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
CALDOLOR	O
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Ibuprofen	B-D007052

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

CALDOLOR	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Ibuprofen	B-D007052
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
CALDOLOR,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
GI	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
CALDOLOR	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

NSAIDs,	O
including	O
CALDOLOR	O
may	O
increase	O
the	O
Risk	B-D012306

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorder,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

CALDOLOR	O
must	O
be	O
diluted	O
prior	O
to	O
use	O

Infusion	O
of	O
the	O
drug	O
product	O
without	O
dilution	O
can	O
cause	O
Hemolysis	B-D006461

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
CALDOLOR	O
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Ophthalmological	O
Effects	O
Blurred	O
or	O
diminished	O
vision,	O
Scotoma	B-D012607

Discontinue	O
Ibuprofen	B-D007052

5.15	O
Aseptic	O
Meningitis	B-D008581
Aseptic	O
Meningitis	B-D008581

Although	O
it	O
is	O
probably	O
more	O
likely	O
to	O
occur	O
in	O
Patients	B-D010361

If	O
signs	O
or	O
symptoms	O
of	O
Meningitis	B-D008581

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
The	O
most	O
common	O
adverse	O
reactions	O
are	O
Nausea	B-D009325

The	O
most	O
common	O
adverse	O
reactions	O
in	O
pediatric	O
Patients	B-D010361

(6)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Cumberland	O
Pharmaceuticals	O
Inc	O

at	O
1-877-484-2700	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

Adult	B-D000328
Population	B-D011153
During	O
clinical	O
development,	O
560	O
Patients	B-D010361

In	O
the	O
Pain	B-D010146

In	O
the	O
Fever	B-D005334

The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
oral	O
Ibuprofen	B-D007052

Pain	B-D010146
Studies	O
The	O
Incidence	B-D015994

Table	O
1:	O
Post-operative	O
Patients	B-D010361
with	O
Adverse	O
Reactions	O
Observed	O
in	O
≥	O
3%	O
of	O
Patients	B-D010361
in	O
any	O
CALDOLOR	O
Treatment	O
Group	O
in	O
Pain	B-D010146
Studies*	O
*	O
All	O
Patients	B-D010361

Event	O
CALDOLOR	O
Placebo(N=287)	O
400	O
mg(N=134)	O
800	O
mg(N=304)	O
Any	O
Reaction	O
118	O
(88%)	O
260	O
(86%)	O
258	O
(90%)	O
Nausea	B-D009325
77	O
(57%)	O
161	O
(53%)	O
179	O
(62%)	O
Vomiting	B-D014839
30	O
(22%)	O
46	O
(15%)	O
50	O
(17%)	O
Flatulence	B-D005414
10	O
(7%)	O
49	O
(16%)	O
44	O
(15%)	O
Headache	B-D006261
12	O
(9%)	O
35	O
(12%)	O
31	O
(11%)	O
Hemorrhage	B-D006470
13	O
(10%)	O
13	O
(4%)	O
16	O
(6%)	O
Dizziness	B-D004244
8	O
(6%)	O
13	O
(4%)	O
5	O
(2%)	O
Edema	B-D004487
peripheral	O
1	O
(<1%)	O
9	O
(3%)	O
4	O
(1%)	O
Urinary	B-D016055
Retention	I-D016055

In	O
hospitalized	O
febrile	O
Patients	B-D010361

In	O
hospitalized	O
febrile	O
Patients	B-D010361

Table	O
2:	O
Patients	B-D010361
with	O
Adverse	O
Reactions	O
Observed	O
in	O
≥	O
3%	O
of	O
Patients	B-D010361
in	O
any	O
CALDOLOR	O
Treatment	O
Group	O
in	O
All-Cause	O
Fever	B-D005334
Study	O
Event	O
CALDOLOR	O
Placebo	O
N=28	O
100	O
mg	O
N=30	O
200	O
mg	O
N=30	O
400	O
mg	O
N=31	O
Any	O
Reaction	O
27	O
(87%)	O
25	O
(83%)	O
23	O
(74%)	O
25	O
(89%)	O
Anemia	B-D000740
5	O
(17%)	O
6	O
(20%)	O
11	O
(36%)	O
4	O
(14%)	O
Eosinophilia	B-D004802
7	O
(23%)	O
7	O
(23%)	O
8	O
(26%)	O
7	O
(25%)	O
Hypokalemia	B-D007008
4	O
(13%)	O
4	O
(13%)	O
6	O
(19%)	O
5	O
(18%)	O
Hypoproteinemia	B-D007019
3	O
(10%)	O
0	O
4	O
(13%)	O
2	O
(7%)	O
Neutropenia	B-D009503
2	O
(7%)	O
2	O
(7%)	O
4	O
(13%)	O
2	O
(7%)	O
Blood	B-D001769
Urea	B-D014508

The	O
most	O
common	O
adverse	O
reactions	O
(incidence	O
greater	O
than	O
or	O
equal	O
to	O
2%)	O
in	O
pediatric	O
Patients	B-D010361

Cardiovascular	O
Risk	B-D012306
NSAIDs1	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Etodolac	B-D017308
Tablets	B-D013607

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
non-steroidal	O
anti-inflammatory	O
drug	O

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse-reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
to	O
1,000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
or	O
Equal	O
to	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064

Nervous	B-D009420
System	I-D009420

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566

Musculoskeletal	O
-	O
Arthralgia	B-D018771
	O

*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566

Musculoskeletal	O
-	O
Muscle	O
Pain	B-D010146

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
–	O
Sepsis	B-D018805
,	O
Death	B-D003643

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Urogenital	B-D014566
System	I-D014566

Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

Other	O
adverse	O
reactions	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
Appetite	B-D001066

To	O
report	O
SUSPECTED	O
ADVERSE	O
EVENTS,	O
contact	O
Watson	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
http://www.fda.gov/	O
for	O
voluntary	O
reporting	O
of	O
adverse	O
reactions	O

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

•	O
Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
(see	O
WARNINGS)	O
•Hepatotoxicity	O
(see	O
WARNINGS)	O
•Hypertension	O
(see	O
WARNINGS)	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
•Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
•Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
•Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

This	O
Risk	B-D012306

•	O
Fenoprofen	B-D005279
Calcium	B-D002118

Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
During	O
clinical	O
studies	O
for	O
Rheum	B-D012250

These	O
encompass	O
Observation	B-D019370

For	O
comparison,	O
data	O
are	O
also	O
presented	O
from	O
complaints	O
received	O
from	O
the	O
266	O
Patients	B-D010361

During	O
short-term	O
studies	O
for	O
Analgesia	B-D000698

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
≥	O
1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
:	O
During	O
Clinical	B-D016430
Trial	I-D016430

In	O
descending	O
order	O
of	O
frequency,	O
these	O
reactions	O
included	O
Dyspepsia	B-D004415

2.3%	O
placebo),	O
Nausea	B-D009325

7.1%),	O
Constipation	B-D003248

1.5%),	O
Vomiting	B-D014839

1.9%),	O
Abdominal	B-D015746
Pain	I-D015746

1.1%)	O
and	O
Diarrhea	B-D003967

4.1%)	O

The	O
drug	O
was	O
discontinued	O
because	O
of	O
adverse	O
gastrointestinal	O
reactions	O
in	O
less	O
than	O
2%	O
of	O
Patients	B-D010361

Nervous	B-D009420
System	I-D009420
:	O
The	O
most	O
frequent	O
adverse	O
neurologic	O
reactions	O
were	O
Headache	B-D006261

7.5%)	O
and	O
somnolence	O
(8.5%	O
vs	O

6.4%)	O

Dizziness	B-D004244
(6.5%	O
vs	O

5.6%),	O
Tremor	B-D014202

0.4%)	O
and	O
Confusion	B-D003221

none)	O
were	O
noted	O
less	O
frequently	O

Fenoprofen	B-D005279
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Skin	B-D012867
and	O
Appendages:	O
Increased	O
Sweating	B-D013546

0.4%),	O
Pruritus	B-D011537

0.8%)	O
and	O
rash	O
(3.7%	O
vs	O

0.4%)	O
were	O
reported	O

Fenoprofen	B-D005279
was	O
discontinued	O
in	O
about	O
1%	O
of	O
Patients	B-D010361

Special	O
Senses:	O
Tinnitus	B-D014012
(4.5%	O
vs	O

0.4%),	O
blurred	O
vision	O
(2.2%	O
vs	O

none)	O
and	O
decreased	O
Hearing	B-D006309

none)	O
were	O
reported	O

Fenoprofen	B-D005279
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Cardiovascular:	O
Palpitations	O
(2.5%	O
vs	O

0.4%)	O

Fenoprofen	B-D005279
was	O
discontinued	O
in	O
about	O
0.5%	O
of	O
Patients	B-D010361

Miscellaneous:	O
Nervousness	O
(5.7%	O
vs	O

1.5%),	O
Asthenia	B-D001247

0.4%),	O
peripheral	O
Edema	B-D004487

0.4%),	O
Dyspnea	B-D004417

none),	O
Fatigue	B-D005221

1.5%),	O
upper	O
respiratory	O
infection	O
(1.5%	O
vs	O

5.6%)	O
and	O
nas	B-C015378
opharyngitis	O
(1.2%	O
vs	O

none)	O

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
<	O
1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
:	O
Gastritis	B-D005756
,	O
Peptic	B-D010437
Ulcer	I-D010437

Increases	O
in	O
Alkaline	B-D000469
Phosphatase	I-D000469

Cardiovascular:	O
Atrial	B-D001281
Fibrillation	I-D001281

Genitourinary	O
Tract:	O
Renal	O
failure,	O
Dysuria	B-D053159

Hyper	O
sensitivity:	O
Angioedema	B-D000799
(angioneurotic	O
Edema	B-D004487

Hematologic:	O
Purpura	B-D011693
,	O
bruising,	O
Hemorrhage	B-D006470

Nervous	B-D009420
System	I-D009420
:	O
Depression	B-D003863
,	O
disorientation,	O
Seizures	B-D012640

Special	O
Senses:	O
Burning	O
Tongue	B-D014059

Skin	B-D012867
and	O
Appendages:	O
Exfoliative	O
Dermatitis	B-D003872

Miscellaneous:	O
Anaphylaxis	B-D000707
,	O
Urticaria	B-D014581

WARNINGS	O
There	O
is	O
the	O
potential	O
for	O
cross-sensitivity	O
to	O
acetylsalicylic	O
acid,	O
phenylacetic	B-C025136
acid	I-C025136
derivatives,	O
and	O
other	O
nonsteroidal	O
Anti-Inflammatory	B-D000893
Agents	I-D000893

Therefore,	O
caution	O
should	O
be	O
used	O
when	O
treating	O
individuals	O
who	O
have	O
previously	O
exhibited	O
sensitivities	O
to	O
these	O
drugs	O

With	O
some	O
nonsteroidal	O
anti-inflammatory	O
drugs,	O
there	O
exists	O
the	O
potential	O
for	O
increased	O
Bleeding	B-D001760
Time	I-D001760

There	O
have	O
been	O
reports	O
that	O
ocularly	O
applied	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
may	O
cause	O
increased	O
bleeding	O
of	O
ocular	O
Tissues	B-D014024

PRECAUTIONS	O
General:	O
All	O
topical	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
slow	O
or	O
delay	O
healing	O

Topical	O
corticosteroids	O
are	O
also	O
known	O
to	O
slow	O
or	O
delay	O
healing	O

Concomitant	O
use	O
of	O
topical	O
NSAIDS	O
and	O
topical	O
Steroids	B-D013256

Use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
Keratitis	B-D007634

In	O
some	O
susceptible	O
Patients	B-D010361

These	O
events	O
may	O
be	O
sight	O
threatening	O

Patients	B-D010361
with	O
evidence	O
of	O
Cornea	B-D003315

Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
suggests	O
that	O
Patients	B-D010361

Topical	O
NSAIDs	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
also	O
suggests	O
that	O
use	O
more	O
than	O
24	O
hours	O
prior	O
to	O
surgery	O
or	O
use	O
beyond	O
14	O
days	O
post-surgery	O
may	O
increase	O
patient	O
Risk	B-D012306

It	O
is	O
recommended	O
that	O
ACULAR®	O
ophthalmic	O
solution	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
adverse	O
events	O
reported	O
with	O
the	O
use	O
of	O
Ketorolac	B-D020911
Tromethamine	I-D020911

These	O
events	O
were	O
reported	O
by	O
up	O
to	O
40%	O
of	O
Patients	B-D010361

Other	O
adverse	O
events	O
occurring	O
approximately	O
1%	O
-	O
10%	O
of	O
the	O
Time	B-D013995

Other	O
adverse	O
events	O
reported	O
rarely	O
with	O
the	O
use	O
of	O
Ketorolac	B-D020911
Tromethamine	I-D020911

Clinical	O
Practice:	O
The	O
following	O
events	O
have	O
been	O
Id	B-D007060

Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

The	O
events,	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
Ketorolac	B-D020911
Tromethamine	I-D020911

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Sulfite	O
Allergic	O
Reactions	O
(5.1)•	O
Slow	O
or	O
Delayed	O
Healing	O
(5.2)•	O
Potential	O
for	O
Cross-Sensitivity	O
(5.3)•	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
(5.4)•	O
Keratitis	B-D007634
and	O
Cornea	B-D003315
l	O
Reactions	O
(5.5)•	O
Contact	O
Lens	O
Wear	O
(5.6)	O
5.1	O
Sulfite	O
Allergic	O
Reactions	O
PROLENSA	O
ophthalmic	O
solution	O
contains	O
sodium	B-C025026
sulfite	I-C025026
,	O
a	O
sulfite	O
that	O
may	O
cause	O
allergic-type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
Life	B-D019369

The	O
Overall	B-D016424

Sulfite	O
sensitivity	O
is	O
seen	O
more	O
frequently	O
in	O
Asthma	B-D001249

5.2	O
Slow	O
or	O
Delayed	O
Healing	O
All	O
topical	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs),	O
including	O
bromfenac	B-C053083
,	O
may	O
slow	O
or	O
delay	O
healing	O

Topical	O
corticosteroids	O
are	O
also	O
known	O
to	O
slow	O
or	O
delay	O
healing	O

Concomitant	O
use	O
of	O
topical	O
NSAIDs	O
and	O
topical	O
Steroids	B-D013256

5.3	O
Potential	O
for	O
Cross-Sensitivity	O
There	O
is	O
the	O
potential	O
for	O
cross-sensitivity	O
to	O
acetylsalicylic	O
acid,	O
phenylacetic	B-C025136
acid	I-C025136
derivatives,	O
and	O
other	O
NSAIDs,	O
including	O
bromfenac	B-C053083
	O

Therefore,	O
caution	O
should	O
be	O
used	O
when	O
treating	O
individuals	O
who	O
have	O
previously	O
exhibited	O
sensitivities	O
to	O
these	O
drugs	O

5.4	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
With	O
some	O
NSAIDs,	O
including	O
bromfenac	B-C053083
,	O
there	O
exists	O
the	O
potential	O
for	O
increased	O
Bleeding	B-D001760
Time	I-D001760

There	O
have	O
been	O
reports	O
that	O
ocularly	O
applied	O
NSAIDs	O
may	O
cause	O
increased	O
bleeding	O
of	O
ocular	O
Tissues	B-D014024

It	O
is	O
recommended	O
that	O
PROLENSA	O
ophthalmic	O
solution	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.5	O
Keratitis	B-D007634
and	O
Cornea	B-D003315
l	O
Reactions	O
Use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
Keratitis	B-D007634

In	O
some	O
susceptible	O
Patients	B-D010361

These	O
events	O
may	O
be	O
sight	O
threatening	O

Patients	B-D010361
with	O
evidence	O
of	O
Cornea	B-D003315

Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
suggests	O
that	O
Patients	B-D010361

Topical	O
NSAIDs	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
also	O
suggests	O
that	O
use	O
more	O
than	O
24	O
hours	O
prior	O
to	O
surgery	O
or	O
use	O
beyond	O
14	O
days	O
postsurgery	O
may	O
increase	O
patient	O
Risk	B-D012306

5.6	O
Contact	O
Lens	O
Wear	O
PROLENSA	O
should	O
not	O
be	O
instilled	O
while	O
wearing	O
Contact	B-D003261
Lenses	I-D003261

Remove	O
Contact	B-D003261
Lenses	I-D003261

The	O
preservative	O
in	O
PROLENSA,	O
benzalkonium	O
chloride,	O
may	O
be	O
absorbed	O
by	O
soft	O
Contact	B-D003261
Lenses	I-D003261

Lenses	B-D007909
may	O
be	O
reinserted	O
after	O
10	O
minutes	O
following	O
administration	O
of	O
PROLENSA	O

6	O
ADVERSE	O
REACTIONS	O
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
in	O
3	O
to	O
8%	O
of	O
Patients	B-D010361

(6.1)	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Bausch	O
&	O
Lomb	O
Incorporated	O
at	O
1-800-321-4576	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
following	O
use	O
of	O
PROLENSA	O
following	O
Cataract	B-D002386

These	O
reactions	O
were	O
reported	O
in	O
3	O
to	O
8%	O
of	O
Patients	B-D010361

Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Flurbiprofen	B-D005480
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
Pain	B-D010146

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
TABLE	O
2	O

Reported	O
adverse	O
events	O
in	O
Patients	B-D010361

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
Fever	B-D005334

This	O
Risk	B-D012306

(5.1)	O
Fenoprofen	B-D005279

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

This	O
Risk	B-D012306

[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O

Fenoprofen	B-D005279

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Fenoprofen	B-D005279

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Fenoprofen	B-D005279

If	O
Fenoprofen	B-D005279

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Fenoprofen	B-D005279

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361
:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Fenoprofen	B-D005279

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Fenoprofen	B-D005279

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Fenoprofen	B-D005279

Avoid	O
the	O
use	O
of	O
Fenoprofen	B-D005279

If	O
Fenoprofen	B-D005279

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Fenoprofen	B-D005279

The	O
renal	O
effects	O
of	O
Fenoprofen	B-D005279

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Fenoprofen	B-D005279

If	O
Fenoprofen	B-D005279

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Fenoprofen	B-D005279
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Fenoprofen	B-D005279

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
fenoprop	B-C009264
fen,	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Fenoprofen	B-D005279

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Fenoprofen	B-D005279
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Fenoprofen	B-D005279

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Fenoprofen	B-D005279

NSAIDs,	O
including	O
Fenoprofen	B-D005279

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Fenoprofen	B-D005279

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Ocular	O
Effects	O
Studies	O
to	O
date	O
have	O
not	O
shown	O
changes	O
in	O
the	O
Eye	B-D005123

However,	O
adverse	O
ocular	O
effects	O
have	O
been	O
observed	O
with	O
other	O
anti-inflammatory	O
drugs	O

Eye	B-D005123
examinations,	O
therefore,	O
should	O
be	O
performed	O
if	O
visual	O
disturbances	O
occur	O
in	O
Patients	B-D010361

5.15	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects	O
Caution	O
should	O
be	O
Exercise	B-D015444

5.16	O
Impact	O
on	O
Hearing	B-D006309
Since	O
the	O
Safety	B-D012449

6	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥	O
5%)	O
are	O
Dyspepsia	B-D004415
,	O
Headache	B-D006261

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sterling	O
Knight	O
Pharma	O
at	O
(662)	O
661-3232	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
(6)	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

During	O
clinical	O
studies	O
for	O
Rheum	B-D012250

These	O
encompass	O
Observation	B-D019370

For	O
comparison,	O
data	O
are	O
also	O
presented	O
from	O
complaints	O
received	O
from	O
the	O
266	O
Patients	B-D010361

During	O
short-term	O
studies	O
for	O
Analgesia	B-D000698

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
>1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—	O
During	O
Clinical	B-D016430
Trial	I-D016430

In	O
descending	O
order	O
of	O
frequency,	O
these	O
reactions	O
included	O
Dyspepsia	B-D004415

2.3%	O
placebo),	O
Nausea	B-D009325

7.1%),	O
Constipation	B-D003248

1.5%),	O
Vomiting	B-D014839

1.9%),	O
Abdominal	B-D015746
Pain	I-D015746

1.1%),	O
and	O
Diarrhea	B-D003967

4.1%)	O

The	O
drug	O
was	O
discontinued	O
because	O
of	O
adverse	O
gastrointestinal	O
reactions	O
in	O
less	O
than	O
2%	O
of	O
Patients	B-D010361

Nervous	B-D009420
System	I-D009420
—	O
The	O
most	O
frequent	O
adverse	O
neurologic	O
reactions	O
were	O
Headache	B-D006261

7.5%)	O
and	O
somnolence	O
(8.5%	O
vs	O

6.4%)	O

Dizziness	B-D004244
(6.5%	O
vs	O

5.6%),	O
Tremor	B-D014202

0.4%),	O
and	O
Confusion	B-D003221

none)	O
were	O
noted	O
less	O
frequently	O

Fenoprofen	B-D005279
Calcium	B-D002118
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Skin	B-D012867
and	O
Appendages—	O
Increased	O
Sweating	B-D013546

0.4%),	O
Pruritus	B-D011537

0.8%),	O
and	O
rash	O
(3.7%	O
vs	O

0.4%)	O
were	O
reported	O

Fenoprofen	B-D005279
Calcium	B-D002118
was	O
discontinued	O
in	O
about	O
1%	O
of	O
Patients	B-D010361

Special	O
Senses	O
—	O
Tinnitus	B-D014012
(4.5%	O
vs	O

0.4%),	O
blurred	O
vision	O
(2.2%	O
vs	O

none),	O
and	O
decreased	O
Hearing	B-D006309

none)	O
were	O
reported	O

Fenoprofen	B-D005279
Calcium	B-D002118
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Cardiovascular	O
—	O
Palpitations	O
(2.5%	O
vs	O

0.4%)	O

Fenoprofen	B-D005279
Calcium	B-D002118
was	O
discontinued	O
in	O
about	O
0.5%	O
of	O
Patients	B-D010361

Miscellaneous	O
—	O
Nervousness	O
(5.7%	O
vs	O

1.5%),	O
Asthenia	B-D001247

0.4%),	O
peripheral	O
Edema	B-D004487

0.4%),	O
Dyspnea	B-D004417

none),	O
Fatigue	B-D005221

1.5%),	O
upper	O
respiratory	O
infection	O
(1.5%	O
vs	O

5.6%),	O
and	O
nas	B-C015378
opharyngitis	O
(1.2%	O
vs	O

none)	O

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
<1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—Gastritis,	O
Peptic	B-D010437
Ulcer	I-D010437

Increases	O
in	O
Alkaline	B-D000469
Phosphatase	I-D000469

Cardiovascular—Atrial	O
fibrillation,	O
Pulmonary	B-D011654
Edema	I-D011654

Genitourinary	O
Tract—Renal	O
failure,	O
Dysuria	B-D053159

Hypersensitivity	B-D006967
—Angioedema	O
(angioneurotic	O
Edema	B-D004487

Hematologic—Purpura,	O
bruising,	O
Hemorrhage	B-D006470

Nervous	B-D009420
System	I-D009420
—Depression,	O
disorientation,	O
Seizures	B-D012640

Special	O
Senses—Burning	O
Tongue	B-D014059

Skin	B-D012867
and	O
Appendages—Exfoliative	O
Dermatitis	B-D003872

Miscellaneous—Anaphylaxis,	O
Urticaria	B-D014581

Cardiovascular	O
Thrombotic	O
Events	O
1.Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

2.Etodolac	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Risk	B-D012306
1.NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse-reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
to	O
1000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064

Nervous	B-D009420
System	I-D009420

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566

*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
Death	B-D003643

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
Fever	B-D005334

This	O
Risk	B-D012306

Indomethacin	B-D007213
Capsules	B-D002214
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Indomethacin	B-D007213
Capsules	B-D002214
are	O
contraindicated	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(	O
4	O
)]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Indomethacin	B-D007213

If	O
Indomethacin	B-D007213

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Indomethacin	B-D007213

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Indomethacin	B-D007213

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Indomethacin	B-D007213

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Indomethacin	B-D007213

Avoid	O
the	O
use	O
of	O
Indomethacin	B-D007213

If	O
Indomethacin	B-D007213

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Indomethacin	B-D007213

The	O
renal	O
effects	O
of	O
Indomethacin	B-D007213

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Indomethacin	B-D007213

If	O
Indomethacin	B-D007213

It	O
has	O
been	O
reported	O
that	O
the	O
addition	O
of	O
the	O
Potassium	B-D011188

Indomethacin	B-D007213
and	O
Triamterene	B-D014223

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

Both	O
Indomethacin	B-D007213

The	O
potential	O
effects	O
of	O
Indomethacin	B-D007213

5.7	O
Anaphylactic	O
Reactions	O
Indomethacin	B-D007213
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Indomethacin	B-D007213

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Indomethacin	B-D007213

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Indomethacin	B-D007213
Capsules	B-D002214

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Indomethacin	B-D007213
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Indomethacin	B-D007213

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Indomethacin	B-D007213

NSAIDs,	O
including	O
Indomethacin	B-D007213

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Indomethacin	B-D007213

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects:	O
Indomethacin	B-D007213
may	O
aggravate	O
Depression	B-D003863

If	O
severe	O
CNS	O
adverse	O
reactions	O
develop,	O
Indomethacin	B-D007213

Indomethacin	B-D007213
may	O
cause	O
drowsiness;	O
therefore,	O
Patients	B-D010361

Indomethacin	B-D007213
may	O
also	O
cause	O
Headache	B-D006261

Headache	B-D006261
which	O
persists	O
despite	O
dosage	O
reduction	O
requires	O
cessation	O
of	O
therapy	O
with	O
Indomethacin	B-D007213

5.15	O
Ocular	O
Effects:	O
Cornea	B-D003315
l	O
DEPO	B-C020884

The	O
prescribing	O
physician	O
should	O
be	O
alert	O
to	O
the	O
possible	O
Association	B-D001244

It	O
is	O
advisable	O
to	O
discontinue	O
therapy	O
if	O
such	O
changes	O
are	O
observed	O

Blurred	O
vision	O
may	O
be	O
a	O
significant	O
symptom	O
and	O
warrants	O
a	O
thorough	O
ophthalmological	O
examination	O

Since	O
these	O
changes	O
may	O
be	O
asymptomatic,	O
ophthalmologic	O
examination	O
at	O
periodic	O
intervals	O
is	O
desirable	O
in	O
Patients	B-D010361

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9	O
)]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11	O
)]	O
Most	O
common	O
adverse	O
(incidence	O
≥	O
3%)	O
are	O
Headache	B-D006261

(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Heritage	O
Pharmaceuticals	O
Inc	O

at	O
1.866.901.DRUG	O
(3784)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
gastroscopic	O
study	O
in	O
45	O
Health	B-D006262

In	O
a	O
double-blind	O
comparative	O
Clinical	B-D000068397
Study	I-D000068397

The	O
Incidence	B-D015994

The	O
adverse	O
reactions	O
for	O
Indomethacin	B-D007213

The	O
Incidence	B-D015994

The	O
Incidence	B-D015994

The	O
Probability	B-D011336

Table	O
1:	O
Summary	O
of	O
Adverse	O
reactions	O
for	O
Indomethacin	B-D007213
Capsules	B-D002214
Incidence	B-D015994
greater	O
than	O
1%	O
Incidence	B-D015994
less	O
than	O
1%	O
GASTROINTESTINAL	O
Nausea	B-D009325

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
Patients	B-D010361

However,	O
in	O
these	O
rarely	O
reported	O
events,	O
the	O
possibility	O
cannot	O
be	O
excluded	O

Therefore,	O
these	O
Observation	B-D019370

Genitourinary	O
:	O
Urinary	O
frequency	O

A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
Fasciitis	B-D005208

Cardiovascular	O
Thrombotic	O
Events	O
•Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

•Etodolac	O
Tablets	B-D013607

Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse	O
reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
mg/day	O
to	O
1000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
Whole	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064
Dyspepsia	B-D004415
(10%),	O
Abdominal	B-D015746
Pain	I-D015746

Nervous	B-D009420
System	I-D009420
Asthenia	B-D001247
/malaise5,	O
Dizziness	B-D004244

Skin	B-D012867
and	O
Appendages	O
Pruritus	B-D011537
,	O
rash	O

Special	O
Senses	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566
Dysuria	B-D053159
,	O
urinary	O
frequency	O

Musculoskeletal	O
Arthralgia	B-D018771
1Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

2Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

3Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

4Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

5Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

6Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
post-marketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319
:	O
Hypertension	B-D006973
,	O
congestive	O
Heart	B-D006333
Failure	I-D006333

Digestive	B-D004064
System	I-D004064
:	O
Thirst	B-D013894
,	O
dry	O
Mouth	B-D009055

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
Ecchymosis	B-D004438
,	O
Anemia	B-D000740

Metabolic	O
and	O
Nutritional:	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420
:	O
Insomnia,	O
somnolence	O

Respiratory	B-D012137
System	I-D012137
:	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
Eosinophilia	B-D004802

Skin	B-D012867
and	O
Appendages:	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
Senses:	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566
:	O
Elevated	O
BUN,	O
renal	O
failure,	O
Renal	B-D051437
Insufficiency	I-D051437

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319
:	O
Arrhythmias,	O
Myocardial	B-D009203
Infarction	I-D009203

Digestive	B-D004064
System	I-D004064
:	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
Colitis	B-D003092

Metabolic	O
and	O
Nutritional:	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420
:	O
Paresthesia	B-D010292
,	O
Confusion	B-D003221

Respiratory	B-D012137
System	I-D012137
:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
Dyspnea	B-D004417

Skin	B-D012867
and	O
Appendages:	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
Senses:	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566
:	O
Cystitis	B-D003556
,	O
Hematuria	B-D006417

Musculoskeletal:	O
Muscle	O
Pain	B-D010146

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
Whole:	O
Sepsis	B-D018805
,	O
Death	B-D003643

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
Cardiovascular	O
Risk	B-D012306
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
Risk	B-D012306

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

Elevated	O
Liver	B-D008099

Discontinue	O
use	O
of	O
CELEBREX	O
immediately	O
if	O
abnormal	O
Liver	B-D008099

New	O
onset	O
or	O
worsening	O
of	O
Hypertension	B-D006973

Blood	B-D001794
Pressure	I-D001794

Fluid	O
retention	O
and	O
Edema	B-D004487

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Renal	O
papillary	O
Necrosis	B-D009336

Use	O
CELEBREX	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
Heart	B-D006333
Failure	I-D006333

Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
CELEBREX	O
in	O
Patients	B-D010361

Serious	O
Skin	B-D012867

Discontinue	O
CELEBREX	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
Skin	B-D012867

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
CELEBREX	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
CELEBREX,	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
CELEBREX,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
Ulcer	B-D014456

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
CELEBREX	O
in	O
Patients	B-D010361

Therefore,	O
treatment	O
with	O
CELEBREX	O
is	O
not	O
recommended	O
in	O
these	O
Patients	B-D010361

If	O
CELEBREX	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

CELEBREX	O
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
CELEBREX	O
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9	O
Pregnancy	B-D011247
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
Treatment	O
CELEBREX	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
CELEBREX	O
should	O
have	O
their	O
hemoglobin	O
or	O
Hematocrit	B-D006400

CELEBREX	O
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
CELEBREX	O
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
Patients	B-D010361

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
CELEBREX	O
in	O
reducing	O
Inflammation	B-D007249

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
CELEBREX	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
Risk	B-D012306

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
CELEBREX-treated	O
Patients	B-D010361

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
CELEBREX	O
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
CELEBREX	O
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
CELEBREX	O
treatment	O
groups	O
were	O
Dyspepsia	B-D004415

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
CELEBREX,	O
Diclofenac	B-D004008

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
CELEBREX	O
were	O
studied	O
in	O
primary	O
Dysmenorrhea	B-D004412

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
CELEBREX	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
Fever	B-D005334

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(	O
5.1)	O
Diclofenac	B-D004008
Sodium	B-D012964

(	O
4	O
)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(	O
5.2)	O
Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Use	O
the	O
lowest	O
effective	O
dose	O
of	O
Diclofenac	B-D004008

(	O
5.1)	O
NSAIDs	O
can	O
cause	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
Inflammation	B-D007249

Prescribe	O
Diclofenac	B-D004008

(	O
5.2)	O
Elevation	O
of	O
one	O
or	O
more	O
Liver	B-D008099

Discontinue	O
Diclofenac	B-D004008

(	O
5.3)	O
Hypertension	B-D006973
can	O
occur	O
with	O
NSAID	O
treatment	O

Monitor	O
Blood	B-D001794
Pressure	I-D001794

(	O
5.4)	O
Use	O
Diclofenac	B-D004008

(	O
5.5)	O
Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Use	O
Diclofenac	B-D004008

(	O
5.6)	O
Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

(	O
5.7)	O
NSAIDs	O
can	O
cause	O
serious	O
Skin	B-D012867

(	O
5.8)	O
Not	O
for	O
use	O
during	O
Pregnancy	B-D011247

(	O
5.9)	O
Do	O
not	O
administer	O
to	O
Patients	B-D010361

(	O
5.10)	O
Avoid	O
exposure	O
of	O
treated	O
Knee	B-D007717

(	O
5.11)	O
Avoid	O
contact	O
of	O
Diclofenac	B-D004008

(	O
5.12)	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs	O

(	O
5.13)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

All	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Inform	O
Patients	B-D010361

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Prescribe	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

For	O
high-risk	O
Patients	B-D010361

5.3	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
(less	O
than	O
3	O
Time	B-D013995

Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
Liver	B-D008099

In	O
Clinical	B-D016430
Trial	I-D016430

In	O
an	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
Patients	B-D010361

In	O
this	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
post	O
Marketing	B-D040541

Post	O
Marketing	B-D040541

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Eosinophilia	B-D004802

To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
inform	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
Diclofenac	B-D004008

Caution	O
Patients	B-D010361

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008

Use	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Patients	B-D010361
taking	O
ACE-inhibitors,	O
Thiazides	B-D049971

5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
Diclofenac	B-D004008

5.6	O
Renal	O
Effects	O
Use	O
caution	O
when	O
initiating	O
treatment	O
with	O
Diclofenac	B-D004008

Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008

Therefore,	O
treatment	O
with	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

Do	O
not	O
prescribe	O
Diclofenac	B-D004008

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Seek	O
emergency	O
help	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Do	O
not	O
apply	O
Diclofenac	B-D004008

NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

5.9	O
Pregnancy	B-D011247
Diclofenac	B-D004008
Sodium	B-D012964

5.10	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross-	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.11	O
Sun	O
Exposure	O
Instruct	O
Patients	B-D010361

The	O
potential	O
effects	O
of	O
Diclofenac	B-D004008

5.12	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
Diclofenac	B-D004008

Advise	O
Patients	B-D010361

5.13	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
Diclofenac	B-D004008

Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
Diclofenac	B-D004008

5.14	O
Corticosteroid	O
Treatment	O
Diclofenac	B-D004008
Sodium	B-D012964

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

For	O
Patients	B-D010361

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.16	O
Hematological	O
Effects	O
The	O
effects	O
of	O
Diclofenac	B-D004008

There	O
was	O
no	O
significant	O
change	O
in	O
Platelet	B-D010974
Aggregation	I-D010974

Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
Blood	B-D001769

Check	O
hemoglobin	O
or	O
Hematocrit	B-D006400

NSAIDs	O
inhibit	O
Platelet	B-D010974
Aggregation	I-D010974

Unlike	O
Aspirin	B-D001241

Carefully	O
monitor	O
Patients	B-D010361

5.17	O
Monitoring	O
Because	O
serious	O
GI	O
tract	O
Ulcer	B-D014456

Check	O
CBC	O
and	O
a	O
Chemistry	B-D002621

Discontinue	O
Diclofenac	B-D004008

6	O

ADVERSE	O
REACTIONS	O
The	O
most	O
common	O
adverse	O
events	O
with	O
Diclofenac	B-D004008

(	O
6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sircle	O
Laboratories	B-D007753
,	O
Inc	O

at	O
1-888-452-9975,	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
Diclofenac	B-D004008

The	O
Population	B-D011153

The	O
most	O
common	O
adverse	O
events	O
with	O
Diclofenac	B-D004008

These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies	O

Application	O
site	O
reactions:	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment	O
related	O
adverse	O
events	O
in	O
Patients	B-D010361

Application	O
site	O
reactions	O
were	O
Character	B-D002605

The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
Skin	B-D012867

In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
Dermatitis	B-D003872

In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
Safety	B-D012449

Adverse	O
events	O
common	O
to	O
the	O
NSAID	O
class:	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
Diclofenac	B-D004008

The	O
combination	O
of	O
Diclofenac	B-D004008

less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
Creatinine	B-D003404

7%),	O
Urea	B-D014508

12%),	O
and	O
hemoglobin	O
(13%	O
vs	O

9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
Liver	B-D008099

Table	O
1:	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
Patients	B-D010361

Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
≥1%	O
of	O
Patients	B-D010361

Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
N=911	O
Topical	O
Placebo	O
N=332	O
Adverse	O
Reaction	O
Preferred	O
Term	O
according	O
to	O
COSTART	O
N	O
(%)	O
N	O
(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non	O
–	O
U.S	O

postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
Diclofenac	B-D004008

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Body	O
as	O
a	O
Whole:	O
Abdominal	B-D015746
Pain	I-D015746

All	O
nonsteroidal	O
...WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
WARNINGS	O
AND	O
PRECAUTIONS	O
SECTION	O
5.1	O
Cardiovascular	O
Thrombotic	O
EventsChronic	O
use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
Patients	B-D010361

5.5	O
Hepatic	O
EffectsBorderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6	O
Renal	O
EffectsLong-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

Therefore,	O
treatment	O
with	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.7	O
Anaphylactoid	O
ReactionsAs	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
ReactionsCelecoxib	O
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9	O
Pregnancy	B-D011247
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
TreatmentCelecoxib	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
EffectsAnemia	O
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

Celecoxib	B-D000068579
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)Celecoxib	O
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
Patients	B-D010361

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.16	O
Concomitant	O
NSAID	O
UseThe	O
concomitant	O
use	O
of	O
Celecoxib	B-D000068579

ADVERSE	O
REACTIONS	O
SECTION	O
Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
TrialsTable	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
StudyIn	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

This	O
Risk	B-D012306

[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
•	O
Celecoxib	B-D000068579
Capsules	B-D002214

[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
Gastrointe	O
stinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O
WARNING:	O
Risk	B-D012306

•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(	O
5.1)	O
•	O
Celecoxib	B-D000068579
Capsules	B-D002214

(	O
4,	O
5.1)	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(	O
5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Celecoxib	B-D000068579

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

Clinical	B-D016430
Trial	I-D016430

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
]	O

Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Post-	O
MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

•	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

•	O
Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

•	O
Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

•	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Celecoxib	B-D000068579

•	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

The	O
rates	O
of	O
Hypertension	B-D006973

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

nally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

study	O
[	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

The	O
renal	O
effects	O
of	O
Celecoxib	B-D000068579

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Celecoxib	B-D000068579

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Celecoxib	B-D000068579

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
Risk	B-D012306

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
•	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O
•	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3)	O
]	O
•	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)	O
]	O
•	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5)	O
]	O
•	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6)	O
]	O
•	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7)	O
]	O
•	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9)	O
]	O
•	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Macleods	O
Pharma	O
USA,	O
Inc	O

at	O
1-888-943-3210	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
Diarrhea	B-D003967
Dyspepsia	B-D004415
Flatulence	B-D005414
Nausea	B-D009325
4.1%	O
5.6%	O
8.8%	O
2.2%	O
3.5%	O
2.8%	O
3.8%	O
6.2%	O
1.0%	O
4.2%	O
7.7%	O
5.3%	O
12.2%	O
3.6%	O
6.0%	O
9.0%	O
9.3%	O
10.9%	O
4.1%	O
3.4%	O
9.0%	O
5.8%	O
12.8%	O
3.5%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
Peripheral	O
Edema	B-D004487
Injury-Accidental	O
2.8%	O
2.1%	O
2.9%	O
3.6%	O
1.1%	O
2.3%	O
2.2%	O
2.1%	O
3.0%	O
2.6%	O
1.0%	O
2.6%	O
0.9%	O
3.5%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

In	O
placebo-	O
or	O
active-controlled	O
Clinical	B-D016430
Trial	I-D016430

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
-	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

In	O
Cataract	B-D002386

Elevated	O
Intraocular	B-D007429
Pressure	I-D007429

Lacrimation	O
complaints	O
were	O
reported	O
in	O
approximately	O
30%	O
of	O
case	O
studies	O
undergoing	O
incisional	O
refractive	O
surgery	O

The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
approximately	O
10%	O
or	O
less	O
of	O
the	O
Patients	B-D010361

Systemic	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
3%	O
or	O
less	O
of	O
the	O
Patients	B-D010361

Clinical	O
Practice	O
The	O
following	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

The	O
reactions,	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
Diclofenac	B-D004008
Sodium	B-D012964
Ophthalmic	O
Solution,	O
0.1%,	O
or	O
a	O
combination	O
of	O
these	O
factors,	O
include	O
Cornea	B-D003315

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Bausch	O
&	O
Lomb	O
Incorporated	O
at	O
1-800-321-4576	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS	O
.)	O
Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

•	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
3%	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

ADVERSE	O
REACTIONS	O
Of	O
the	O
423	O
Patients	B-D010361

Eighty-seven	O
percent	O
(87%)	O
of	O
the	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
treated	O
Patients	B-D010361

The	O
majority	O
of	O
these	O
reactions	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
resolved	O
upon	O
discontinuation	O
of	O
therapy	O

Of	O
the	O
211	O
Patients	B-D010361

Application	O
site	O
reactions	O
(ASRs)	O
were	O
the	O
most	O
frequent	O
AEs	O
in	O
both	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
and	O
vehicle-treated	O
groups	O

Of	O
note,	O
four	O
reactions,	O
contact	O
Dermatitis	B-D003872

Eighteen	O
percent	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
treated	O
Patients	B-D010361

These	O
discontinuations	O
were	O
mainly	O
due	O
to	O
Skin	B-D012867

Table	O
1	O
below	O
presents	O
the	O
AEs	O
reported	O
at	O
an	O
Incidence	B-D015994

Table	O
1	O

Adverse	O
Events	O
Reported	O
(>1%	O
in	O
Any	O
Treatment	O
Group)	O
During	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
Phase	O
3	O
Clinical	B-D016430
Trial	I-D016430
s	O
Incidence	B-D015994
s	O
for	O
60-Day	O
and	O
90-Day	O
Treatments	O
60-day	O
Treatment	O
90-day	O
Treatment	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
(%)	O
Gel	O
Vehicle	O
(%)	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
(%)	O
Gel	O
Vehicle	O
(%)	O
N=48	O
N=49	O
N=114	O
N=114	O
BODY	O
AS	O
A	O
WHOLE	O
21	O
20	O
20	O
18	O
Abdominal	B-D015746
Pain	I-D015746
2	O
0	O
1	O
0	O
Accidental	O
Injury	O
0	O
0	O
4	O
2	O
Allergic	O
Reaction	O
0	O
0	O
1	O
3	O
Asthenia	B-D001247
0	O
0	O
2	O
0	O
Back	B-D001416
Pain	I-D001416
4	O
0	O
2	O
2	O
Chest	B-D002637
Pain	I-D002637
2	O
0	O
1	O
0	O
Chills	B-D023341
0	O
2	O
0	O
0	O
Flu	O
Syndrome	B-D013577
10	O
6	O
1	O
4	O
Headache	B-D006261
0	O
6	O
7	O
6	O
Infection	O
4	O
6	O
4	O
5	O
Neck	B-D019547
Pain	I-D019547
0	O
0	O
2	O
0	O
Pain	B-D010146
2	O
0	O
2	O
2	O
Cardiovascular	B-D002319
System	I-D002319

Adverse	O
Reactions	O
Reported	O
for	O
Oral	O
Diclofenac	B-D004008
Dosage	O
Form	B-D020478
(not	O
topical	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel):	O
*Incidence	O
Greater	O
than	O
1%	O
marked	O
with	O
asterisk	O

Body	O
as	O
a	O
Whole:	O
Abdominal	B-D015746
Pain	I-D015746

Cardiovascular:	O
Hypertension	B-D006973

Digestive:	O
Diarrhea	B-D003967

Hemic	O
and	O
Lymph	B-D008196
atic:	O
hemoglobin	B-C032001
D	I-C032001

Metabolic	O
and	O
Nutritional	O
Disorders:	O
Azotemia	B-D053099

Nervous	B-D009420
System	I-D009420
:	O
Dizziness	B-D004244

Respiratory:	O
Epistaxis	B-D004844

Skin	B-D012867
and	O
Appendages:	O
rash*,	O
Pruritus	B-D011537

Special	O
Senses:	O
Tinnitus	B-D014012

Urogenital:	O
Nephrotic	B-D009404
Syndrome	I-D009404

BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
·	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

·	O
Ibuprofen	B-D007052
Tablets	B-D013607
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
Ibuprofen	B-D007052

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052

Adverse	O
reactions	O
observed	O
during	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
Observation	B-D019370

More	O
than	O
500	O
of	O
these	O
Patients	B-D010361

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
Clinical	B-D016430
Trial	I-D016430

The	O
increases	O
in	O
Incidence	B-D015994

Incidence	B-D015994
Greater	O
than	O
1%(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINAL	O
Nausea	B-D009325
*,	O
epigastric	O
Pain	B-D010146

Henoch-Schonlein	O
Vasculitis	B-D014657

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
Patients	B-D010361

**Reactions	O
are	O
classified	O
under	O
“Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“CausalRelationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O
CARDIOVASCULAR	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Diclofenac	B-D004008
Potassium	B-D011188

GASTROINTESTINAL	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
non-steroidal	O
anti-inflammatory	O
drug	O

ADVERSE	O
REACTIONS	O
In	O
718	O
Patients	B-D010361

In	O
a	O
6	O
month,	O
double-blind	O
trial	O
comparing	O
Diclofenac	B-D004008

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

This	O
Risk	B-D012306

[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(	O
5.1	O
)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

(	O
4	O
,	O
5.1	O
)	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(	O
5.2	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Celecoxib	B-D000068579

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

The	O
rates	O
of	O
Hypertension	B-D006973

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

The	O
renal	O
effects	O
of	O
Celecoxib	B-D000068579

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
Sulfonamides	B-D013449

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Celecoxib	B-D000068579

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
Patients	B-D010361

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Celecoxib	B-D000068579

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
Risk	B-D012306

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Actavis	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
Greater	O
Than	O
or	O
Equal	O
to	O
2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
Placebo	O
NAP	O
DCF	O
IBU	O
N=4146	O
N=1864	O
N=1366	O
N=387	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

In	O
placebo-	O
or	O
active-controlled	O
Clinical	B-D016430
Trial	I-D016430

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(greater	O
than	O
or	O
equal	O
to	O
5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(greater	O
than	O
or	O
equal	O
to	O
5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
Greater	O
Than	O
or	O
Equal	O
to	O
5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies	O
:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

